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ABSTRACT 
Nowadays, one of the biggest concerns that permanently keep the 
attention of main important sectors of human society is health. 
Modern medical science is compromised with not only providing good 
adequate treatments but also effective specific solutions for each type 
of disease or human pathology. 
In this direction, innovative approaches like tissue engineering or 
regenerative medicine, controlled drug delivery systems and 
nanomedicines emerge to bring alternatives to situations hard to solve 
with conventional treatment and strategies, including the replacement 
of damaged or diseases tissues and/or organs.  
Specifically, this research is mainly aimed to design a combined system 
for controlled, stable and localized release of therapeutic agents that 
are able to exert their effect selectively on the area that warrants 
treatment. 
This construct will have enough versatility to be adapted to almost any 
kind of treatment, from cancer to tissue regeneration, always that the 
key requirement of the treatment was the need to provide the 
treatment of localized, stable and controlled manner. 
With the purposes of making easier the understanding as well as the 
design of the system, I was decided, for the proof of concept, to use 
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drugs and materials with known activity applied on tissue regeneration 
and for the treatment of chronic wounds. 
The system in question consists of three main elements: 
1) The first element is the polymer conjugates of therapeutic agents, 
which contribute to increasing the selectivity of the therapeutic 
action of the drug, as well as improved stability, bioavailability and 
biocompatibility thereof. If the drug is hydrophobic, conjugation 
contributes to increase its solubility in water, and in the case of 
proteins used as therapeutic agents, the combination helps reduce 
the body's immune response, increasing the chance of successful 
of the treatment. 
2) The second element are the biodegradable polymeric 
microparticles, which in this case act like encapsulation agents for 
polymeric conjugate , thus allowing to have a second control point 
in the release kinetics of the therapeutic agents . Simultaneously, 
the microparticles also play a role in modifying the texture of the 
final construct, ascribing mechanical and physicochemical 
properties that help to improve some biological properties of the 
final material, such as the affinity, adhesion and cell proliferation. 
3) The third element consists of a nanoporous membrane made of a 
biodegradable polymer by electrospinning, which constitute the 
unifier element of the whole system.  This membrane provides 
manageability to the construct and is itself the last point of control 
in the release kinetics of the therapeutic agent or agents.  Besides, 
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it must be biocompatible and stable at ambient conditions, since 
this probably is going to be exposed to the environment while 
protecting the wound, in the case of this kind of application. 
These three elements, which themselves are complex systems 
separately, are systematically combined to achieve a synergistic 
relationship between them so that each one power the qualities of the 
other two. 
The resulting construct was characterized and it demonstrated to have 
characteristic properties that can be used as a control parameter 
during manufacture of this new material. Also, preliminary biological 
studies developed “in vitro” indicated that the proposed system may 
be a good candidate for deeper studies as alternative treatment for 
chronic wounds and other pathologies that require localized 
administration for long periods of time. 
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RESUMEN 
Actualmente, una de las mayores preocupaciones que 
permanentemente laman la atención de los principales sectores de la 
sociedad humana es la salud.  La ciencia médica moderna está 
comprometida no solo con suministrar tratamientos adecuados, sino 
más bien ofrecer soluciones efectivas y específicas para cada tipo de 
enfermedad o patología humana. 
En este sentido, estrategias innovadoras como la ingeniería de tejidos 
o la medicina regenerativa, los sistemas de liberación controlada de 
fármacos y las nanomedicinas, surgen como buenas alternativas para 
abordar situaciones difíciles de resolver aplicando los tratamientos y 
estrategias terapéuticas convencionales, como es el caso cuando se 
hace necesario reemplazar tejidos o incluso órganos dañados por 
algún traumatismo o enfermedad. 
Concretamente, el presente trabajo de investigación tiene por objetivo 
principal diseñar un sistema combinado para la liberación controlada, 
estable y localizada de agentes terapéuticos que sean capaces de 
ejercer su efecto de forma selectiva sobre la zona que amerita el 
tratamiento. 
Este constructo tendrá la versatilidad suficiente como para poder 
adaptarse a casi cualquier tipo de tratamiento, desde el cáncer hasta 
la regeneración de tejido, siempre que el requisito clave del 
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tratamiento sea la necesidad de suministrar el tratamiento de manera 
localizada, estable y controlada. 
Para efectos de facilitar la compresión y el diseño del sistema se 
escogió para la prueba de concepto materiales y fármacos asociados a 
la regeneración de tejidos,  como tratamiento para casos de heridas 
crónicas. 
El sistema en cuestión está constituido por tres elementos principales: 
1) El primer elemento son los conjugados poliméricos de agentes 
terapéuticos que contribuirán a aumentar la selectividad de la 
acción terapéutica del fármaco, así como también a mejora la 
estabilidad, biodisponibilidad y biocompatibilidad de los mismos.  
En caso de que el fármaco sea hidrofóbico, la conjugación 
contribuye a aumentar su solubilidad en agua, y en el caso de usar 
proteínas como agentes terapéuticos, la conjugación contribuye a 
disminuir la respuesta inmunológica del cuerpo incrementando las 
posibilidad de éxito del tratamiento. 
2) El segundo elemento son micropartículas poliméricas 
biodegradables, que en este caso actúan con agentes de 
encapsulación para los conjugados poliméricos, permitiendo así 
contar con un segundo punto de control en la cinética de 
liberación de los agentes terapéuticos.  Simultáneamente, las 
micropartículas también cumplen un papel de modificador de la 
textura del constructo final, adjudicándole propiedades mecánica 
y fisicoquímicas que contribuyen a mejorar las propiedades 
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biológicas del material final, como son la afinidad, la adhesión y la 
proliferación celular.  
3) El tercer elemento consiste en una membrana polimérica 
biodegradable nanoporosa hecha por electrospinning, que 
constituyen el elemento unificados del sistema, aporta 
manejabilidad al constructo y es en sí mismo el último punto de 
control en la cinética de liberación del agente terapéutico.  Este 
último debe ser biocompatible y estable en condiciones 
ambientales, puesto que probablemente este expuesto al 
ambiente mientras protege la herida, en el caso concreto de este 
tipo de aplicación. 
 
Estos tres elementos, que en sí mismos constituyen sistemas 
complejos por separado, se han combinado sistemáticamente para 
alcanzar una relación sinérgica entre ellos de manera que cada 
uno potencia las cualidades de los otros dos. 
 
El constructo resultante se caracterizó demostrando tener 
propiedades características que se pueden utilizar como 
parámetro de control durante la fabricación del mismo.    Así 
mismo estudios in vitro del sistema desarrollado señalan que 
puede ser un buen candidato para el tratamiento de heridas 
crónicas entre otras patologías que requieran tratamientos 
localizados. 
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RESUM 
Actualment, una de les majors preocupacions que permanentment 
llepen l'atenció dels principals sectors de la societat humana és la 
salut. La ciència mèdica moderna està compromesa no solament amb 
subministrar tractaments adequats, sinó més aviat oferir solucions 
efectives i específiques per a cada tipus de malaltia o patologia 
humana. 
En aquest sentit, estratègies innovadores com l'enginyeria de teixits o 
la medicina regenerativa, els sistemes d'alliberament controlat de 
fàrmacs i les nanomedicines, sorgeixen com a bones alternatives per a 
abordar situacions difícils de resoldre aplicant els tractaments i 
estratègies terapèutiques convencionals, com és el cas quan es fa 
necessari reemplaçar teixits o fins i tot òrgans danyats per algun 
traumatisme o malaltia. 
Concretament, el present treball de recerca té per objectiu principal 
dissenyar un sistema combinat per a l'alliberament controlat, estable i 
localitzada d'agents terapèutics que seguen capaços d'exercir el seu 
efecte de forma selectiva sobre la zona que amirita el tractament. 
Aquest constructe tindrà la versatilitat suficient com per a poder 
adaptar-se a quasi qualsevol tipus de tractament, des del càncer fins a 
la regeneració de teixit, sempre que el requisit clau del tractament 
sega la necessitat de subministrar el tractament de manera localitzada, 
estable i controlada. 
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Per a efectes de facilitar la compressió i el disseny del sistema es va 
escollir per a la prova de concepte materials i fàrmacs associats a la 
regeneració de teixits, com a tractament per a casos de ferides 
cròniques. 
El sistema en qüestió està constituït per tres elements principals: 
1) El primer element són els conjugats polimèrics d'agents 
terapèutics que contribuiran a augmentar la selectivitat de l'acció 
terapèutica del fàrmac, així com també a millora l'estabilitat, 
biodisponibilitat i biocompatibilitat dels mateixos. En cas que el 
fàrmac sega hidrofòbic, la conjugació contribueix a augmentar la 
seua solubilitat en aigua, i en el cas d'usar proteïnes com a agents 
terapèutics, la conjugació contribueix a disminuir la resposta 
immunològica del cos incrementant les possibilitat d'èxit del 
tractament. 
2)  El segon element són microparticles polimèriques biodegradables, 
que en aquest cas actuen amb agents d'encapsulació per als 
conjugats polimèrics, permetent així comptar amb un segon punt 
de control en la cinètica d'alliberament de l'agent terapèutics. 
Simultàniament, les microparticles també compleixen un paper de 
texturitzant del constructe final, adjudicant-li propietats mecànica 
i fisicoquímiques que contribueixen a millorar la propietats 
biològiques del material final, com són l'afinitat, l'adhesió i la 
proliferació cel·lular.  
  
21 
 
3) El tercer element consisteix en una membrana polimèrica 
biodegradable nanoporosa feta per electrospinning, que 
constitueixen el element unificats del sistema, aporta 
manejabilitat al constructe i és en si mateix el ultimi punt de 
control en la cinètica d'alliberament de l'agent terapèutic. Aquest 
últim ha de ser biocompatible i estable en condicions ambientals, 
ja que probablement aquest exposat a l'ambient mentre protegeix 
la ferida, en el cas concret d'aquest tipus d'aplicació. 
 
Aquests tres elements que en si mateixos constitueixen sistemes 
complexos per separat, s'han combinat sistemàticament per a 
aconseguir una relació sinergètica entre ells de manera que 
cadascun potencia les qualitats dels altres dos. 
 
El constructe resultant es va caracteritzar demostrant tenir 
propietats característiques que es poden utilitzar com a paràmetre 
de control durant la fabricació del mateix. Així mateix estudis in 
vitro del sistema desenvolupat assenyalen que pot ser un bon 
candidat per al tractament de ferides cròniques entre altres 
patologies que requeriren tractaments localitzats. 
 
 
 
  
22 
 
 
  
  
23 
 
1 INTRODUCTION 
Nowadays, one of the biggest concerns that permanently keeps the 
attention of main important sectors of human society is health. 
Modern medical science is compromised with not only providing good 
adequate treatments but also effective specific solutions for each type 
of disease or human pathology. 
In this direction, innovative approaches like tissue engineering or 
regenerative medicine, controlled drug delivery systems and 
nanomedicines emerge to bring alternatives to situations hard to solve 
with conventional treatment and strategies, including the replacement 
of damaged or diseases tissues and/or organs.  
Taking into account the vast range of application of these 
biotechnologies and provided that it is difficult to circumvent a desired 
disease target with a single technology, it is natural that they have 
been combined in order to develop better strategies to improve the 
treatments of this kind of pathologies with special needs. 
In the recent literature, overwhelming examples of biomaterials for 
tissue repair/engineering have been reported. The review article from 
Stevens’ group in the well-known journal Nature Materials included a 
list of commercial tissue engineering products and biomaterials at 
various stages of development for the treatment of vast amount of 
diseases and injuries, including applications for burns, legs ulcers, 
diabetic foot ulcers, wounds, spinal function, bone injury, dental bone, 
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bone defects, heart valves replacement, nerve injuries, diabetes 
mellitus, among others1. The remarkable idea is that all these 
pathologies could be treated applying technologies based on tissue 
engineering. 
Furthermore, in some cases, when tissues have an innate capacity to 
regenerate, like skin and bones, cells can be stimulated to form new 
tissue under the adequate conditions, just using biomaterial-based 
approaches, taking profit of the own body as a ‘bioreactor’1. 
Nevertheless, this strategy is not always applicable, since there are 
other tissues which need more complex matrixes to stimulate their 
growth, maybe from stem cells. In those cases, having controlled 
delivery systems for the bioactive agents that are responsible to 
promote tissue regeneration could be crucial.  
On the other hand, the successful clinical application of nanomedicines 
such as polymer–protein conjugates (PEGylated enzymes and 
cytokines) and the promising results arising from clinical trials with 
polymer-bound chemotherapy have established the potential of 
Polymer Therapeutics (PT) as anticancer therapy 2–4. Furthermore, 
these examples have also provided a firm foundation for a more 
sophisticated second-generation of constructs whose main research 
lines included the use of controlled architectures properly 
characterized, the application of polymer–based drug combinations 
and the direction towards new molecular targets, including 
regenerative medicine, and tissue repair 5–8.  
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Until now these two approaches for drug delivery have provided 
important information about mechanism for tissue regeneration and 
they represent interesting and viable alternatives as future therapies 
in this field. Unfortunately, the effect of the combination of both 
technologies has not been deeply studied yet. With that in mind, the 
aim of this project is to design intelligent composite system for tissue 
regeneration through the combination of biomaterial science and 
nanoconjugate synthesis, in order to have a structure with double 
control on drug release kinetics, and with the possibility to be used on 
different clinical applications, such as implants in damage tissue.  
The proposed strategy in this work will offer a wide range of 
advantages over other systems. In the concrete case of protein 
therapy, it allows to overcome most of the limitations of this field 
since the use of nanosystems makes possible to keep protein or 
growth factors protected during circulation before being released from 
their scaffolds holding their activity with higher stability9. Moreover, 
by the application of these technologies, body residence time of the 
delivered protein/growth factor is dramatically increased, what in 
consequence, increases the therapeutic value10. In the case of the 
delivery of small drugs, this approach will increase the sustained and 
controlled release through a system with dual mechanism of control, 
the conjugate and the scaffold, what allows a specific local delivery of 
the drug, holding the therapeutic dose during the desired time lapse of 
application required11–14.  
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Nevertheless, most of these nanosystems are design for systemic 
administration, limiting their range of application to pathologies that 
could be treated this way and making more difficult their use when 
local administration for local treatment is required.  This kind of 
limitations could be overcome combining polymer therapeutics with 
an appropriate scaffolds made with innovative techniques in order to 
obtain a construct which was an optimum approach to be used as 
topic or surgical implants able to promote tissue regeneration but with 
a double function, provide support for cellular growth, as usually id 
done with scaffold of biomaterials15–22, while supplied locally bioactive 
agents with specific therapeutic activity to improve local  treatment, 
all at the same time with the same system. 
Likewise, this approach could be implemented in therapies thought to 
improve the wound healing and promote tissue repair or even tissue 
regeneration, which could be treated in a better way modulating the 
drugs release kinetics to prolong the therapeutic effect of one dose 
that could be administered locally in the affected area. The expected 
result would be: increasing the efficiency of the treatment, reducing 
the time recovery of patients, and in consequence improving their live 
quality, that is the real goal of all and every one therapeutic strategy. 
Having all these ideas in mind, the present research was conceived 
with the aim to develop a novel biomedical device designed for 
controlled and localized delivery of nanomedicines to promote tissue 
regeneration.  
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As mentioned, our approach is based on the development of a novel 
biomedical device that consists on a hybrid system composed by three 
main elements:  
 Polymer conjugates (PC): These nanomedicines (polymers 
conjugated to drugs or proteins) improve the stability, solubility, 
bio-compatibility and bio-availability of therapeutic agents such as 
hydrophobic drugs or biomacromolecules (for example, proteins) 
which are fundamental for the treatment of the desired 
pathology8,23–25. Besides, polymer conjugates by themselves 
constitute the first point of control in the release kinetics of the 
therapeutic agent.  
 Biodegradable polymeric micro-particles (MPs):  This component 
accomplishes the function of vehicles for polymer conjugates, 
which will be encapsulated inside the micro-particles representing 
the second point of control in the release kinetics. MPs are also 
responsible of modifications in mechanical, surface, physico-
chemical and biological properties of the final device26,27.  
 Biodegradable polymeric membranes: It is the element that 
unifies all components, making possible the handling of the final 
device. Loaded MPs will be effectively immobilized in the matrix of 
these membranes.    
These three elements, which are complex systems by themselves, are 
supposed to be combined systematically and in the proper way in 
order to obtain a synergetic effect among them. The resulting single 
  
28 
 
structure will hold with particular physico-chemical, mechanical and 
biological properties, characteristics of a new biomaterial. 
 
Figure 1.1 Diagram of composite system approach 
 
As a proof of concept, the composite system proposed in this research 
could be used as model for different bioapplications. Wound healing 
was chosen as example to simplify its evaluation. 
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In order to complete the device three compounds were selected as 
model molecules of therapeutic agents: 
 Curcumin (is a fluorescent hydrophobic small molecule drug, a 
natural polyphenolic compound, extracted from Curcuma longa, 
with various therapeutic properties, such as anti-inflammatory, 
anti-oxidant, antiviral, antibacterial and antitumor activity, able to 
promote hepatoprotection, as well as early-epithelialization, 
improved neovascularization and migratory activity of various cells 
into the wound bed, among others biological functions 28–31) 
 Trypsin (protein with proteolytic enzymatic activity frequently 
used as model protein for evaluation of controlled drug delivery 
systems32–34) 
 In the following paragraphs each element is going to be described to 
provide a better understanding of the whole system. 
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1.1 Regenerative Medicine 
The idea of being able to augment or repair parts of our body dates to 
antiquity, when natural materials such as wood were used in an 
attempt to structurally replace tissues lost due to disease or trauma35. 
This concern has continued evolving until today to become one of the 
main areas of study of modern science. 
Tissue engineering (TE), also called regenerative medicine is defined by 
the US National Institutes of Health as “the process of creating living, 
functional tissues to repair or replace tissue or organ function lost due 
to age, disease, damage, or congenital defects”36.  Currently, it is an 
interdisciplinary field involving knowledge from medicine, biology, 
engineering and material science fields.37–40  
Tao Jiang et al.,38 defined “Regenerative Engendering” as the 
convergence of advanced materials science, nanotechnology, stem cell 
science, and developmental biology and state that this field represent 
the next multidisciplinary paradigm to engineer complex tissues. There 
is not any doubt that repair and regeneration of human tissues and 
organs using biomaterials, cells, and/or growth factors represents 
nowadays a great challenge for tissue engineers and surgeons. 
As it was suggested at the beginning of this section, the TE concept 
was born from the need to find out alternative approaches to cover 1) 
the lack of organs for transplantation, 2) create tissue/organs analogs 
as substitutes to make the organs functional, 3) replace or restore a 
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damaged tissue or organ and 4) significantly improve the quality of life 
of millions of patients41 . 
First steps through biomaterial science and technology where taken at 
1950’s, and big progress have been seen since then. Three overlapping 
generations of biomaterials for surgical implants have evolved over 
time: from inert (with minimal tissue interaction, 1950’s), to bioactive 
(with incorporated biologically interactive components to elicit a 
controlled reaction in the tissues, 1980’s) and, finally, to 
biointeractive, integrative and resorbable (~2000>), able to regenerate 
functional tissue. This third generation involved the seeding of cells 
onto a scaffold, the in vitro culturing and finally the implantation into 
the body as prosthesis when matured. With engineered surfaces and 
bulk architectures tailored to specific applications, ‘‘third generation’’ 
biomaterials are intended to stimulate highly precise reactions with 
proteins and cells at the molecular level. Such materials provide the 
scientific foundation for molecular design of scaffolds that could be 
seeded with cells in vitro for subsequent implantation or specifically 
attract endogenous functional cells in vivo. The key concept is that a 
scaffold can contain specific chemical and structural information that 
controls tissue formation, in a manner analogous to cell–cell 
communication and patterning during embryological development. 
The natural tissue regeneration processes take place, blood vessels 
infiltrate the structure and the scaffold eventually degrades leading 
the newly formed tissue in place42. 
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Even though to date the aim is still the same, we continue looking for 
the appropriate combination to be able to replace or facilitate the 
regrowth of damage or diseased tissue. The big difference is that now 
we possess more information about the importance of hierarchical 
tissue architecture and signaling pathway with bioactive molecules, 
influence of materials with nanotopographic features to promote the 
interaction between growth factors and their receptors and other 
important biological details specifics for each kind of tissue, organ or 
disease.  
During the last years regenerative medicine has incorporated the 
advances in nanotechnology to strengthen its achievements.  
A very instructive review written by Koel Chaudhury et al. 43described 
several recent advances in nanomaterials use in this discipline, which 
have been trial in vitro and/or in vivo models. They explain that the 
advantages that nanotechnology offers to regenerative medicine lie in 
the fact that it can influence and even alter cellular behavior, which 
ultimately enhances the function of tissue or organs. These works, 
carried out between 2009 and 2014, were designed for applications in 
organ systems where considerable research is ongoing, encompassing 
bone, cartilage, peripheral nervous system, central nervous system, as 
well as myocardial tissue, dental, hepatic, ocular and skin 
regeneration. The newer and rational approaches include the 
combination of the traditional methods in nanotechnology: 1) 
nanoparticles; 2) scaffolds with nanofibers; 3) scaffolds with 
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nanotopographic modification; 4) drug/gene delivery; and 5) 
extracellular matrix (ECM) patterning43.  
Thus, the future of tissue engineering is closely related to the search of 
radical approaches which took advantage of emerging strategies such 
as the incorporation of nanomedicines and nanotechnology to well-
known biomaterials such as scaffolds with nanofibers and micro-
particulate systems, in order to be able to design a proof of concept of 
a novel platform to promote tissue repair/regeneration. As already 
stated, the aim of this project deals with that, focusing on applications 
related to prevent post-surgical undesired cell adhesion and wound 
healing as starting point. However, our expectancies are that this 
platform could be implemented in a broad range of tissue 
regenerative applications. 
1.1.1 Wound Healing. 
Skin is the largest organ in mammals. It forms a unique and flexible 
interface between our internal milieu and the external environment 
and possesses sensory, thermoregulatory, metabolic, and 
immunological functions. It is flexible enough to resist permanent 
distortion from movement and thin enough to allow the perception of 
stimuli. It also provides mechanical support to inner organs and plays a 
critical role in the synthesis of vitamin D. Besides, it is the more prone 
to mechanical injuries and infection, because it is directly exposed to 
potentially harmful microbial, thermal, mechanical and chemical 
influences43,44.  
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Wound healing is a natural process that takes place spontaneously in 
healthy tissues after injury. There are two different mechanisms that 
cells an tissues can initiate after suffering practically any insult that 
causes tissue destruction: 1) Tissue regeneration and 2) Tissue repair.  
Tissue regeneration refers to the proliferation of cells and tissues to 
replace lost structures, and complete recovery of tissue functionality. 
Actually, this mechanism rarely happens in mammals, but it also truth 
that tissues with high proliferative capacity, such as the hematopoietic 
system, the epithelia of the skin and gastrointestinal tract, are able to 
renew by themselves continuously after injury as long as the stem cells 
of these tissues are not destroyed. Tissue repair, on the other hand, 
consist on the formation of a scar by deposition of collagen and a 
compensatory tissue with some loss of the original functionality.40 
Natural (acute) wound healing of skin or any soft tissue proceeds 
through several largely overlapping phases that involve: 1) hemostasis, 
2) inflammatory response and associated cellular migration, 4) 
proliferation, 5) matrix deposition, and 6) tissue remodeling. 45 
If the wound healing cascade is negatively affected at any time, by 
interruption or deregulation of one or more phases of the wound-
healing process, it might be slowed down or the wound can become 
chronic (non-healing) 45. When the affected area of skin is too large 
and therefore cannot be successfully treated with conventional 
techniques, dramatic situations including patient death might take 
place39. 
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Bryan K. Sun and co-workers have recently published in a review about 
the advances in skin grafting and treatment of cutaneous wounds, 
which explains than the skin, as the body’s external epithelium, 
sustains and repairs injuries throughout a lifetime and therefore the 
ability of the skin to repair itself after injury is vital to human survival. 
The authors emphasized that there are a wide variety of factors that 
influence skin wounding and the speed and quality of healing which 
affect its vital role. Particularly warning is that several of such factors 
include a number of medications and common diseases, including age, 
infection, diabetes/vascular disease, and cancer, as well as smoking, 
alcohol and recreation drugs, can negatively affect the healing process 
in ways that are currently poorly understood. All previously said 
underscores the broad relevance of cutaneous wound healing issues 
to medicine, public health, and the global burden of disease46 
Reinforcing this trend, in December 2014, Science Translational 
Medicine45, also published a review about the state of art entitle 
“Wound repair and regeneration: Mechanisms, signaling, and 
translation” written by Sabine A. Eming and co-workers, whom 
introduced the article pointing out that traumatic injury is a leading 
cause of mortality in Europe and United States of America, in addition 
to the millions of surgical wounds created annually in the course of 
routine medical care. 
Both articles emphasized that worldwide population should be aware 
of the number of patients suffering from chronic wounds. Moreover, 
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impaired healing conditions is reaching epidemic proportions and is 
expected to become even more burdensome in both human health 
and economic terms.36,47,48   
In addition to acute wounds, the modern society way of life has 
promoted the prevalence of diabetes, obesity, and vascular disease in 
an aging population, and in consequence a steady rise in chronic skin 
wounds such as pressure ulcers and diabetic foot ulcers, which now 
affect more than 1% of all people during their lifetime. For instance, 
chronic skin wounds affect >6 million people at the US, what is 
translated in a cost of >$25 billion per year46. 
Advances in regenerative medicine have made possible the 
replacement of traditional wound dressing by more sophisticated 
devices. This is a very good incentive to continue investing in research, 
developing and innovation. 
1.1.2 Biodegradable Polymeric Micro-particles for controlled 
delivery and tissue repair/regeneration 
This section of the introduction is dedicated to remind why 
microparticulate systems are still valid alternatives as controlled drug 
delivery strategies for localized applications. There is always a 
controversy in the classification of nano and microparticles regarding 
sizes. Thus, it is worthy to point out that for this work, microparticles 
will be considered as those between 1–1000 µm and nanoparticles if 
they are between (1–1000 nm) 44 
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Since 1987 to date, more than a hundred of research works have been 
published with the word “microparticles” and “delivery systems” in 
the title, according to a search made in PubMed in October 2015, 
using those key words. In this time is possible to observe how 
particulate drug delivery systems evolved from being scientific 
curiosities to become in an area with very active research interest, to 
clinical applications, as notice Dr. Kohane on his review about 
“Microparticles and Nanoparticles for Drug Delivery” published in 
200749. In this work, he explained that one of the most useful features 
of this kind of systems is that they are not only easy to inject, both, 
into tissue or intravenously, but also they are easily adapted to other 
milieus, for inhalation as a dry powder, or topically in an appropriate 
vehicle. This versatility lies on the fact that they can be injected or 
deposited directly at the site of action, providing a high local drug level 
over an extended period, while minimizing system toxicity. They can 
also be used as depot systems, injected at a convenient site (e.g. 
subcutaneously) with the intent of slowly releasing the drug for effect 
throughout the body. Particles themselves can also be distributed 
inclusive systemically but sent to specific desired sites at which to 
release their drugs, using active or passive targeting methods49   
Micro and nanoparticles have properties that can make them more or 
less useful for any one of those types of applications. And one of the 
critical aspects that must be taken in account for designing the 
particles for a specific application is the size, together with the nature 
of polymeric material of what are going to be made of. Specifically, for 
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particles obtained by single and double emulsion methods, size have a 
direct relation with drug payload and, in the other hand, the polymer 
hardness will define the release kinetics mechanism and rate, as well 
as the “burst release” 49. 
Single emulsion method involves the dispersion of an aqueous solution 
of the hydrophilic therapeutic agent (drug, protein, or any other 
compound) in an organic solution containing the polymer, leading to 
the formation of the primary water in oil (W/O) emulsion. 
The double emulsion method involves the formation of a secondary oil 
in water (O/W) emulsion by dispersing, using continuous mechanical 
agitation, the primary W/O emulsion in an aqueous medium 
containing stabilizers such as poly(vinyl alcohol) (PVA) or poly(ethylene 
glycol) (PEG). Microspheres are produced by the evaporation of the 
organic solvent from the emulsion droplets. The microspheres are 
then collected either by centrifuging or filtration, washed and 
lyophilized to obtain the free flowing and dried microspheres. Revers 
systems are also possible, with w/o/w double emulsion. In any case, 
loaded microparticles can be formed either through chemical cross-
linking or by solvent extraction50. 
According to  Zeliha Gul Degim44 the most common polymers for the 
preparation of microparticulate system for skin wound healing and 
drug delivery could be classify in the following manner. The most 
popular synthetic polymers used to synthesized microparticles are 
poly(lactic acid) (PLA) and poly(lactic glycolic acid) (PLGA), while the 
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natural polymers more used from de family of protein-based polymer 
are albumin and gelatin, from polysaccharide hyaluronic acid is a very 
well-known and commonly used. Among positively charged natural 
polymers the most frequently used are chitosan and trimethyl 
chitosan.  Of course, there are several modified natural polymers that 
include starches, gums, fats, and waxes which have also been used in 
many different types of preparations for dermal and transdermal 
delivery with successful results.  
Overall, the most commonly preferred polymers in wound healing are 
biodegradable and biocompatible polymers because of their surface 
properties, such as hydrophilicity, lubricity, smoothness, permeability, 
and degradability, and their biocompatibility with tissues and blood.  
Some examples of application of microparticulate systems to tissue 
engineering field will be described.  
Lee and colleagues51 (2002) studied a laminin-modified infection-
preventing collagen membrane containing silver sulfadiazine–
hyaluronan microparticles. They prepared hyaluronan-based 
microparticles containing silver sulfadiazine (AgSD) incorporated into 
the two collagen layers (AgSD content 50mg/cm2). They were able to 
demonstrate that the laminin-coated AgSD-medicated collagen 
membrane exhibited a higher wound size reduction and vessel 
proliferation and lower inflammation than the polyurethane control, 
suggesting that the laminin AgSD-medicated collagen membrane 
substantially improves dermal wound healing. 
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Haigang G. and Zhilian Y.52 (2012) developed a controlled release 
strategy based on biodegradable microparticles for neurodegenerative 
disease therapy. MPs were made of Poly(lactide-co-glycolide) (PLGA; 
lactic acid/glycolic acid = 75/25) and loaded with a neurotrophic factor 
named Nerve growth factor (NGF). This protein has shown to improve 
the learning and memory ability as well as the survival of basal 
forebrain cholinergic neurons in aged or fimbria-fornix injured animals. 
Nevertheless, neurotrophic factors (NTFs) are large molecular proteins 
that do not really cross the blood-brain-barrier (BBB) and have short 
biologic half-life. Therefore, to improve their therapeutic efficacy and 
patient compliance, local and controlled delivery of NTFs directly to 
the desired brain area are preferred. The in vivo efficacy of these MPs 
was evaluated in a rat model of AD (Alzheimer’s disease).  Researchers 
affirm that compared to other existing approaches, the strategy based 
on biodegradable microparticles has demonstrated several advantages 
such as: 1) easier administration to the targeted area of brain, avoiding 
open operation and damage to surrounding tissue, 2) preservation of 
drug activity during encapsulation and storage. 3) localized, controlled 
released profile for a desire period, resulting in enhanced therapeutic 
effect while minimizing side effects, and 4) better safety profiles 
compared with gene therapy.  
Feng S. and colleagues53 (2015) carried on a study with mizolastine-
loaded microparticles made of PLGA-mPEG, to evaluated the feasibility 
of use of this system as therapy for atopic dermatitis-like lesions in 
animal models.   Microparticles were prepared using the oil-in-water 
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(O/W) emulsification-solvent evaporation method yielding a total drug 
loading of 4.2wt% (percentage in weight). Atopic dermatitis was 
induced to inner and outer sides of right ears in BALB/c mice model by 
repeated topical application of dinitrofluorobenzene. They applied two 
kinds of treatments and compared the effects on different groups of 
mice. Those mice which received daily mizolastine injection treatment 
showed almost complete recovery after 8 days as well as mice which 
receive one-dose treatment of mizolastine microparticles suspension 
by tail vein injection after the same time. Inflammatory cells 
infiltration into the ears and the plasma level of immunoglobulin E 
(IgE) were also suppressed by mizolastine microparticles according to 
the histopathology analysis. In conclusion, the researches affirm that 
these results suggested that the drug-loaded microparticulate systems 
proposed by them could be a proper candidate for the treatment of 
skin diseases.   
Wang X. and co-workers54 (2015) published their advances with a 
double wall microparticulate system made of poly(l-lactic acid) and 
poly(glycolic acid), designed to improves diabetic wound healing 
through redox modulation of wound microenvironment, through the 
early controlled release of peroxisome proliferator-activated receptor 
β/δ agonist GW501516. Microparticles are loaded with GW501516 
(GW) as a wound healing drug, which is a peroxisome proliferation 
activated receptor PPARβ/δ agonist. This group based their work on 
the fact that diabetic wounds are imbued with an early excessive and 
protracted reactive oxygen species (ROS) production and previous 
  
42 
 
studies which support that PPARβ/δ is a valuable pharmacologic 
wound-healing target. Therefore they decided to synthesize double-
layer encapsulated GW microparticles (PLLA:PLGA:GW). The study of 
different drug release profiles showed to have a significant influence 
on the therapeutic efficacy of GW and consequently in the diabetic 
wound closure. 
Summarizing, in tissue engineering, drugs are classically adsorbed to 
the surface or encapsulated within the core of microspheres. Drug 
release from the microsphere matrix usually features a burst release 
associated with smaller quantities of drug attached to the surface of 
the microsphere, followed by a sustained release, which is associated 
with degradation of the polymer and release of encapsulated drug. In 
vitro trials are used to give promising results but when they are 
delivered in vivo, microspheres are sometimes susceptible to being 
cleared out of the animal and/or migrating away from the 
defect/implantation site. To maintain local treatment, microspheres 
are often combined with scaffolds or hydrogels in composite delivery 
systems55 
Polymer scaffolds can also be manufactured from loaded 
microspheres with any therapeutic agent. Scaffold fabrication from 
microspheres could range from fusing of microparticles to form 
scaffolds. Nevertheless, a clear disadvantage associated to this kind of 
systems is the incompatibility of their mechanical properties with 
those required for the desire application. For this reason, composite 
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systems have been proposed as alternative to be able to take profit of 
all benefits of microparticulate system plus some improvement in 
biomechanical characteristics. 
1.2 Nanotechnology for Controlled Drug 
Delivery Systems and Tissue Engineering 
In the human body there are some tissues that contain cells capable of 
initiating regeneration or repair after injury. However, this ability 
varies between different cell types and depends on the nature of the 
injury or insult as reported by Sokolsky et al. For instance, there are 
tissues in constant renewing such as the skin, bone marrow and 
intestinal mucosa, which are capable of showing complete regrowth. 
Nevertheless, this ability highly depends on different factors including 
the size and the cause of the injury as well as the age of the individual. 
On the other hand, there are other types of tissues like heart muscle 
and nerves that lack of mechanisms for regeneration in adults. In these 
cases, stem cell biology offers the potential to grow tissue by following 
a developmental pathway that can be supported on a controlled drug 
delivery system50. 
In this context, scaffolds are very important components of many 
tissue engineering strategies as they provide an architectural structure 
in which extracellular matrix, cell-cell and growth factor interactions 
are combined to generate regenerative niches. Because of this, the 
materials used in their synthesis must be not only safe but also 
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suitable for the specific tissue that is desire to repair/regenerate. In 
general, a proper scaffold designed for clinical application should 
accomplish the following characteristics: 50 
1) Possess mechanical properties matching those of the tissue at 
the implantation site and/or sufficient to shield cells from 
damaging compressive or tensile force without inhibiting 
appropriate biomechanical cues. 
2) Acceptable biocompatibility and toxicity profiles. 
3) Mimic the native extracellular matrix (ECM), and endogenous 
substances that surround the cells, into tissues and provide 
signals that aid cellular development and morphogenesis. 
4) Possess Interface adherence: defined as how cells or proteins 
attach on the scaffold surface. The scaffold should support cell 
adhesion and proliferation, facilitating cell-cell contact and cell 
migration. 
5) Appropriate Degradation rate: biodegradable scaffold should 
be bio-adsorbed at pre-determined time period, whereas the 
space initially occupied by the scaffold should be replaced by 
newly grown tissue. 
Likewise, specific scaffolds designed with the additional purpose to 
work as drug delivery platforms should also address the following 
criteria50: 
1) High drug loading capacity: defined as the amount of bioactive 
agent that can be carried by the scaffold. 
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2) Extended drug distribution: the bioactive agent needs to be 
dispersed homogeneously throughout the scaffold or in 
discrete areas if the spatial patterning of release is pretended 
to occur. 
3) Low binding affinity. The binding affinity is defined as how 
tightly the bioactive agent interacts or binds to the scaffold; 
this binding affinity must be sufficiently low to allow release. 
4) Controlled drug release kinetics. Kinetics of drug release needs 
to be controlled to allow the appropriate dose of bioactive 
agent required to reach the cells over a given period of time. 
5) Sufficient stability: the stability of the therapeutic agents when 
incorporated within the scaffold at physiological temperature 
must be enough in order to maintain their structure and 
activity over a prolong period of time. 
Those requirements were taken in account to design the proof of 
concept of our system. 
At this respect, Electrospinning (ES) is one of the most widely studied 
techniques used to construct biomaterials for their use as scaffolds to 
be cultivated with cells, and it has also been demonstrated to have 
given the most promising results in terms of tissue engineering 
applications. The interest about this technique has significantly 
increased after 200056, since it makes possible to obtain scaffolds with 
nanoscale architecture made of fibers from few nanometers to 
micrometers in diameter, high porosity and large surface areas, which 
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can mimic the extracellular matrix structure in terms of the chemistry 
and dimensions.57 
1.2.1 Biodegradable Polymeric Membranes obtain by 
Electrospinning as scaffolds for tissue regeneration 
Electrospinning (ES) could be defined as the deliberate application of 
the phenomenon of electrostatic spraying which occurs when 
electrical forces at the polymer solution overcome the surface tension, 
forming a polymer solution jet. The jet produces a fiber with diameters 
in the micron to nanoscale range (usually below 50 nm) as the solvent 
evaporates. 50 
The main components of an ES device are: 1) a syringe provided with a 
nozzle, 2) a pump, 3) a counter electrode (generally a metal plate), and 
4) a source of electrical field. Briefly, the solution to be electro-spun, is 
applied to the system via the syringe’s nozzle and is pulsed by the 
pump. It is then subjected to a difference in an electrical voltage 
present between the nozzle and the counter electrode. This electrical 
voltage generated by the source causes a cone-shaped deformation of 
the drop of the polymer solution. The solvent in the solution 
evaporates on its way to the counter electrode and, at the end of the 
process, solid continuous filaments are yielded. Gravitational forces do 
not interfere in the process because the acceleration of the fiber 
formation is up to 600 m/s2, which is close to two orders of magnitude 
greater than the acceleration of gravitational forces and this fact 
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makes possible to form fibers of a wide range of arrangements 
including from top-down or bottom-up.56 
Although the electrospinning process can be considered a simple 
method, there are several variables (multitude of molecular, 
processing and technical parameters) which must be taken in account 
to obtain fibers and mats with the desire characteristics. This includes: 
1) environmental parameters, such as solution temperature, humidity 
and air velocity in the ES chamber; 2) solution properties, such as 
elasticity, viscosity, conductivity and surface tension; and 3) governing 
variables, such as distance between the tip and counter electrode, 
electrical potential, flow rate, molecular weight of the selected 
polymers, geometry of the collector, among others 57 
The choice of the right parameters is critical in order to be able to 
fabricate large and complex 3D structures to allow the cells to fill the 
structure in a 3D manner. 
As deeper the knowledge about the parameters and polymer behavior 
are, more variation of the traditional process are proposed. The most 
recent modifications are related to coaxial ES (two components feed 
through different coaxial capillary channels) to obtain polymer core–
shell fibers, hollow polymer core–shell fibers, hollow fibers containing 
polymer and/or ceramics and for the immobilization of functional 
objects or molecules. This methodology is very useful for drug and/or 
protein delivery, for the encapsulation of cells, bacteria, viruses, 
growth factors and others 15,56 
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As stated before, fibers constructed by ES have the capability of closely 
mimicking the structure of the native environment of the cells. 
Nevertheless, the polymers that are commonly used to construct the 
scaffolds do not possess any specific groups for selective interactions 
with the cells. Therefore, the incorporation of biomolecules into the 
electrospun fibers could lead to a biofunctional scaffold, which would 
determine the efficiency of these fibers in regenerating biological 
functional tissues16. Due to the importance of this strategy, scientists 
around the world have been studying biomolecules to be 
incorporated, as well as ways of improving the efficiency of the 
incorporation of these agents.56  
There are overwhelming examples that reveal the extraordinary 
potential and versatility of this technology in regenerative medicine, 
and also in combination with others micro and nano-technological 
devices. Selected relevant examples are summarized in this section to 
complete a global idea of its power.  
Guorui Jin and colleagues18,58 investigated the potential of human 
bone marrow (BM)-derived Mesenchymal Stem Cells (MSC) for 
epidermal cell differentiation in vitro on electrospun collagen/poly(L-
lactic acid)–co-poly(3-caprolactone) (Coll/PLACL) nanofibrous 
scaffolds. The authors found out evidences that suggested their 
potential application in skin regeneration without regional 
differentiation. Subsequent studies about the effect of encapsulated 
multiple epidermal induction factors (EIF) into this kind of mat over 
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the epidermal differentiation potential of adipose-derived stem cells 
(ADSCs) was evaluated. The researchers observed that after 15 days of 
cell culture, the proliferation of ADSCs on EIF encapsulated core-shell 
nanofibers was promoted, demonstrated that the EIF encapsulated 
core-shell nanofibers might serve as a promising tissue engineered 
graft for skin regeneration.  
Byung-Moo Min and co-workers20 fabricated by ES silk fibroin (SF) 
nanofiber nonwovens for cell culture of normal human keratinocytes 
and fibroblasts. They found evidences in the cell activity assessment 
pointing out that the electrospun SF nanofibers were able to promote 
cell adhesion and spreading of type I collagen, because they provided 
a high level of surface area for cells to attach, provided their three-
dimensional feature and their high surface area-to-volume ratio. 
Vatankhah and colleagues59 used electrospun cellulose acetate/gelatin 
membranes to study their potential as effective simulator of the 
structure and composition of native skin and their performance as a 
scaffold for either skin tissue engineering or as a wound dressing was 
evaluated. Their results demonstrated that electrospun Ac/Gel 
scaffolds are able to mimic both the morphological and structural 
features of normal skin and can be used either as a tissue-engineered 
scaffold or wound dressing just modulating their compositional ratios. 
As Curcumin was chosen as model drug for this research some of the 
works related with electrospun system loaded with this compound are 
reviewed in the following lines.  
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Brahatheeswaran and co-worker56,60 used zein protein (a class of 
prolamine protein found in corn) to form fibers for the delivery of 
curcumin, which was only mixed with the ES solution. The hydrolysis 
studies showed a burst release of the drug in the first hours, followed 
by a slight delivery. In vitro assays of zein–curcumin fibrous scaffold 
did not shown to induce any cytotoxic effects in the mouse fibroblast 
system.  
Thi Thu Trang Mai and colleagues61 published their finding with a 
nanofiber Cur-loaded poly(lactic) acid constructed by electrospinning. 
They reported that they were able to obtain PLA nanofiber mats with a 
total drug loading of 5wt% and fibers with mean diameter between 
200 to 300 nm. Drug release kinetic was investigated in phosphate 
buffer saline (PBS) containing ethanol and after 24 h, 50% of the 
curcumin was released from curcumin-loaded PLA fibers.  
Gyuldzhan Yakub and co-workers62 also studied Curcumin-loaded 
poly(l-lactide-co-D,l-lactide) electrospun fibers and analyzed their 
antioxidant, anticoagulant, and antibacterial properties. PEG was 
added in the mixture to also develop other mats with the purpose of 
comparing the effect of the polymeric matrix over curcumin biological 
activity. They found that the polymer matrix composition had an 
impact on the capacity of curcumin to exhibit its antibacterial activity: 
coPLA/Сurc displayed a stronger antibacterial effect than the 
coPLA/PEG/Сurc mats. The fibrous materials obtained were suitable 
for wound dressing applications. 
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Gandhimathi C. and colleagues63 studied biocomposite nanofibrous 
strategies for the controlled release of biomolecules for skin tissue 
regeneration. In this case, the study was performed to gain some 
insights into the applications of poly(l-lactic acid)-co-poly-(ε-
caprolactone) (PLACL)/silk fibroin (SF)/vitamin E (VE)/curcumin 
nanofibrous scaffolds and to assess their potential as substrates for 
the culture of human dermal fibroblasts for skin tissue engineering. 
The electrospun nanofiber diameter obtained was between 198±4 nm 
and 332±13 nm for PLACL, PLACL/SF, PLACL/SF/VE, and 
PLACL/SF/VE/Curcumin nanofibrous scaffolds. The in vitro assays 
showed that the fibroblast proliferation, cell morphology, F-actin, 5-
chloromethylfluoresein diacetate (CMFDA) dye expression, and 
secretion of collagen were significantly increased in 
PLACL/SF/VE/Curcumin when compared to PLACL nanofibrous 
scaffolds. Therefore, they concluded that due the accessibility of 
human dermal fibroblasts cultured on PLACL/SF/VE/Cur nanofibrous 
scaffolds, such systems are proved to be a potential scaffold for skin 
tissue regeneration. Their application is envisage in cell adhesion and 
proliferation to collagen secretion; and help support the sustained, 
localized delivery of biomolecules to the site of interest; so as to 
accelerate wound healing in skin tissue regeneration. 
ES technique is so versatile than it can be successfully adapted to 
elaborate 3D-scaffolds for the healing and repair of diseased 
musculoskeletal tissues, that is a very complex matrix rely on many 
signaling pathways, involving numerous growth factors and their 
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receptors. One of the great challenges in this field, according to Tao 
Jiang et al, is to mimic closely the hierarchical architecture and 
properties of the extracellular matrices (ECM) of the native tissues 38 
However, not always cell adhesion is a property desirable in some 
application. This is the case of the work published by Arnal-Pastor64 
and colleagues. They accomplished to elaborate electrospun 
adherent–antiadherent bilayered membranes based on cross-linked 
hyaluronic acid for advanced tissue engineering applications where 
was sought to transplant cells on a tissue surface and keep them 
protected from the environment. To be more specific, the concept was 
to obtain a patch to prevent post-surgical adherences, which are a 
major issue in many surgeries. In vitro assays with L929 cell line of 
mouse fibroblasts shows very promising results. Their materials 
resulted to be not cytotoxic. Furthermore, the PLLA nanofiber face was 
cell friendly and promotes cell attachment and spreading therefore it 
could be used as a cell supply vehicle, while the HA face hindered cell 
adhesion and thus might prevent undesired adherences. Co-axial 
electrospinning technique was used in this case.  
Likewise, during the last years several studies have been published 
that supports the fact that electrospun fibers can be associated with 
angiogenic and/or vasculogenic factors, epidermal factors and 
molecules with anti-inflammatory and antimicrobial properties to 
favor and enhance skin regeneration19,21,38,58,59,65–69 
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Taking into account the wide range of opportunities, we decided to 
explore the possibilities of composites material which combine ES with 
encapsulation of therapeutic agents directly into de fibers or inside a 
vehicle such as microparticles to promote tissue regeneration/repair.  
The next section summarizes some relevant examples of composite 
systems that include electrospun mats as main component.  
1.2.2 Composite Polymeric scaffolds with Nanofibrous 
architecture  
 
Donald C. Aduba70 and co-workers reported to have fabricated 
electrospun dendrimer-containing nanocomposite fibers with the 
purpose to obtain a functionalized system for drug delivery. In their 
design, the authors took profit of the possibility to chemically 
functionalize the surface groups of dendrimers to form a cross-linked 
network following electrospinning to further enhance structural 
stability and mechanical properties of the dendrimer-based fibrous 
mats. Although further studies must be done in order to assess their 
applicability, these systems represent a potential platform for drug 
delivery and tissue engineering applications. 
Hongxu Qi et al.71 published in 2006 their advances with the 
encapsulation of drug reservoirs in fibers by emulsion electrospinning 
and made preliminary release assessment. This work in particular was 
used as methodological reference for the present research. In this 
paper, they prepared composite fibers via electrospinning from either 
W/O or O/W emulsion and proved this technique to be an effective 
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method for microencapsulation. As a practical application, Ca-alginate 
microspheres, loaded with bovine serum albumin (BSA) as a model 
protein, were prepared in a reverse emulsion and then incorporated 
into poly (l-lactic acid) (PLLA) fibers by electrospinning. In the in vitro 
release test, BSA, which was released from composite fibers, achieved 
prolonged release profiles and lower burst release rates than those 
from naked Ca-alginate microspheres. They conclude that in 
comparison with other well-established techniques to prepare 
microcapsules, such as solvent evaporation and spray-drying 
techniques, emulsion electrospinning offers some advantages and 
opens the gate to try with other emulsion systems to fabricate new 
types of functional structures. 
McCullen and co-workers72, in 2007, were able to fabricate 
electrospun nanocomposites scaffolds by encapsulating multi-walled 
carbon nanotubes (MWNT) in poly (lactic acid) (PLA) nanofibers and 
studied their biocompatibility with adipose derived human 
mesenchymal stem cells. They observed that cells were able to 
proliferate until 14 days after been seeded. Furthermore, the authors 
arrived to the conclusion that, with the addition of MWNT to 
electrospun PLA fibers they are able to reduce the fiber diameter, 
increase the conductivity of the scaffold, and potentially provide a 
functional composite for tissue engineering. 
Ionescu and co-workers 73 in 2010 designed a fabrication technique to 
entrap drug-delivering microspheres within nanofibrous scaffolds to 
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obtain an anisotropic nanofiber/microsphere composite with 
controlled release of biomolecules to promote musculoskeletal tissue 
regeneration. Their results showed that microspheres ranging from 10 
~ 20 microns in diameter could be electrospun in a dose-dependent 
manner to form nanofibrous composites. In this case, the release 
profiles of the composite structures were similar to free microspheres, 
with an initial burst release followed by a sustained release of the 
model molecules over 4 weeks. Furthermore, multiple model 
molecules were released from a single scaffold composite, 
demonstrating the capacity for multi-factor controlled release ideal for 
complex growth factor delivery from these structures. Precisely this 
last characteristic, the multi-facto delivery capability, through an 
alternative way to use microspheres for drug delivery without 
disrupting the scaffold mechanical properties were the main 
contribution of this work. 
Jiqing Xu and co-workers in 2011 published their proposal for 
controlled dual release of hydrophobic and hydrophilic drugs from 
electrospun poly (l-lactic acid) fiber mats loaded with chitosan 
microspheres (CH-MPs). At difference of Hongxu Qi et al work, 
microparticles loaded with BSA (hydrophilic model drug) were 
previously made by spray drying, benzoin (hydrophobic model drug) 
was dissolved directly in PLLA solution and CH-MPs were suspended 
into this solution. Poly(vinylpirrolidone) (PVP) was added into PLLA 
solution to tune drug release behaviors. Their results showed that they 
were able to obtain a dual drug delivery system with sustain and 
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different rate of release for each component (BSA was released faster 
than Benzoin) and the released of both drugs could be adjusted by 
changing the ratio of PLLA/PVP. 
Bhaarath and co-workers 74 published their findings with an 
electrospinning of curcumin loaded chitosan/poly (lactic acid) nanofilm 
and the evaluation of its medicinal characteristics in 2013. According 
to their results the better healing efficiency can be attributed to the 
presence of curcumin and chitosan. The optimal conditions to 
fabricate the nanofilm are: chitosan/PLA, 5.5% (w/v); curcumin, 11% 
(w/v); applied voltage, 20 kV. The maximum release rate was achieved 
between 120 and 360 min, when deposit over polyester and bamboo. 
The in vitro cytotoxicity test conducted on L-929 fibroblast showed no 
toxicity from the curcumin loaded chitosan/PLA nanofilm. In vivo 
wound healing studies on excision and incision wounds created on rat 
model showed significant reduction of wound area when compared to 
untreated group of rat. Finally, they concluded that these results 
suggested that the curcumin loaded chitosan/PLA nanofilm based 
bioactive wound healing material could be developed for wound 
management. 
1.2.3 Polymer therapeutics 
Polymers therapeutics are nanosized composite constructs that 
covalently combine a bioactive agent with a hydrosoluble polymer. 
They are considered the first nano-sized (5-100 nm) polymer-based 
medicines. Their definition involves rationally designed 
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macromolecular drugs and encompasses polymeric drugs (polymeric 
molecules that are biologically active in their own right); polymer-drug 
conjugates; polymer-protein conjugates; polymeric micelles to which 
drug is covalently bound, and multi-component polyplexes being 
developed as non-viral vectors for gene delivery. From the industrial 
standpoint, these nanosized medicines are more like considered ‘new 
chemical entities’ rather than conventional 'drug delivery systems or 
formulations' which simply entrap, solubilize or control drug release 
without resorting to chemical conjugation. 9 
Polymer therapeutics (PT) can be underlined as one of the 
most successful first generation of nanomedicines, with 15 products in 
routine clinical use. Furthermore, 2 of them are within the US Top 10 
selling drugs, the polymeric drug glatiramer acetate for the treatment 
of multiple sclerosis (Copaxone®, Teva Pharm; $3.7 billion), and the 
polymer conjugate polyethylene glycol (PEG)-filgrastim for the 
treatment of neutropenia (Neulasta®, Amgen; $3.6 billion).18 
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Figure 1.2 Schematic representation of the Polymer Therapeutics 
family. Redrawn from Duncan.19 
 
Since the 1940s synthetic polymers have been explored as 
therapeutics with a dramatic increase in publications over the years. 3 
PT are already well-established in the clinics for several treatments as 
single agents or as elements of combination, in particular for cancer 
therapy. The first generation of marketed PT are in Table 1 and those 
in clinical development are represented in Table 2.4 
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Table 1-1  First generation marketed polymer therapeutics. Adapted and updated from refs.14, 40 
Product name Technology Indication Route Information source 
Polymer-protein conjugates 
Zinostatin stimalmer® Styrene maleic anhydride 
neocarzinostatin (SMANCS) 
Cancer-hepatocellular 
carcinoma 
Local via hepatic 
artery infusion 
Yamanouchi
a
 Japan 
Oncaspar® PEG-asparaginase Cancer-acute 
Lymphocytic leukemia 
(ALL) 
i.v./i.m. Enzon
a
 
Peg-intron® PEG-Interferon alpha 2b Hepatitis C s.c. Schering-Plough
a
 
Pegasys® PEG-Interferon alpha 2a Hepatitis C s.c. Roche
a
 
Neulasta
TM
  PEG-hrGCSF Chemotherapy-
induced neutropenia 
s.c. Amgen
a
 
Adagen® PEG-adenosine deaminase Severe combined 
immune deficiency 
syndrome 
i.m. Enzon
a
 
Somavert® PEG-HGH antagonist Acromegalia s.c. Pfizer
a
 
Mircera® PEG-EPO (polyethylene glycol-
epoetin beta) 
Treatment of anemia 
associated with chronic 
kidney disease  
i.v./ s.c. Roche
a
 
Cimzia (certolizumab 
pegol) 
PEG-anti-TNF Fab Rheumatoid arthritis 
Crohn’s disease 
s.c. UCB
a
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Product name Technology Indication Route Information source 
Krystexxa
TM
 pegloticase PEG-uricase Chronic gout i.v. Savient Pharmaceuticals 
Polymer-aptamer conjugate 
Macugen® PEG-aptamer (apatanib) AMD Intravitreous OSI-Eyetech
a
 
Polymer-drug conjugate 
Movantik
TM
/Moventig® 
(NKTR-118) 
PEG-naxolol Opiod-induced 
constipation 
Oral AstraZeneca/ Daiichi 
Sankyo Co, Ltd. 
Polymeric drugs 
Copaxone® Glu, Ala, Tyr copolymer  Multiple sclerosis s.c. Teva
a
 
Renagel® Phosphate binding polymer End stage renal failure Oral  Genzyme (Daiichi Co, Ltd. 
Licensed)
a
 
Welchol® Cholesterol binding polymer Type 2 diabetes Oral Genzyme 
*Ala: Alanine, ALL: Acute lymphoblastic leukemia, AMD: Age-related Macular Degeneration, EPO: Epoetin beta; Fab: Fragment antigen-
binding, HGH: Human Growth Hormone, hrGCSF: human recombinant Granulocyte-Colony Stimulating Factor, i.m.: intramuscular, i.v.: 
intravenous, s.c.: subcutaneous, Tyr: Tyrosine, TNF: Tumor Necrosis Factor. 
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Table 1-2  Examples of polymer therapeutics in clinical development. Adapted and updated from refs
14, 40
 
Product name Technology Indication Route Stage Information source 
Polymer-protein conjugates 
ADI-PEG 20 PEG-arginine deaminase Cancer-hepatocellular 
carcinoma, melanoma 
i.v. Phase III Polaris Group 
Hemospan® MP40X PEG-hemoglobin Delivery of O2 in post-surgery 
and trauma patients 
i.v. Phase III Sangart 
CDP 791 PEG-anti VEGFR-2- 
Fab 
Cancer-NSCLC i.v. Phase II UCB Pharma 
Polymer-aptamer conjugate 
ARC1779 PEG-anti-platelet-
binding function of von 
Eillebrand Factor 
Thrombotic microangiopathies i.v. Phase II Archemix 
E10030 PEG-anti-PDGF aptamer 
combination with 
Lucentis ® 
AMD Local 
intravitreal 
Phase III Ophthotech 
Polymeric drugs 
AMG 223 Phosphate binding 
polymer 
Hyperphosphatemia in CKD 
patients on hemodialysis 
Oral Phase II Amgen 
VivaGel® Lysine-based dendrimer microbiocide Topical Phase III Starpharma 
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Product name Technology Indication Route Stage Information source 
Polymeric Drug-Conjugates 
CT-2103; Xyotax; 
Opaxio 
Poly-glutamic acid 
(PGA)-paclitaxel 
Cancer-NSCLC, ovarian, various 
other cancers and 
combinations 
i.v. Phase III Cell Therapeutics Inc 
Prolindac® HPMA-copolymer-DACH 
platinate 
Cancer-melanoma, ovarian i.v. Phase III Access Pharmaceuticals 
FCE 28068 (PK1) HPMA-copolymer-DOX Breast, lung and colon cancer i.v. Phase II Pfizer 
FCE 28069 (PK2) HPMA-copolymer-DOX Hepatocellular carcinoma i.v. Phase I/II Pfizer 
PEG-SN38 Multiarm PEG-
camptothecan  
Cancer-various i.v. Phase II/III Enzon Inc 
CRLX101  CD-PEG-camptothecin Cancer-various i.v. Phase I/II Cerulean Pharma 
CRLX301 CD-PEG-Docetaxel Solid tumors i.v. Phase I Cerulean Pharma 
DEP
TM
 Docetaxel Dendrimer-Docetaxel Solid tumors i.v. Phase I Starpharma/AstraZeneca 
NKTR-181 PEG-naloxone Chronic pain Oral Phase III Nektar 
NKTR-171 PEG-Na
+
 channel blocker Neuropathic pain Oral Phase I Nektar 
NKTR-102 PEG-irinotecan Cancer-various i.v. Phase II/III Nektar 
XMT-1001 
(Fleximer® based) 
Polyacetal-camptothecin  Cancer-various i.v. Phase I/II Mersana  
XMT-1107 Polyacetal-fumagillin Solid tumors i.v. Phase I Mersana/Teva 
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Product name Technology Indication Route Stage Information source 
Micelles  
SP1049C 
Biotransport
TM
 
Pluronic® formulation of 
DOX 
Cancer-upper GI, NSCLC 
colorectal 
i.v. Phase III Supratek Pharma Inc 
NK 105 
(Nanocarrier® 
technology) 
Paclitaxel block 
copolymer micelle 
Breast cancer i.v. Phase III Nippon Kayaku Co 
NC-6004, 
Nanoplatin
TM
 
Cisplatin block 
copolymer micelle 
Cancer-various i.v. Phase I/II NanoCarrier Co./ Orient 
Neuropharma 
NC-4016 
(Nanocarrier® 
technology) 
Oxaliplatin block 
copolymer micelle 
Solid Tumors i.v. Phase I NanoCarrier Co 
NC-6300 (K-912) Epirubicin bock 
copolymer micelle 
Solid Tumors i.v. Phase I NanoCarrier Co./Kowa 
*CD: Cyclodextrin, CKD: Chronic Kidney Disease, DACH: 1,2-diaminocyclohexane, GI: Gastro-Intestinal, NSCLC: Non-Small Cell Lung 
Cancer, PDGF: Platelet Derived Growth Factor, VEGF: Vascular Endothelial Growth Factor. 
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Clinical proof of concept for Polymer Therapeutics has been already 
achieved, however, many challenges and opportunities still lay ahead 
providing scope to develop this platform technology further. Through 
clinical use of polymer–protein conjugates (Table 1.1), and clinical 
development of polymer–anticancer drug conjugates (Table 1.2), PT is 
already well established as a new therapeutic class not only for cancer 
treatment,36-38 but is also expanding its use to treat diseases other 
than cancer (i.e. PEG–interferon alpha conjugate known as Pegasys® 
or Peg-intron® can be used to cure hepatitis). Besides, many recent 
studies using polymer-drug conjugates have embraced a broad 
number of pathologies, including tissue regeneration.39  
Lessons learned from the development of the first generation of 
polymer conjugates have facilitated the development of an improved 
second generation of PT. These improvements encompass the 
optimization of polymerization techniques and linking chemistry, as 
well as data gained in efficacy profiles, clinical toxicities and side 
effects. Current efforts are directed towards practical and cost-
effective designs for specific targets with defined routes of 
administrations and dosage in order to reach personalize medicine as 
the ultimate goal. Towards this aim, four major research lines are now 
being explored including: : (1) the synthesis of novel biodegradable 
polymeric carriers with defined architectures; (2) the implementation 
of innovative physico-chemical characterization methods; (3) the use 
of polymer-based combination therapy to enhance treatment 
specificity and efficacy always looking for drug synergism and (4) their 
application in diseases other than cancer with an important focus on 
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pathologies related to the aging population and infectious diseases.24,8. 
All these strategies are summarized in Figure1. 3 
 
Figure 1.3. Current research lines in PT field: novel molecular targets 
in cancer as well as other disease, polymer-based combination 
therapy, new architectures and polymeric systems, and an 
exhaustive physico-chemical characterization essential to clinical 
translation following regulatory indications. Redrawn from ref24 
 
Although many early products to market were developed to treat 
infectious diseases and cancer, i.e. life-threatening diseases, as already 
mentioned, there has been a continuing move towards PT directed 
against new molecular targets, and a wider range of therapeutic 
indications; especially those diseases of the ageing population that 
affect quality of life3. In particular application to tissue regeneration 
are one the most exciting and promising areas. In this respect, the 
transfer to market of Cimzia as a treatment for rheumatoid arthritis 
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and Crohn's disease, and Macugen for age-related macular 
degeneration have been important landmarks for PT being developed 
as treatments for chronic diseases that impact of quality of life.3 
 
Progress continues with two polymer therapeutics being featured in 
the US Top 10 selling drugs list for 2013 Neulasta® and Copaxone®, 
and more products are arriving to market as innovator (new) products 
(e.g. Lymphoseek® (Tilmanocept), a mannonsylated dextran-based 
sentinel lymph node imaging agent for melanoma and breast cancer 
patients, and also into clinical trial as ‘follow-on’ (generic) products 
(e.g. PEG-G-CSF (DA-3031)  6 
1.2.3.1 Polymer Conjugates. 
Polymer conjugates are water-soluble, composite constructs designed 
for systemic administration and fall into two main categories, polymer-
protein conjugates and polymer-drug conjugates. Polymer conjugation 
to proteins reduces immunogenicity, prolongs plasma half-life and 
enhances protein stability. Polymer-drug conjugation promotes tumor 
targeting by the enhanced permeability and retention (EPR) effect and, 
at the cellular level following endocytic capture allows lysosomotropic 
drug delivery. 
The original idea of covalently conjugating a low molecular weight 
drug to a hydrophilic polymer carrier to increase its therapeutic effect 
was proposed by Helmut Ringsdorf in 1975. Ringsdorf model consisted 
of four different components: a polymeric carrier, a drug, a 
biodegradable linker and a targeting group. A lot of studies were done 
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in collaboration with Ruth Duncan an Jindrich Kopecek that resulted in 
the clinical evaluation of HPMA copolymer-doxorubicin 
(DOX)(FCE28068, PK1) in 1994, which represented the first synthetic 
polymer-anticancer drug conjugate to be tested in humans5,75. At the 
same time Maeda and colleagues were carrying out studies on 
SMANCS (Zinostatin stimalamer®; a polymer (styrene-co-maleic 
anhydride (SMA))-anticancer protein (neocarzinostatin; NCS) 
conjugate, highlighted for the first time the tendency of 
macromolecules to passively accumulate in the tumor tissue. This 
effect is now well-described and is due to two contributing factors, (i) 
the hyperpermeability of tumor vasculature which allows selective 
extravasation of macromolecules into the tumor, (ii) the lack of an 
effective lymphatic drainage which provides increased retention of 
macromolecules in the tumor. This effect was described by Maeda 
who coined the phrase “enhanced permeability and retention effect” 
(EPR) and it is possibly the most important factor for macromolecular 
targeting to solid tumors25.  For applications in cancer and inflamed 
areas (such as wound healing) polymer-drug conjugation promotes 
passive tumor targeting by the enhanced permeability retention (EPR) 
effect and allows for lysosomotropic drug delivery following endocytic 
capture. 
Both polymer-drug and polymer-protein conjugates are tailor-made 
using a basic tripartite structure and they content a water-soluble 
polymer, a linker and a bioactive agent. It has become clear that the 
molecular mass and physico-chemical properties of the polymer are 
frequently the most important drivers governing biodistribution, 
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elimination and metabolism of the conjugate as a whole. The water-
soluble polymeric carrier must be non-toxic, non-immunogenic and 
suitable for repeated administration. Poly(ethylene glycol) (PEG), poly( 
N-(2-hydroxypropylmetacrylamide)) p(HPMA) copolymers and 
poly(glutamic acid) (PGA) are the most widely tested in a clinical 
setting. Of these polymers, only PGA is biodegradable; consequently, 
the molecular masses of PEG and HPMA copolymers have been limited 
to <40KDa to ensure the eventual renal elimination. In the case of non-
degradable polymers, the polymer-drug or protein linker is an 
important design feature 2 
 Polymer-Drug Conjugates 
The concept of targetable polymer-drug conjugate was develop 
starting from the De Duve realization that the endocytic pathway 
might be useful for “lysosomotropic drug delivery” and the vision of 
Ringsdorf for the idealized polymer chemistry for drug conjugation. 
Drug conjugation to a water-soluble polymer platform restricts cellular 
uptake to the endocytic pathway and hence, allows tumor specific 
targeting of low-molecular-mass chemotherapeutic agents in addition 
to limiting the access of the conjugate to the normal site of toxicity. 
Use of a water-soluble polymers as a platform also helps to solubilized 
hydrophobic drugs, making a more convenient formulation to 
administer intravenously. The ideal polymer-drug linker is stable 
during transport to the tumor, but able to release drug at an optimum 
rate on arrival; because many of the drugs being transported exert 
their effects through an intracellular pharmacological receptor, it is 
essential that drug release actually occurs. Adequate drug carrying 
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capacity, in relation to the potency of the agent being carried, is 
essential, as is the ability to target the tumor by an active (receptor-
ligand) or a passive (pathophysiological) mechanism: both of these are 
important design features 2 
There are several strategies to design intelligent systems able to 
response according to the environment where delivery is desired to be 
accomplished. In this research we are going to focus on systems with  
pH-sensitive polymers25  
There are two main approaches: 1) nanocarriers composed of pH-
sensitive polymers or 2) nanocarriers containing pH-sensitive linkers  
Most of the work on pH-sensitive nanocarriers is based on the first 
approach, with polymers which alter their properties upon changes in 
the pH of the medium. These alterations occur either through 
hydrolytic degradation or through changes in the physicochemical 
properties, resulting in the disassembly of the carrier and thus the 
release of their cargo. 
The pioneering work on polymeric systems comprising pH-sensitive 
polymers was done by Ulbrich and co-workers76, with the synthesis 
and characterization of biodegradable polymeric prodrugs based on 
salicylic acid (the active component of aspirin) linked to 
poly(anhydride-ester). This prodrug was found to be stable under 
acidic conditions (pH 3), but released salicylic acid slowly at normal 
physiological pH (pH 7.4) and more quickly in basic conditions (pH 10), 
owing to the hydrolytic degradation of the polymer backbone. 
Potential applications for systems like this are the treatment of 
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gastrointestinal disease, where release in the basic environment of the 
lower intestine is necessary. 
In the same line, POLYACETALS achieved through the reaction 
between vinyl ether and alcohols were first described by Heller et al. 
(1980)77. These systems can be hydrolyzed under mildly acidic 
conditions (pH 6.5), but are stable at physiological pH (7.4) as shown 
by Tomlinson et al in 200278. Later in 2003 they also demonstrated a 
prolonged blood half-life and enhanced tumor accumulation for 
aminopendant polyacetal (APEG)–doxorubicin (DOX) conjugates when 
compared to the clinical conjugate N -(2-hydroxypropyl) 
methacrylamide (HPMA) copolymer−DOX, as well as lower liver and 
spleen uptake. In vitro cytotoxicity analysis confirmed that the serinol-
succinoyl-DOX released during degradation remained active. In vivo 
studies were also performed in B16F10 melanoma-bearing mice79. A 
further step was reported by Vicent et al. in 200480 when the non-
steroidal oestrogen diethylstilbestrol (DES) was incorporated within 
the polyacetal main chain. The first pH-responsive polymeric (tert-DES) 
drug adequate for lysosomotropic delivery was achieved in this way. 
These conjugates rapidly released DES at acidic pH (65% in 96h at pH 
5.5) but were stable at neutral environment (4% in 96h at pH 7.4). 
Furthermore, the second generation of DES-polyacetals12,81 with more 
controlled solution conformation has recently been described by 
Giménez et al in 2012 81. 
Following similar strategies, Tang and co-workers reported in 2010 the 
synthesis and characterization of similar systems based on curcumin-
polyacetals82, which were shown to be highly cytotoxic in vitro against 
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ovarian and breast cancer cell lines (SKOV-3, OVCAR-3 and MCF-7) and 
in vivo, with remarkable antitumor activity in a SKOV-3 ovarian cancer 
model in mice.  
Recently, England et al. (2012) 12 confirmed the versatility of these 
carriers by reporting the first family of nanomedicine (polyacetal–
stilbene conjugates) modulators of hypoxia inducible factor-1 (HIF-1), 
a key transcription factor involved in key cell processes. 
The second strategy, based on nanocarriers containing pH-sensitive 
linkers often applied in the design of pH-sensitive nanoconstructs is 
the responsiveness of the polymer–drug linker. Hydrazone (HYD) 
(R1R2C=NNH2) is one of the best known within this family, mostly via 
pioneering work from Ulbrich’s group. In their studies the behavior of 
HYD-linked DOX to HPMA copolymer has been exhaustively described, 
with important therapeutic efficacy in vivo upon injection in tumor-
bearing mice.76,83–85 
Another pH-sensitive linker used for the preparation of smart 
nanocarriers for drug delivery is the cis-aconitic spacer. Choi et al., in 
1999, conjugated DOX to HPMA through this spacer and observed 
increased release in acidic pH, resulting in significant cytotoxicity upon 
incubation with human ovarian carcinoma cells. 
Interestingly, in a subsequent paper, Ulbrich et al (2003) compared 
HPMA–DOX conjugates containing DOX bound either through HYD or 
through a cis-aconitic spacer. A slower release from the cis-aconitic 
conjugates was observed at pH 5 as compared to the HYD ones, as well 
as a lower cytotoxicity in vitro. Consequently, the aconityl conjugates 
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did not show any therapeutic effect in vivo, indicating that drug 
release from the conjugate occurred but was not sufficient to result in 
therapeutic efficacy. 
 Polymer-Protein Conjugates 
David Abuchowski86 and colleagues in 1970s carried out pioneering 
researches and developed the concept of polyethylene glycol (PEG)-
protein conjugation (PEGylation).  
The continuing entry of PEGylated proteins into the routine clinical use 
has been responsible for a paradigm shift in the acceptance of polymer 
based macromolecular medicines. This technique is used to increase 
protein solubility and stability, and reduce protein immunogenicity; 
moreover, polymer conjugation prolongs plasma half-life through 
prevention of renal elimination and avoidance of receptor-mediated 
protein uptake by cells of the reticuloendothelial system (RES)25.  
Consequently, polymer-conjugated therapeutics requires less frequent 
dosing, which is a great benefit to the patient. For an optimized 
synthesis of a polymer-protein conjugate, a semi-telechelic polymer 
(one with a single reactive group at one terminal end) is required to 
avoid protein cross-linking during conjugation; the linker used must be 
carefully chosen to ensure that the linking chemistry will not generate 
toxicity or immunogenicity. Appropriate stability characteristics and 
reproducible site specific protein modification are also required2,25.  
Linear and branched PEGs of different molecular masses can be used 
but this is very important because it has a great impact on their 
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pharmacokinetics.  PEGylation could reduce the protein bioactivity but 
degradable PEG-protein linkage can be used to maximize the protein 
bioactivity25. 
Another important findings in this field has been reported by 
Hardwicke et al. (2008)87, who designed Dextrin-rhEGF conjugates as 
bioresponsive nanomedicines for wound repair. These systems have 
very interesting application in impaired dermal wound healing like 
venous leg ulcers, diabetic foot ulcers and pressure sores. It is known 
that growth factors act in concert to promote wound repair, but their 
topical application rarely leads to a significant clinical improvement of 
chronic wounds due to premature inactivation in wound environment. 
The aim of this study was to synthesize a polymer–growth factor 
conjugate and investigate whether the novel concept called Polymer-
masking-UnMasking-Protein Therapy (PUMPT) might be used to 
generate bioresponsive PT as nanomedicines able to promote tissue 
repair. The biodegradable polysaccharide dextrin, and recombinant 
human epidermal growth factor (rhEGF) were chosen here as models. 
It was expected that dextrin-rhEGF conjugate has the potential to treat 
acute and chronic wounds, most simply by topical administration or 
alternatively, via intravenous (i.v.) administration, to localize the rhEGF 
using enhanced vascular permeability at sites of inflammation (EPR 
effect). 
Succinoylated dextrin ( 85,000g/mol; 19mol% succinoylation), and 
rhEGF were chosen as a first model combination. The conjugate 
synthesized contained 16%wt rhEGF and <1% free protein. It 
exhibited increased stability towards proteolytic degradation by 
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trypsin and the clinically relevant enzyme neutrophil elastase. The 
dextrin component was degraded upon addition of α-amylase leading 
to sustained release of free rhEGF over time (52.7% release after 
168h). When biological activity was assessed (±α-amylase) in 
proliferation assays using epidermoid carcinoma (HEp2) cells and 
HaCaT keratinocytes, as anticipated, polymer conjugation reduced 
rhEGF bioactivity (p=0.0035). However, exposure to physiological 
concentrations of α-amylase triggered dextrin degradation and this led 
to protein unmasking with restoration of bioactivity to the level seen 
for unmodified rhEGF. Indeed, prolongation of HEp2 proliferation was 
observed over 8days. The inability of dextrin, succinoylated dextrin or 
α-amylase alone to induce proliferative effects, and the ability of α-
amylase-exposed dextrin–rhEGF to induce phosphorylation of the 
epidermal growth factor receptor (EGFR) in HEp2 cells confirmed a 
mechanism of action by stimulation of classical signal transduction 
pathways.  
These observations suggested that this dextrin–rhEGF, and other 
dextrin-growth factor conjugates have potential for further 
development as bioresponsive nanomedicines for tissue repair87 
Polymer conjugates in tissue regeneration  
One of the first approaches in using polymer conjugates to promote 
tissue repair was published by Shaunak et al.(2004). They synthesized 
polyvalent dendrimer glucosamine conjugates to prevent scar tissue 
formation. Dendrimers are hyperbranched synthetic macromolecules 
that can be made using controlled sequential processes to give them 
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defined structural and molecular weight characteristics. The authors 
conjugated anionic polyamidoamine generation of 3.5 (PAMAM) 
dendrimer (Dendritech) with the aminosaccharides D(+)glucosamine 
and D(+)glucosamine-6-sulfate to obtain water-soluble conjugates 
with immuno-modulatory and antiangiogenic properties respectively. 
In vitro studies showed dendrimer glucosamine inhibited Toll-like 
receptor 4-mediated lipopolysaccharide induced synthesis of pro-
inflammatory chemokines and cytokines from human dendritic cells 
and macrophages but allowed upregulation of the costimulatory 
molecules CD25, CD80, CD83 and CD86. Dendrimer glucosamine 6-
sulfate blocked fibroblast growth factor-2 mediated endothelial cell 
proliferation and neoangiogenesis in human Matrigel and placental 
angiogenesis assays. Both conjugates were used in combination in a 
validated and clinically relevant rabbit model for scar tissue formation 
after glaucoma filtration surgery and they notice combination 
increased the long-term success of the surgery from 30% to 80% 
(p=0.029). Finally they concluded that dendrimers tailored to have 
specific immune-modulatory and antiangiogenic properties can be 
designed and used synergistically to prevent scar tissue formation. 
Vicent M. and Perez-Payá (2006) developed the first antiapoptotic 
polymer conjugate nanomedicine that has been demonstrated to have 
therapeutic potential as a targeted drug delivery system that offers 
great capabilities as an inhibitor of apoptosis or programmed cell 
death. Apoptosis is a key cellular mechanism involved in a broad range 
of physiological processes. Deregulated apoptosis is associated with 
several human pathologies, such as cancer, ischemic injuries, and 
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neurological disorders. The aim of this study was to design, synthesize, 
and characterize a polymer conjugate that, by carrying a novel 
apoptotic protease activating factor 1 (Apaf-1) inhibitor (peptoid), 
would rescue cells from inappropriate apoptosis. Poly-L-glutamic acid 
(PGA) was chosen as a polymeric carrier because it can be readily 
degraded by lysosomal enzymes, it is stable in plasma, it contains 
functional groups for drug attachment and has excellent 
pharmacological properties. The rational of this study was based on 
the fact that to accomplish the full therapeutic potential of a bioactive 
agent, it is crucial that it is delivered to the disease area. It is known 
that PT can ensure the efficient release of the bioactive agent to the 
required intracellular compartment within and specific period of time. 
Therefore they conjugate the peptoid they had previously developed, 
a new structural class of Apaf-1 ligands (peptoid 1) as apoptosome 
inhibitor, with PGA to increase its therapeutic potential. They actually 
observed that this macromolecule PGA-peptoid 1 clearly enhance the 
antiapoptotic activity of peptoid 1 and diminish it cytotoxicity in 
different cell models. 
Another important finding in this field has been reported by Hardwicke 
et al.87, who designed Dextrin-rhEGF conjugates as bioresponsive 
nanomedicines for wound repair. These systems were previously 
described in section of polymer-protein conjugates. 
One of the most recent approaches in this field was published by 
Conejos et al. in 2014 88. They proposed a novel specific nanoconjugate 
for the treatment of amyloidosis, and in particular familiar amyloidotic 
polyneuropathy. Their rational design started from an active 
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biomolecule of peptidic nature (RAGE peptide) that recognizes the TTR 
prefibrillar aggregates responsible to promote cell death in FAP 
patients. The clinical progress of this promising inhibitor was masked 
by the well-known limitations of peptides, such as low solubility, low 
stability and possible immunogenicity. PEGylation through various 
linking strategies was successfully accomplished here as a solution for 
the named drawbacks, using a systematic approach to maintain 
peptide activity and receptor binding specificity. The data relating to 
TTR binding affinity, conjugate linker stability and the conjugate size 
distribution in solution of PEG–RAGE peptide conjugates indicated that 
the conjugates containing amide linkers have the greatest potential for 
further development as FAP inhibitors. Moreover, this novel conjugate 
has promising possibilities as a FAP therapeutic to be used alone in the 
early stages of the disease or as part of rationally designed 
combination therapy. Preliminary in vivo studies (biodistribution) 
demonstrated the enhanced plasma stability of the peptide upon 
conjugation, showing no specific accumulation in any organ and renal 
excretion88.  
Conejos et al. (2015),13 also proposed a novel library of PGA-
doxycycline (DOXY) conjugates that were rationally designed to treat 
an inherited rare amyloidosis, FAP, with no current pharmacological 
clinical treatment available in particular for advanced disease stages. 
Screening their activity as fibril disrupters, PGA-CONH-DOXY 
conjugates bearing non-biodegradable polymer-drug linkers, showed 
the best response within all conjugates synthesized and parent drugs, 
promoting a greater activity at equal doxy equivalents. This fact 
confirmed that drug release was unnecessary to induce TTR fibril 
 78 
 
disruption. PGA-X-DOXY conjugates were not hemolytic and were 
stable after plasma incubation, which confirmed their suitability for i.v. 
administration. With the selected candidate, biodistribution 
experiments were performed through optical imaging and Positron 
emission tomography (PET) techniques. Studies agreed on a clear renal 
elimination of the conjugate and a non-specific accumulation in any 
organ, establishing the suitability of the carrier for the purposed 
objective. A deeper understanding on organ toxicity through 
histological analysis disclosed a typical morphology structure without 
toxic evidences, corroborating the safety of the conjugate. Future 
directions will encompass in vivo evaluation in old FAP model, the 
possible development of combination therapies as well as the possible 
application in other amyloid-related diseases where doxycycline has 
evidenced its potential13. 
As can be notice either drug delivery systems based on nanofiber 
scaffolds as well as the polymers therapeutics controlled release 
systems are very promising for novel therapeutic strategies, this is the 
reason why in the present work they are combined to increase their 
efficiency for a local application, exploring the potential of composite 
systems in tissue regeneration. 
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2 OBJECTIVES 
2.1 General Objective 
The general objective of this thesis is based on the design and 
development of intelligent composite system for tissue regeneration 
through the combination of biomaterial science and nanoconjugate 
synthesis, in order to have a well-defined biodegradable and 
biocompatible system with dual mechanism of control on drug release 
kinetics, and with the possibility to be used on different clinical 
applications, such as implants in damaged tissue. This overall goal can 
be broken down into different individual specific objectives as 
highlighted in the following epigraphs. 
2.1 Specific Objectives 
 Design and development of novel biodegradable polymeric 
carriers based on the versatile pH-sensitive polyacetals with 
improved properties (good solubility, reduced polydispersity, 
higher loading capacity) as potential carriers to be used in the 
synthesis of polymer conjugates in combination with 
biodegradable polymeric scaffold. 
 Design, synthesis and characterization of polymer-drug 
conjugates of model drugs and/or polymer-proteins 
conjugates with model proteins as prototypes, both with a 
specific biological activity to promote cellular proliferation and 
tissue regeneration in vitro. 
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 Design, synthesis and characterization of controlled and well-
defined reproducible Microparticles of biocompatible and 
biodegradable materials such as hyaluronic acid, to serve as 
polymeric scaffolds to encapsulate the polymer conjugates 
selected from previous objectives. 
 Design and construction of a biocompatible device based on 
poly-L-lactic acid  in order to develop highly versatile patches 
as ultimate platform to incorporate the microparticles bearing 
polymer conjugates. This system will allow us to modulate 
drug release kinetics in applications that require localized 
supplied of medicines to promote tissue regeneration. 
 Systematic in vitro studies of drug release kinetics at different 
pHs of polymer conjugates alone, after their inclusion within 
the scaffolds, and compared with the same system but loaded 
with free drug without previous conjugation.  
 In vitro and in vivo evaluation of the systems, including 
cytotoxicity and proliferation studies in selected 
representative cell lines 
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Figure 2.1.  General flow diagram of research objective 
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3 MATERIALS AND EXPERIMENTAL 
TECHNIQUES 
3.1 Materials 
3.1.1 Polymers 
3.1.1.1 Poly(ethylene glycol) (PEG): 
Chemical named as alpha-Hydro-omega-hydroxypoly(oxy-1,2-
ethanediyl) is a polyether compound with many applications from 
industrial manufacturing to medicine. It is soluble in water, methanol, 
ethanol, acetonitrile, benzene, and dichloromethane, and is insoluble 
in diethyl ether and hexane. It is coupled to hydrophobic molecules to 
produce non-ionic surfactants89. 
Specifically in medical applications, PEG is frequently used as an 
excipient in many pharmaceutical products, was approved by the FDA 
for been used as the basis of laxatives, and the most relevant for this 
research porpoise, several PEGylated-proteins nanomedicine have 
been also approved for clinical regular use in treatment of different 
diseases as for example PEG-interferon alpha, which is used to treat 
hepatitis C, as it was previously described in the introduction section 
about Polymer Therapeutics.  
For this research platelets of PEG with average molecular weight Mn 
4000, were used as supplied from Sigma-Aldrich (Dorset, UK), as one 
of the monomers in the synthesis of poly(acetals). 
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Figure 3.1. PEG4000 Chemical Structure  
 
Functionalized PEG were used in order to synthesize two families of 
PEGylated-trypsin conjugates.  
 
3.1.1.2 α-methoxy-ω-carboxylic acid poly (ethylene glycol) (MeO-
PEG-COOH),  
First family, with MeO-PEG-COOH of different molecular weights: 1) 
MW=20000Da with Mw/Mn=1.08; 2) Mw=11153Da, with 
Mw/Mn=1.08, and 3) Mw=1892Da with Mw/Mn=1.00.  These products 
were used as supplied by IRIS Biotech GmbH (Germany). 
H3CO
O
COOH
n  
Figure 3.2. MeO-PEG-COOH Chemical Estructure 
 
3.1.1.3 α-methoxy-ω-hydroxyl poly (ethylene glycol) (MeO-PEG-
OH),  
Second family with MeO-PEG-OH of different molecular weights: 1) 
MW=20000Da with Mw/Mn=1.08; 2) Mw=11153Da, with 
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Mw/Mn=1.08, and 3) Mw=1892Da with Mw/Mn=1.00, These products 
were used as supplied by IRIS Biotech GmbH (Germany). 
H3CO
O
OH
n  
Figure 3.3.. MeO-PEG-OH Chemical Estructure 
 
3.1.1.4 Poly(L-lactic) acid (PLLA),  
PLA or poly-lactide was discovered in 1932 by Carothers (at DuPont).  
In comparison to other biopolymers, the production of PLA has 
numerous advantages including: (a) production of the lactide 
monomer from lactic acid, which is produced by fermentation of a 
renewable agricultural source corn; (b) fixation of significant quantities 
of carbon dioxide via corn (maize) production by the corn plant; (c) 
significant energy savings; (d) the ability to recycle back to lactic acid 
by hydrolysis or alcoholysis; (e) the capability of producing composite 
paper-plastic packaging that is compostable; (f) reduction of landfill 
volumes; (g) improvement of the agricultural economy; and (h) the all-
important ability to tailor physical properties through material 
modifications90. Briefly, PLA is based on agricultural (crop growing), 
biological (fermentation), and chemical (polymerization) sciences and 
technologies. 
It is classified as generally recognized as safe (GRAS) by the United 
State Food and Drug Administration (FDA) and is safe for all food 
packaging applications (Conn and others 1995; FDA 2002).91  
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Likewise, in the field of regenerative medicine, different devices made 
of PLA have been thoroughly study with very promising results.  For all 
this reasons it was decided to use PLA as bulk material to prepared 
thin microporous membranes through the technique of 
electrospinning. 
PLA used for this research was supplied by Ingeo™ Lactides, 
Natureworks, is a commercial amorphous PLA, specific for injection 
mold grade and having a 96:4 L:D ratio content and MW 66000g/mol. 
*
O
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Figure 3.4. Poly(L-lactic) acid (PLLA) Chemical Structure 
 
3.1.1.5 Hyaluronic acid sodium salt (HA): 
HA is a linear polysaccharide composed of alternating d-glucuronic 
acid (GlcUA) and N-acetyl-d-glucosamine (GlcNAc) units.  This anionic, 
non-sulfated glycosaminoglycan is the major component of the ECM.  
It is widely distributed in connective, epithelial and neural tissue92. 
Hyaluronan, as is also known, due to its ionic nature, interacts with a 
number of cell surface receptors, such as CD44, RHAMM (receptor for 
HAmediated motility) and ICAM-1 (intercellular adhesion molecule 1) 
and contributes to tissue hydrodynamics, cell proliferation and 
migration.  Due to its high biocompatibility and low immunogenicity, 
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HA is gaining popularity as a biomaterial for tissue engineering and 
tissue regeneration93. 
For this research HA was used as row material to obtain micro-
particles cross-linked with di-vynyl-sulfone, which were loaded with 
drugs, proteins and the respective polymeric conjugates, in order to 
study the release kinetic of each system afterward.   Hyaluronic acid 
sodium salt from Streptococcus equi (HA, Poly(β-glucuronic acid-
[1→3]-β-N-acetylglucosamine-[1→4]), alternating) supplied by Sigma-
Aldrich, with average Mw 1.63x106 Da. 
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Figure 3.5. Chemical Structure of hyaluronic acid (HA). 
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3.1.1 Model Drugs  
Curcumin (Cur) 
This hydrophobic small drug is a natural polyphenolic compound, 
extracted from Curcuma longa, with proof anti-oxidant, anti-
inflammatory, antiviral, antimicrobial and anticancer activity28–31 
Curcumin ≥95% (HPLC) powder, was supplied by sigma-aldrich. 
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Figure 3.6. Chemical structure of curcumin 
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3.1.2 Model Protein 
Trypsin  
It is protein with proteolytic enzymatic activity frequently used as 
model protein for evaluation of controlled drug delivery systems32–34 
In this work it was used Trypsin from porcine pancreas, Type IX-S, 
presented as a lyophilized powder, of 13,000-20,000 BAEE units/mg 
protein.  Protein was supplied by Sigma-Aldrich 
Porcine Trypsin [Green: Backbone, Red: Disulfide bonds]
http://prince.openwetware.org/FASP.html  
Figure 3.7.  Virtual Model of trypsin 
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3.1.3 Chemical reactive and solvents. 
Tri(ethylene glycol) divinyl ether (TEGDVE), poly(ethylene glycol) (PEG) 
Mw 4000Da, p-toluenesulfonic acid monohydrate (p-TSA), 2-amino-
1,3-propanediol (Serinol), 9-Fluorenylmethyloxycarbonyl chloride 
(Fmoc-Cl),  succinic anhydride, , Dioctyl sulfosuccinate sodium salt, 
98% (AOT), Divinylsulfon 97% (DVS), 4-(Dimethylamino)pyridine 
(DMAP) purum ≥98.0%, N,N-Diisopropylethylamine (DIEA) reagent 
plus, 1,4-dithio-dl-threitol (DTT), bromophenol blue ACS reagent, 
ammonium persulfate (APS) for electrophoresis, Nα-benzoyl-D,L-
arginine-p-nitroanilide hydrochloride (L-BAPNA), Bradford solution,  2-
mercaptoethanol, 2,4,6-trinitrobenzene sulfonic acid (TNBS), N-
hydroxysuccinimide 98% (NHS) and N-hydroxysulfosuccinimide sodium 
salt (sulfo-NHS) ≥98.5% were used as supplied from Sigma-Aldrich 
(Dorset, UK). Diisopropilcarbodiimide (DIC), 1-ethyl-3-
(3dimethylaminopropyl) carbodiimide hydrochloride (EDAC), 1-
hydroxybenzotrialzole monohydrate 99.7% (HOBT), were supplied by 
IRIS Biotech GmbH (Germany)., Triethylamine was from Fluka Chemika 
(Masserschmittstr, D). 
AppliChem(Germany) supplied 2,2’-dihydroxy-(2,2’-bi-indan)-1,1’,3,3’-
tetrone (Hydrindantin dihydrate). Ninhydrin GR for analysis was from 
MERCK (Germany).  Tris(hydroxymethyl)aminomethane (Tris base) and 
sucrose were from Roche Biotest.  Glycine (Gly), sodium dodecyl 
sufate (SDS), N,N,N,N’-tetramethylethylendiamine (TEMED), were 
from VWR (Germany).  A 40% solution of acrylamide/bis(acrylamide) 
(ratio 29:1, 3.3%C) Acrylamid: N,N’-methylenbisacrylamid 
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electrophoresis purity reagent from Bio-Rad Laboratories (United 
States of America). 
Solvents: 2,2,4-Trimethylpentane (isooctane) CHROMASOLV®, for 
HPLC, ≥99%, 1-heptanol 98% (1-HP) was used as supplied from Sigma-
Aldrich (Dorset, UK)., Tetrahydrofuran (THF) anhydrous (before use, 
THF was distilled from a sodium-benzophenone solution.), N,N-
dimethylformamide (DMF) were from Fluka Chemika 
(Masserschmittstr, D). Dichloromethane (CH2Cl2) synthesis grade with 
approx. 50ppm of amylene, Ethanol (EtOH) absolute GR for analysis, 
Methanol (MeOH) HPLC grade and acetonitrile (AcCN) HPLC grade 
were from Scharlau (Spain). ), n-hexane analytic grade were from VWR 
(Germany) The solvents used to obtain 1H RMN and 13C RMN spectra 
were chloroform-d 99.8 atom %D (CDCl3), deuterium oxide 99.8 atom 
%D (D2O) from Carlo Erba Réactifs-SDS (France), and Dimethyl 
sulfoxide-D6 99.8% from MERCK (U.K.). 
Resins for liquid chromatography Sephadex LH-20 and Sephadex G-10 
and pre-packet PD-10 columns were from GE healthcare (U.K.). 
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3.2 Experimental Techniques  
3.2.1 NMR Spectroscopy:  1H and 13C.  
Professor Joseph P. Hornak from Rochester Institute of Technology, 
explain on his book “The Basis of NMR” that Nuclear magnetic 
resonance, or NMR, is a phenomenon which occurs when the nuclei of 
certain atoms are immersed in a static magnetic field and exposed to a 
second oscillating magnetic field.  Nuclear magnetic resonance 
spectroscopy is the use of the NMR phenomenon to study physical, 
chemical, and biological properties of matter. As a consequence, NMR 
spectroscopy finds applications in several areas of science. NMR 
spectroscopy is routinely used by chemists to study chemical structure 
using simple one-dimensional techniques. Two-dimensional 
techniques are used to determine the structure of more complicated 
molecules94.  
In this experimental work, this technique was applied to corroborate 
the structures of polytacetals synthetized, their purity and effective 
drug loading after conjugation reaction. 
Nuclear Magnetic Resonance analyses were performed using a 
BRUKER ADVANCE AC-300 (300 MHz) spectrometer in Centro de 
Investigación Príncipe Felipe in Valencia and NMR data were 
processed using the program Topspin 1.3 (Bruker GmbH, Karlsruhe, 
Germany). The chemical shifts of the nucleus are reported as s 
(singlet), d (doublet), t (triplet), q (quartet) or m (multiplet) and 
expressed by  (ppm) taking as an intern reference the 
tetramethylsilane signal (TMS) 0.00 ppm, and the intermediate signal 
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in the quintuplet (49.86 ppm) in the carbon spectra. The J-coupling 
constants are expressed in hertzs (Hz). Besides 1H and 13C NMR 
experiments, two-dimensional NMR experiments were done also to 
including Correlation spectroscopy (COSY), and Diffusion-ordered 
spectroscopy (DOSY) to remove spectral overlap, facilitates spectral 
assignment, and obtain information related to number of different 
species present in a sample, available from resonance intensities and 
the diffusion coefficient of the polymers obtained.   
3.2.2 UV Spectrophotometer.   
UV spectroscopy technique was used to determine total drug loading 
in polymer-protein and polymer-drug conjugates, dissolving the 
compounds in PBS 1X pH 7.4 to prepare solutions of 1 to 3 mg/mL in 
polymer, depending on the absorbance on each case. 
The calibration curve was built using a solution of de drug/protein that 
it was pretend to conjugate dissolved in the same solution than the 
polymer.   
Hydrophobic drug was previously dissolve in ethanol and then diluted 
in PBS 1X pH 7.4. 
Measurements were done with an UV-Vis double-beam 
spectrophotometer with single monochromator to cover a spectral 
wavelength range from 190 to 2700 nm.  Equipment model was Jasco 
UV-670. Samples were analyzed in quartz cuvettes with a light path 
1mm.   
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3.2.3 Gel Permeation Chromatography (GPC).  
GPC, is an important analytical tool used to evaluate polydispersity 
(PDI) and molecular weight (Mw) characteristics of natural or synthetic 
polymers and proteins. Unlike HPLC, GPC relies, under ideal 
conditions, on a pure physical separation, where theoretically no 
chemical interactions of the sample with the GPC column (stationary 
phase) should be observed95,96.   To be more precise, GPC separates 
molecules upon their size in solution, which is directly proportional to 
their hydrodynamic volume (Vh).  
Calibration was accomplished with well-defined poly(ethylene 
glycol)/Polyethylen oxide (PEG) standards (GPC calibrating kit, supplied 
by MERCK) in order to be able to use them as reference to stablish a 
relative comparison with the polymers synthesized as part of this 
research, making possible to applied GPC technique to determine 
molecular weights of polymeric conjugates as well as following their 
degradation profile in solution at different pH (7.4, 6.5, 5.5) with time. 
Gel permeation chromatograms were obtained in DMF/THF and 
Phosphate buffer solution (1X, pH 7.4) using two Waters Styragel 
7.8x300mm Columns (HR3 and HR4) for DMF and two TSK-Gel 
Columns (G2500 and 3000) for samples in PBS and a Viscotek TDA 302 
triple detector Array with refractive index (RI), Small Angle Light 
Scattering, Right Angle Light Scaterin, viscosimeter and a model 2501 
UV as detector. OmniSec v.4.1 software was used to calculate the 
polydispersity (Mw/Mn) and molecular weight (Mw) characteristics. 
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Mobile phase preparation. 
Aqueous mobil phase.    First, a 10X PBS solution was prepared by 
dissolving the compound mentioned below in the amounts specified in 
the table X in 1 L de-ionized, double distiled water.   Then, 1L of PBS 1X 
pH 7.4 solution was prepared by dilution, using  a 1L volumetric flask 
and a graduated cylinder to be accurate.  Following this protocol the 
final solution should be pH 7.4, and it was corroborated with a pH-
meter.  This way the variability of composition, ionic strength or pH in 
the mobile phase was prevent. The solution was then filtered through 
a nylon membrane filter (0.2 μm) and sonicated for 30min before use. 
Organic mobil phase. THF (2.5 L bottle), of HPLC grade already 
stabilized with BHT (250 ppm) by the supplier was used as organic 
mobile phase. The solvent was used without further preparation 
because system was equipped with a degasser. 
Sample preparations and running conditions 
For the GPC measurements, samples were prepared with a known 
concentration (6mg/ml, 2 mL) dissolved in the previously prepared 
mobile phase (THF or PBS).  Prior injection, the samples were filtered 
through single-use syringe filters with 0.2 μm nylon membrane. Then 
100 μL of samples were loaded into the loop by the automatic sampler 
system, and running for 35min or 60min, at 30 °C with a 1mL/min flow 
rate. 
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3.2.4 Reverse Phase High performance liquid chromatography (RP-
HPLC)  
To determined free drug amount in polymer-drug conjugates, samples 
of 3mg/mg dissolved in ACN were analyzed using RP-HPLC technique.  
Calibration curve was built using solutions of different concentrations 
of the model drug dissolved in ACN. 
Analyses were performed with a Shimadzu analytical HPLC system 
using 717plus auto-sampler and a LIChroCART®, Cat.1.50943 
LIChrospher® 100, RP-18 (125 x 4 mm, 5 µm) column (Lot. L 56118817 
No. 721869) purchased from Waters Ltd. (UK).   Buscar datos de HPLC 
del -1 y de CBIT 
3.2.5 Fast Protein Liquid Chromatography (FPLC)  
This instrument was an AKTA PURIFIER from Amersham Biosciences 
(now GE Healthcare) it has a dual-pump system (P900) with a Monitor 
pH/C-900 for On-line measurement of pH and conductivity. The 
machine is provided with an online UV detector (UV-900) which can be 
set for a maximum of three wavelengths covering a range from the far 
UV region (214nm) to the visible range (700nm).  System includes an 
injector (INV-907) and a fraction collector (FRAC-900). It is handled 
with software Unicorn 4.11.  In this case it was used a column HiPrep 
Sephacryl S300 XK26/60 and a column Superdex 200; both were 
purchased from GE Healthcare Bio-Sciences.  
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3.2.6 Circular Dicroism (CD) Spectrophotometer  
This instrument was a Jasco J-1100, wavelength range 180 – 600 nm, 
sample were measure with microsampling quartz cuvettes.  
All these equipments are located at Centro de Investigación Príncipe 
Felipe (Spain). 
3.2.7 Differential Scanning Calorimetry (DSC)  
Measurements were done with a METTLER-TOLEDO DSC model 823e 
(Mettler-Toledo Inc., Columbus, OH, USA) to determine thermal 
properties of different materials. Samples were accurately weighted in 
standard 30µL aluminum pans and pierced.  Scanners were undergone 
precooling samples from room temperature to -30ºC at 10ºC/min, 
then analyses were programed to follow three cycles: heating-cooling-
heating, since -30ºC to 300ºC and back.    Row data was processed 
with the software that is provided with the equipment (MettlerSTARe 
software) to determine values of glass transition (tg) and heat capacity 
(ΔCp). 
3.2.8 Thermo Gravimetric Analysis (TGA)  
The equipment used was a METTLER-TOLEDO model TGA/SDTA 851 
operated through the software provide with the device STARexx. 
Samples were weighted in platinum crucibles and scanned from 30ºC 
to 800ªC at 10ºC/min under N2 flow of  20mL/min. 
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3.2.9 Particle Size Analyzer 
The instrument used for measuring particles average size was Malvern 
instrument, model Mastersizer 2000, Laser light scattering, based on 
Mie and Fraunhofer scattering analytical methodology.  Data 
acquisition rate was 1 kHz; Optic system is composed by a Red light 
source (Max. 4mW He-Ne, 632.8nm), a Blue light source (Max. 0.3mW 
LED, 470nm), and Reverse Fourier (convergent beam) Lens 
arrangement.  Particle size range measurement is 0.02 - 2000 µm, 
depending on sample and sample preparation, with accuracy better 
than 1% (polydisperse standard) and reproducibility better than 1% 
variation (polydisperse standard).  Data Analysis was accomplished 
with Malvern Software Mastersizer 2000 v.5.60.    
3.2.10 Contact angle measurements. 
Materials surface wettability was estimated with a equipment 
Dataphysics OCA (DataPhysics Instruments GmbH, Filderstadt, 
Germany), measuring the contact angle between the material surface 
and a distilled water drop. Final values are the average from at list 10 
measures by each sample. 
3.2.11 Mechanical Tensile test.  
The stretching assay of electrospun mats were performed in a stress-
strain machine model Microtest SCM3000 95 (Microtest SA, Madrid, 
Spain). Samples were cut as rectangles of 0.5 x 1.5 cm2 approximately.  
Stress rate was 0.2mm/min until fracture.  Row data was process and 
plotted as stress (σ)-strain (ε), in order to calculate the elastic moduli 
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from the slope of the linear region of the curves.  Final value is the 
average of at least 5 measures.  
3.2.12 Scanning Electron Microscopy (SEM).   
Equipment JEOL model JSM-6300 (JEOL Ltd., Tokyo, Japan) was used 
with samples previously sputter-coated with gold under vacuum. 
Analyses were carried out at 15kV of acceleration voltage and 15mm 
of distance working.     
3.2.13 Optical Microscopy.   
NIKON Eclipse microscope, model E6000, with objectives x20, x50 and 
x100 was used to analyzed samples placed over glass microscope 
slides.  
3.2.14 Ultra-thin nanofibers microporous membranes made by 
Electrospinning.  
Home-made electrospinning equipment, composed for a syringe pump 
from New Era Pump, Inc. and a high voltage source power Glassman 
High Voltage, Inc., model PS/FC30P04, input 220V, output +30kV, 
4.0mA. All these equipments are located at Universidad Politècnica de 
Valencia (Spain). 
3.2.15 Synthesis of Micro-particles by reverse phase Emulsion 
technique 
Stirrer model IKA T-25-ULTRA TURRAX was used to prepared w/o 
emulsions. To obtain the micro-particles it was used a stirrer OST 20 
basic digital IKA Yellow line.  
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4. SYNTHESIS AND CHARACTERIZATION OF 
POLYMER PROTEIN CONJUGATES USING 
TRYPSIN AS MODEL PROTEIN.  
4.1. Introduction 
As stated in chapter 2, one of the objectives of this work was the 
encapsulation of polymer protein conjugates into microparticles and 
finally into membranes of PLLA fibers in order to provide a proteic 
nature drug with a greater stability in plasma once release from the 
scaffold enhancing in such manner its possible therapeutic output. 
Looking at the polymeric carriers well-known for protein conjugation, 
polyethyleneglycol (PEG) appears as the most relevant as described in 
the introduction chapter, however, this carrier is non-biodegradable 
and even though has already demonstrated clinical safety, 
biodegradable polymers could offer benefits mainly if a chronic life-
threating disease is considered as target. For this reason the two 
different strategies for protein conjugation were taken into account in 
this work, using trypsin as model protein: a) Protein PEGylation32,97,98, 
as example of system with non-biodegradable polymer carriers and b) 
Protein conjugation with PEG-polyacetals79,99, as example of a pH-
responsive  polymeric carrier. 
The field of Polymer-Protein conjugates is experiencing an exponential 
growth in its use for the daily treatments applied in the clinic. 
However, there are still some important challenges to face regarding 
its formulations and clinical use.  Before they reach their targets in the 
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body, these proteins can be degraded by the blood proteases or in the 
liver, suffer a fast renal excretion or generate an immunogenic 
response. Other drawbacks arise from their chemical nature, e.g., poor 
water solubility in some cases, lack of proper target specificity within 
the body, or low internalization kinetics24.  
Polymer-protein conjugates (also polymer-aptamer) have been 
introduced in the market in order to overcome these problems. Most 
of these nanomedicines are conjugates of poly(ethylene)glycol (PEG). 
Thus, Oncaspar® and NeulastaTM are already approved for cancer 
chemotherapy, PEG-Intron® and Pegasys® for Hepatitis C treatment, 
Cimzia® for Rheumatoid arthritis and Crohn’s disease, Mircera® for the 
treatment of the anemia, Somvert® in the case of Acromegalia and 
Adagen® for the severe combined immune deficiency syndrome10. 
Nevertheless this first generation of conjugates shows still some 
weaknesses. The use of PEG in therapies where a chronic 
administration is required is limited due to its lack of biodegradability, 
which enables the risk of accumulation in the body during the 
treatment.98,100 Therefore there is a need of developing a smarter 
second generation of polymer-protein conjugates. 
The replacement of PEG by a biodegradable polymer in such 
compounds gives rise to a recently reported approach in Polymer 
Therapeutics. The so called polymer-masking-unmasking-protein 
therapy (PUMPT), first described by Duncan et al87,99, provides a 
versatile strategy with potential to enable the protection of proteins 
normally inactivated while traveling to their therapeutic target and/or 
to allow controlled release with time of active proteins at the target 
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site promoted by the polymer degradation. Depending on the 
pharmacological target, the degradation must take place either 
extracellularly (as in the case of the growth factor, cytokines or 
antibody against membrane receptors) or after being internalized by 
endocytosis (e.g, with cytosolic enzyme delivery, in this case 
endosomolytic polymers are required or lysosomal replacement 
therapy). 
Two different families of PUMPT has been described, namely these 
which use dextrin (DEX as partner polymer) and the ones with 
hyaluronic acid (HA). DEX-trypsin was originally chosen as a prove-of-
concept model to illustrate PUMPT. Masking growth factors with DEX 
has also been successfully achieved and applied to inhibition of 
melanin production in B16F10 cells. Another prominent example is the 
case of DEX - rhEGF conjugated, which has proved its effectivity in 
vitro, as well as ex vivo and in vivo wound healing experiments with 
remarkable results. Fergusson et al101,102 has enlarged the window of 
applicability of PUMPT by implementing a DEX-phospholipase 
conjugate, namely DEX-PLA2, in Polymer enzyme liposome therapy 
(PELT). The release of a non-soluble drug encapsulated in a liposome is 
controlled by the unmasking of the co-administered PUMPT conjugate. 
HA-Trypsin and HA-EGF have been described as HA conjugate models 
in an attempt of combining PUMPT-guided delivery control with the 
inherent properties of this polymer, including tissue regeneration and 
wound healing103.  
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Very recently in the group, Poly-L-glutamic acid (PGA)has been also 
explored as alternative carrier for PUMPT104.  PGA is biodegradable(by 
lysosomal enzyme cathepsin B), multivalent, non-immunogenic, non-
toxic polymer105, and some PGA-drug conjugates have already reached 
the clinic, in fact one of the most advanced polymer-drug conjugates is 
Opaxio® in advanced phase III clinical trials, which was recently 
granted as an orphan drug for the treatment of glioblastoma when 
combined with radiotherapy6,10  By rationally re-designing the PUMPT 
concept, PGA conjugates with anticancer enzymes can have high 
potential for the treatment of cancer, as they can accumulate in tumor 
tissues through the EPR effect106.  In addition, due to the cellular 
uptake of PGA conjugates by endocytosis, PGA-based PUMPT 
conjugates can also have great potential for enzyme replacement 
therapy in lysosomal storage diseases, a family of diseases caused by 
deficiencies of lysosomal enzyme107–109. A new variation of the PUMPT 
concept was presented with PGA, where unmasking and subsequent 
protein release relies on the cleavage of a reduction sensitive linker in 
specific sites of the body104.  In this study lysozyme was used as model 
protein recovering after polymer unmasked almost all proteolytic 
activity. 
 
Degradation of DEX, HA or PGA requires the presence of a determined 
enzyme (α-amylase, hyaluronidase and cathepsin B, respectively) in 
significant amounts in the biological compartment where the wrapped 
protein has to be unmasked, ensuring the specificity of the delivery. 
These enzymes may not be necessarily involved in many crucial 
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processes of the body such as inflammation, response to the presence 
of a tumor, arthritis, tissue regeneration or wound healing among 
others. Importantly, a drop in the pH has been observed during these 
processes around the affected area. Therefore, alternative solutions to 
this so-restricted unmasking step must be explored in order to expand 
the applicability of this technology. 
Polyacetals are macromolecules that can be achieved under gentle 
conditions by an acid catalyzed addition of a diol to divinyl ether.  
Stability of the acetal moiety both, at basic and at neutral pH arises 
from the lack of chemical mechanism of replacement of any of the 
substituents of acetal carbon. However, protonation in acid media of 
the oxygen enables the disruption of the polymeric chain with a pH-
dependent kinetics rate11,78–80,110. 
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Figure 4.1. Scheme of PUMPT mechanism based on polyacetals 
degradation triggered by acidic pH. 
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Additional interesting physico-chemical properties of the main 
polymer chain can be tuned by the use of conveniently chosen diols.   
Copolymerization with functionalized diols allows the insertion of 
reactive centers in the backbone that can be used for multiple 
bioconjugation of a drug or a biologically active protein and to increase 
their payload. Reaction of the divinyl ether with short molecular 
weight PEG based diols ensures the water solubility of the resulting 
polyacetal as well as the retention of most of the other PEG-related 
properties above mentioned, while the polymer keeps the ability of 
self-degradation at acidic pH. This fact clearly overcomes the problem 
of PEGylated nanodrug accumulation in chronic treatments.  
The aim of this study was to develop a degradable PEG-mimicking 
PUMPT system capable of unmasking the protein only under acidic 
conditions. Functionalized new PA backbones (containing fragments of 
PEG-diol 4000 Da units and serinol moieties with adequate 
functionalities) have been synthesized and physico-chemically 
characterized. Trypsin has been used as a model enzyme in order to 
build our PUMPT. Influence of linker (succinoylated PA) and the effect 
of the proportion of polymer to protein in the masking/unmasking 
capability of the PA have been investigated.  The biological activity of 
the masked and unmasked protein has been assessed using N-benzoyl-
L-arginine-p-nitroanilide (L-BAPNA) as a substrate. Finally, the ability of 
the protein to recover its full initial activity after the PUMPT process 
has been evaluated.  
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PEG-trypsin conjugate has been also synthesized in order to directly 
compare this FDA approved non-biodegradable polymeric carriers with 
the newly synthesized pH-responsive PA-trypsin conjugate. 
4.2. Methodology 
4.2.1. Synthesis and Characterization of Polyacetals (PA) 
4.2.1.1. Synthesis of amino-pendant PolyAcetals  
 Synthesis of Fmoc-2-amino-1,3-propanediol (Fmoc-serinol, 1) 
Fmoc-Serinol (1) was synthesized following the methodology reported 
by Tomlinson et.al.  Basically, serinol (0.0820 g, 7.500 mmol) was 
dissolved in aqueous Na2CO3 (10% solution in water, 20 mL). Dioxane 
(15 mL) was added, the mixture was cooled down (4 ºC), and Fmoc-Cl 
(0.0290 g, 7.500 mmol) was added carefully. Reaction was carried out 
at 4ºC (4 h) and then at room temperature (12 h). After that, mixture 
was poured in water (100 mL). To recover the final product, it was 
extracted from with ethyl acetate (3 x 100 mL). The organic phase was 
dried, filtered off and concentered. Finally, the product was washed in 
a large excess of hexane to yield a white loose powder. 
Yield 80%. 1H NMR [(δ (ppm), 300 MHz, CDCl3]: δ 7.68 (d, J = 6.2 Hz, 
2H, ArCH-), 7.54 (d, J = 6.2 Hz, 2H, ArCH-), 7.38 (t, J = 6.0 Hz, 2H, ArCH-
), 7.31 (td, J = 6.2, 1.0 Hz, 2H, ArCH-), 5.74 (s, 1H, R’’: R’-O2CNH-R’’’), 
4.91 (d, J = 5.2 Hz, 2H, R’: R-CH2-R’’), 4.72 (t, J = 5.5 Hz, 1H, R: Ar-CHR’-
Ar), 4.35 (dd, J = 21.4, 12.2 Hz, 5H, R’’’: CH2CHR’’CH2), 2.80 (s, 4H, -OH) 
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 Synthesis of amino-pendant Fmoc-serinol protected (PAFS, 2) 
and de-protected ( PANH2, 3) PolyAcetals,: 
PANH2s were synthesized by copolymerization of diol monomers 
(Fmoc-serinol and PEG4000, Mw ≈ 4000 g/mol) with ethylene groups 
of TEGDVE through addition reaction catalyzed in acidic conditions, 
following the protocol published by Gimenez et. al.11 based on the 
procedure described by Tomlinson78,79. Briefly, PEG4000 (1.0100 g, 
0.25 mmol,) and Fmoc-serinol (0.1170 g, 0.375 mmol) were dried 
under high vacuum (15 min) in a Schlenk tube. Dried anhydrous 1,4-
dioxane (Dioxane, 6 mL) was added under inert atmosphere 
conditions. Then, pTSA (1 mL of a previously prepared 2mg/mL 
solution in dioxane, 0.0023 g, 0.010 mmol) was dropped over the 
reaction mixture, which was then warmed (60 ºC) until complete 
dissolution of the reactants. The system was left stirring until cooled 
down at room temperature (21ºC) and then TEGDVE (128 μL, 0.1264 g, 
0.625 mmol) was carefully added. The solution was covered from light 
and left reacting for 1h. After this time the polymer obtained was the 
Fmoc-serinol amino-pendant polyacetal (PAFS, 2). Small sample was 
isolated to be analyzed by 1H NMR in order to follow the reaction and 
to determine the amount of Fmoc protected amino group moieties 
present in the polymer main chain. Once quantification was 
performed, the reaction was quenched with KOH (2mL, 1M in 
methanol) to ensure the complete deprotection of the amino group as 
well as the total neutralization of catalyst, pTSA. The solution was 
poured over a mixture of hexane: diethyl ether, 4:1 (100 mL), and the 
precipitate obtained was washed three times by re-dissolving it in 
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ethyl acetate and precipitating it in ether.  The suspension was 
centrifuged and the pellet dried under a N2 stream. The obtained 
amorphous white solid was identified as the amino-pendant polyacetal 
(PANH2, 3) (0.6510 g, yield: 78%). Polymers were characterized by 1H-
NMR (identity and reaction success) and GPC (to determine the Mw). 
Ninhydrin assay showed that the amount of amino groups loaded in 
the polyacetal. 
PAFS (2): 1H NMR (300 MHz, Acetone) δ 7.86 (d, J = 6.0 Hz, 2H, ArCH-), 
7.71 (d, J = 7.4 Hz, 2H, ArCH-), 7.42 (dd, J = 12.0, 5.0 Hz, 2H, ArCH-), 
7.34 (dd, J = 12.8, 5.5 Hz, 2H, ArCH-),  4.76 (dd, J = 10.5, 5.3 Hz, 3H, 
acetal-CH-), 4.34 (d, J = 15.3 Hz, 2H, R-CH2-R), 4.24 (s, 1H, Ar-CH-Ar), 
3.85 – 3.78 (m, 3H), 3.78 – 3.39 (m, 420H, PEG-CH2-O), 3.39 – 3.29 (m, 
3H), 2.52 (s, 1H), 2.30 (d, J = 2.4 Hz, 1H), 2.26 (qt, J = 4.4, 2.2 Hz, 1H), 
1.86 – 1.82 (m, 1H), 1.25 (d, J = 1.6 Hz, 4H, acetal-CH3), 1.24 (d, J = 1.5 
Hz, 5H, acetal-CH3). Mw 12257 g/mol; Mw/Mn = 1.9. 
PANH2 (3): 
1H NMR [(δ (ppm), 300 MHz, Acetone]: δ 4.85 – 4.56 (m, 
3H, acetal CH), 3.97 – 3.22 (m, 337H, PEG -CH2-CH2-), 1.38 (s, 1H), 1.26 
(t, J = 7.7 Hz, 12H, acetal -CH3). GPC (PBS 100mM, pH 7.4, T=35◦C) Mw 
10889 g/mol; Mw/Mn = 1.8. TNBSA assay reveled the amount of 
amino groups loaded in the polyacetal was 1.6wt%. 
 Synthesis of PASucc (4):  
PASucc (4) was obtained by succinoylation of PANH2 (3). Briefly, 
0.5000 g of PANH2 10889 g/mol, 0.4946 g, 0.0065 mmol-equivalent of 
NH2,) was dried in the Schlenk tube under high vacuum and N2 
atmosphere for 10 min; then it was dissolved in anhydrous THF 
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recently distilled (10mL), followed by the addition of succinic 
anhydride (0.0125 g, 0.125mmol) and DMPA (0.0153g, 0.125mmol). 
Reaction mixture pH was adjusted to 8 with Et3N and left reacting 
under vigorous stirring and N2 atmosphere (24h, 21ºC). A white 
powder was obtained after precipitation of the reaction mixture in 
hexane: diethyl ether (4:1, 100mL). The solid was isolated by 
centrifugation, re-dissolved in THF (10mL) and precipitated as describe 
in the previous step. This process was repeated 3 times. The resulting 
solid was dried under a N2 stream, dissolved in milliQ water (15mL) 
and concentrated with centrifugal concentrators tubes (VivaspinTM) 
(20mL MWCO 10000, 6000 rpm, 25º fixed angle rotor, 4ºC, 3x). The 
concentrated solution (5mL) was freeze dried. The product was 
recovered and characterized by 1H NMR. 90% Yield. 1H NMR [(δ (ppm), 
300 MHz, Acetone]: δ 4.69 (qd, J = 5.3, 1.8 Hz, 1H acetal CH), 3.86 – 
3.18 (m, 138H), 2.61 – 2.35 (m, 1H succinoylate CH2-CH2), 1.27 – 1.19 
(m, 3H acetal CH3). GPC (PBS 100mM, pH 7.4, T=35◦C) Mw=10512 
g/mol, Mw/Mn=1.4). Carboxylic group content was 2.3 wt%, 
determined by titration with NaOH (0,02mM).  
 Synthesis of PACOOH (5):  
PACOOHs (5) were synthesized following a similar copolymerization 
process but, replacing serinol by 2,2-tris (hydroxymethyl) propionic 
acid (BHMPA) as monomer to obtain a novel carboxylic pendant 
polyacetal. Briefly, PEG4000 (1.0151 g, 0.250 mmol), BHMPA (0.0335g, 
0.250 mmol) and pTSA (0.0024 g, 0.01 mmol) were dried in the Schlenk 
tube under high vacuum and N2 atmosphere for 10 min. Dioxane (5mL) 
was added, mixture was stirred and warmed (60ºC) until completely 
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dissolution of the reactants. The solution was left cooling down to 
room temperature. TEGDVE (0.1112 g, 112 μL, 2.200 mmol,) was then 
added. The reaction was left covered from light (21ºC room 
temperature, vigorous stirring) until the complete consumption of free 
TEGDVE, followed by disappearing of quadruple signal of free TEGDVE 
at 6.5 ppm monitored by 1H NMR in CDCl3 (1 h in this case). The 
mixture was quenched with KOH (2 mL, 1M in MeOH). The final 
product was purified and dried as describe above for PANH2. A white 
powder was obtained and identified as PACOOH. 80% yield. 1H NMR 
[(δ (ppm), 300 MHz, 6d-DMSO]: δ 4.75 – 4.50 (m, 4H acetal CH), 3.96 – 
2.92 (m, 637H CH2-CH2-O), 1.31 – 1.06 (m, 9H acetal CH3), 0.89 (t, J = 
3.2 Hz, 3H acetal CH3). GPC (PBS 100mM, pH 7.4, T=35
◦C) showed Mw 
10307 g/mol; Mw/Mn=2.1. Carboxylic content was 1.3wt%, 
determined by titration with NaOH (0.02mM).   
4.2.2. Synthesis and characterization of Polyacetal-Trypsin 
conjugates. 
Polyacetylation of the trypsin was achieved through a condensation 
reaction between amino (NH2) groups from the lysine amino acids of 
the protein and the carboxylic groups of polyacetals (4) and (5). 
In both cases, carboxylic moieties of polyacetals (4) and (5) were 
activated in DMF (1mL) with EDAC (1.5 mol excess respect to COOH 
mol, for 10min) and Sulfo-NHS (1.5 mol excess respect COOH mol, 
another 45 more min). Then, protein was added to the reaction 
mixture (dissolved in 0.1M Borate Buffer solution pH 9.2). The amount 
of protein used for each reaction was calculated taking in account a 
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determined molar ratio between functional groups in polyacetals (20 
mmol, 40 mmol or 60 mmol of COOH groups) and in trypsin (by 1 
mmol of NH2 groups). Reactions were carried out during 16h at 4ºC. 
The conjugates from each type of polyacetal were purified with 
centrifugal concentrators tubes (VivaspinTM) (20mL, MWCO 10000, 
6000 rpm, 25º fixed angle rotor, 4ºC), diluting the reaction mixture 
with d.d.H2O up to 15mL.  Samples were concentrated to 5mL and re-
diluted to 15 mL. This step was repeated twice, and the last 5 mL of 
concentrated products were freeze dried. White powders were 
obtained. Products were characterized by 1H-NMR, GPC in aqueous 
phase, FPLC with PBS 100mM solution as mobile phase, DOSY-NMR, 
and CD. 
PASucc-T [(δ (ppm), 300 MHz, 6d-DMSO]:  8.50 – 6.24 (m, ar-CH, 
aromatic amino acid of trypsin), 4.94 – 4.41 (m, acetal CH), 3.78 – 3.47 
(m, PEG CH2), 1.18 (d, J = 5.3 Hz, acetal CH3).  GPC (Mw=26531g/mol, 
Mn/Mw=1.3) 
PACOOH-T 1H NMR [(δ (ppm), 300 MHz, 6d-DMSO]:  8.77 – 6.47 (m, ar-
CH, aromatic amino acid of trypsin), 5.80, 4.67 (dt, J = 20.7, 10.4 Hz, 
acetal CH), 4.23 , 3.98 – 3.06 (m, PEG CH2), 1.47, 1.17 (dd, J = 10.2, 5.2 
Hz, acetal CH3).  GPC (Mw=27400 g/mol, Mn/Mw=1.7) 
Trypsin 1H NMR [(δ (ppm), 300 MHz, 6d-DMSO]: 8.58 – 6.36 (m, 30H, 
aromatic amino acid of trypsin), 4.91 (s, 4H), 4.42 (d, J = 84.6 Hz, 17H), 
3.83 – 2.63 (m, 146H), 2.56 – 2.36 (m, 57H), 2.30 – 0.51 (m, 62H). GPC 
(Mw = 23650 g/mol, Mn/Mw = 1.2) 
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Total amount of protein conjugated to each kind of polyacetal was 
quantified by UV spectroscopy (with BCA assay and with nanodrop, 
absorbance read at 280nm) using the native trypsin solution as 
standard for calibration curve (0.1-0.7 mg/mL). Conjugation efficiency 
was determined by SDS-PAGE (12.5% A.A., 100V) and FPLC (1mL of 
sample, 5mg/mL protein equivalent, PBS 1X, pH 7.4, flow 0.5, 
Sephacryl S-300, 20ºC), by comparison between the peak area of 
trypsin conjugate with free trypsin. Conjugation efficiency was also 
evaluated by quantification of free amino groups of lysine present in 
Trypsin before and after the conjugation reaction, using the standard 
protocol for TNBSA assay111. Briefly, PA-Ts samples with known trypsin 
concentration (50µg/mL) were prepared in 0.1M Sodium Bicarbonate 
(NaHCO3) pH 8.5. Stock solution 0.2mM of Glycine in the same buffer 
was used for calibration curve (0.016 – 0.2 mM). Then, 500 µL of 
sample/standard were added to 1.5mL microtubes, followed by 250 µL 
0.01% TNBSA solution. Samples and standards were incubated at the 
same time for 2h at 37 ºC.  Finally, 250 µL 10% SDS solution and 125µL 
1N HCl were added. Mixture was stirred 5s and absorbance was read 
at 340 nm. Structural integrity of protein after conjugation was 
verified through circular dichroism (CD). With this porpoise samples of 
naked and conjugated trypsin were dissolved in phosphate buffer 
solution 100 mM, with the same trypsin-equivalent concentration. 
Analyses were carried out at 20 ºC in a Jasco V-630 UV/Vis 
spectrophotometer. DOSY analyses were done as complementary 
studies to determine whether more than one macromolecular 
structure could be detected by diffusion within a magnetic field.  
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4.2.3. Study of PUMPT effect with PA-T conjugates.  
4.2.3.1. Determination of PUMPT effect with PA-T conjugates 
Trypsin (T) enzymatic activity was the property selected in order to 
determine if PA-T conjugated systems showed masking-unmasking 
(PUMPT) behavior. L-BAPNA assay was used to determine the 
enzymatic activity. 
 The same protocol was followed for native naked T and its conjugates. 
L-BAPNA was used as trypsin specific substrate. The hydrolysis of L-
BAPNA released p-Nitroanilide (pNA), making possible to follow the 
progress of this reaction in time by measuring the absorbance increase 
of this small molecule. Reaction was followed during the first 10 min in 
a Victor UV reader plate, with filter of 405nm, at 37ºC.  
The range of substrate concentration study was between 0.16-1.0 mM 
of L-BAPNA. Stock solution L-BAPNA (10 mL, 1.609 mM) was prepared 
dissolving first the solid L-BAPNA in DMSO (1mL, 7mg/mL) and finally 
diluting with 0.1M Tris buffer solution and 0.02 M CaCl2, pH 8.2 (9 mL).  
Protein concentration was kept constant for all experiments (20µL, 
1mg/mL trypsin equivalent, final volume 200 µL, final T concentration 
0.1mg/mL ) 
According to literature the unit of activity is defined as the amount of 
enzyme that hydrolyses 1µmol of substrate (L-BAPNA) by unit of time 
(min). 
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Unit of activity (unit/mg) = (ΔAbs410nm x f x l )/( ϵ x m) Equation 4-1 
32 
ΔAbs410nm =measure of absorbance 
f, Factor of conversion = 1000, from mmol to µmol  
l, Light path length = 1cm  
ϵ = 8800 (L/mol.cm) L-BAPNA Molar absortivity, 
m = (mg) protein mass. 
Trypsin from porcine pancreas Type IX-S, lyophilized powder (Sigma 
Aldrich) 
 17000 units/mg protein or 17000units/mg solid 
Enzymatic activity was expressed as relative percentage in comparison 
with native T activity under the same condition of incubation.  In order 
to calculate the kinetic parameters, a Lineweaber-Burk plot model was 
applied. Native T and PA-T conjugates were incubated under the same 
conditions and then enzymatic activity was measured and compared. 
First, samples of naked T as well as PA-T with equivalent amount of T 
were dissolved and incubated in 100mM PBS pH 7.4 at 37°C for 2h. 
After that enzymatic activity of each sample was measured and 
compared among them. 
Second, new samples of naked T as well as PA-T with equivalent 
amount of T were dissolved and incubated in 100mM PBS pH 5.5 and 
6.5 at 37°C for 2h. After that, enzymatic activity of each sample was 
measured and compared among them. 
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4.2.3.2. Effect of PA/T ratio 
Family of PASucc-T conjugates was synthesized in order to study the 
influence of polyacetal/T ratio over the masking-unmasking effect. 
Three different molar ratios between PA functional groups (COOH) and 
Trypsin functional groups (NH2) were evaluated (COOH-PA/NH2-T 
molar ratios = 20:1, 40:1, 60:1). The enzymatic activity of conjugates 
was determined using the L-BAPNA assay, following the procedure 
described in the previous section, keeping constant the relative 
amount of trypsin to be able to establish an appropriate comparison 
among them.  
4.2.3.3. Effect of linker presence  
According to the results of experiments from section 2.4.4, the PA/T 
molar ratio with best results was chosen for PACOOH-T synthesis, with 
the porpoise to determine the influence of having or not a linker 
between polyacetal main chain and trypsin over the masking-
unmasking effect keeping constant the amount of COOH groups by 
NH2 groups of trypsin. Samples of conjugates and naked trypsin 
(1mg/mL equivalent of trypsin) were incubated at pH 7.4, 6.5 and 5.5, 
for 2 h. Enzymatic activity was measured before and after incubation, 
with L-BAPNA assay, to compare PACOOH-T and PASucc-T behavior 
among them and with naked trypsin. 
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4.2.4. PEGylated systems 
4.2.4.1. Synthesis of Trypsin-PEG conjugates. 
Trypsin was chosen as a model protein because its structure and 
activity is well known, this makes easier to follow it through the 
conjugation process and evaluate if it is able to keep the activity.  Also 
it is a good model because it has a molecular weight similar to some 
proteins with specific biological activity (such as IL-6) that could be 
used later in wound healing applications. Using a similar Mw will allow 
the optimization of conjugate and scaffold parameters preventing us 
from the elevated cost of important proteins such as IL-6.  PEG was 
chosen because it is a semitelechelic non-biodegradable polymer  
A modification of the synthetic protocol reported by Duncan et al. was 
used here32.  MeO-PEG-OH and MeO-PEG-COOH both with molecular 
weight 2000 Da were used as polymeric carrier in order to obtain the 
desired PEG-trypsin conjugates. Trypsin (23000Da) was selected as the 
model protein.  A molar ratio of 1:5 Trypsin:PEG2000.  
Two different strategies were followed for each kind of PEG. 
 For strategy 1, applied for MeO-PEG-COOH, the reaction synthesis is 
summarized in figure 4.2 
Briefly, EDAC(0.0158g, 8.29x10-2mmol, and 0.00317g, 1.658x10-
2mmol) was added as solid to an aqueous solution (8mL) of MeO-PEG-
COOH (2000 Da;  COOH; 0.008g, 4.14x10-2mmol of COOH) and left to 
stir for 10 min at RT) then sulfo-NHS (0.001g, 8.29x10-2mmol and) was 
added also as solid, and let to stir for further 40min at RT.  
 120 
 
Trypsin (0.02g, 8.29x10-3mmol) was dissolved in ddH2O (5mL) and 
added drop by drop over the reaction mixture and the pH was 
adjusted to 8 with NaOH 1M.  The reaction was left to react by 18h at 
RT. Same equivalents of EDAC and Sulfo-NHS were added after this 
time in order to enhance reaction yields, the pH was readjusted to 8 
and the reaction let to react for further 8 h. 
 The precipitated urea was filtered off and the conjugate solution 
further first by ultrafiltration (membrane Mw cut off 10000 DA, rpm   
min). DdH2O was added to the upper layer (3x) for exhaustive 
subproduct removal PBS (1 M, pH 7.4) (volume, v = 2 mL, final 
concentration 5 mg/mL) was added to the concentrated aqueous 
trypsin solution (total volume, vt = 20mL)  
Final product was freeze dried and storage at -20ºC to be used latter.
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Figure 4.2. Scheme of strategy 1 for PEG-Trypsin conjugation reaction 
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Strategy 2 for conjugation reaction of Trypsin with MeO-PEG-OH was 
based on the procedure propuosed by Zarafshani et al.112 
Reaction synthesis is summarized in figure 4.3 
First, MeO-PEG-OH succinoylation was accomplished.  Briefly, MeO-
PEG-OH (1.00g, 5.00x10-4 mol) was dried by azeotropic distillation with 
toluene.  Then, MeO-PEG-OH was dissolved in anhydrous DMF (1.00g, 
0,5mmol; MeO-PEG-OH 2000 MW, 10mL).  Following, succinic 
anhydride was added in a molar ratio 4 times bigger than MeO-PEG-
OH (para MeO-PEG-OH2000: 0.20g, 2mmol) followed by DMAP in the 
same proportion than succinic anhydride (0.24g, 2mmol).  This 
solution was stirred by 16h at room temperature, following the 
reaction progress by Thin Layer Chromatography (TLC) using the 
mixture of solvents (BuOH/AcOH/H2O in volume proportion 4:1:1). 
After the reaction time was completed, the mixture was purred into 
ether in order to precipitate the succinoylated PEG, which was 
recrystallized twice in a mixture of CH2CL2/Ether (1:40). 
Acid groups in PEG-Succinoylated were quantified by titration with a 
standard solution of NaOH 1.00x10-4M and Bromothymol blue (also 
known as bromothymol sulfone phthalein and BTB) as pH indicator. 
Next step was trypsin PEGylation.  Fist, PEG-Succinoylated 
(200mg/mL; 0.2315g, 1.10*10-4 PEG-Succinoylated) was dissolved in 
DMF (N,N-Dimethylmethanamide, 1.16mL).  Then EDAC was added in 
a molar proportion 4 times bigger than the amount of trypsin which 
was going to be conjugated (0.0038g, 2.00*10-2mmol) and mixture was 
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stirred by 10 min.  Then sulfo-NHS (Hydroxy-2,5-dioxopyrrolidine-3-
sulfonicacid sodium salt, 0.0043g, 2.00*10-2mmol) and all was stirred 
by 45min. 
Finally, trypsin (0.1151g, 4.8*10-3mmol) was added dissolved in 
aqueous borate buffer (borax/HCl, pH 9 at 20ºC, 2.97mL, final 
concentration of trypsin 40mg/mL) previously cooled at 4ºC. 
Both solutions were mixed adding drop by drop the trypsin solution 
over the PEG-succinoylated solution. 
Reaction mixture was stirred at 4ºC by 4h and latter 2h more at room 
temperature. 
The precipitated urea was filtered off and the conjugate solution 
further first by ultrafiltration (membrane Mw cut off 10000 DA, rpm   
min). DdH2O was added to the upper layer (3x) for exhaustive 
subproduct removal PBS (1 M, pH 7.4) (v= 2 mL, final concentration 5 
mg/mL) was added to the concentrated aqueous trypsin solution 
(vt=20mL)  
Final product was freeze dried and storage at -20ºC to be used latter.
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Figure 4.3. Scheme of Trypsin-PEG conjugates reaction synthesis 
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4.2.4.2. Characterization of PEG-trypsin conjugates and 
trypsin, by FPLC, SDS-PAGE electrophoresis and 
enzymatic activity 
As explained before for PUMPT conjugates, total amount of protein 
conjugated was quantified by UV spectroscopy with BCA assay using 
the native trypsin solution as standard for calibration curve (0.1-0.7 
mg/mL). Conjugation efficiency was determined by SDS-PAGE (12.5% 
A.A., 100V) and FPLC (1mL of sample, 5mg/mL protein equivalent, PBS 
1X, pH 7.4, flow 0.5, Sephacryl S-300, 20ºC), by comparison between 
the peak area of trypsin conjugate with free trypsin. 
The experiment was made preparing SDS polyacrylamide gels at 12.5% 
with 0.75mm of thickness.  Gels were made as follow: Special 
equipment from BIORAD was used. Two glasses plate (outer and inner 
glasses) were assembling into the casting frame, it was put into the 
casting stand to fill up glasses with water to check the water tightness.  
 Water was removed and introduced Resolving buffer (10 mL, 
composition: 3.54mL ddH2O, 2.5 mL TRIS pH 8.8 1.5M, 3.75mL Bis- 
acrylamide 40%, 0.1 SDS 10%, 0.1mL APS 10%, 0.01mL TEMED), added 
50 µL of butanol  and let polymerization developed (10 min). Then 
butanol was removed and washed with ddH2O.  
 Glasses  were filled up with Stacking buffer (4mL, composition: 
4.42mL ddH2O, 1ml TRIS pH 6.8 0.5M, 0.5mL Bis acrylamide, 0.04 SDS 
10%, 0.04 APS 10%, 0.004 mL TEMED) and immediately put the plastic 
comb until  polymerization (10 min). Plastic comb was removed and 
washed with water the glasses were introduced into clamping frame 
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and electrode assembly and finally introduce it in the electrophoresis 
box. Running buffer 1x (1L, composition: 100mL Running buffer 10x, 
5mL SDS 20%, 895mL ddH2O (Running buffer 10x composition: 1L, 
0.25M Trizma Base, glycine 1.92M, ddH2O)) was added. 
Conjugates (1mg/mL in dd H2O), and control sample of free trypsin 
(1mg/mL in dd H2O) were prepared by dilution (1:1) with a denaturing 
solution (loading buffer composition: 3.8mL of H2O, 5mL; 0.5Mtris HCl 
(pH6.8), 8mL 10% w/v SDS, 4mL of glycerol, 2mL 2-mercaptoethanol, 
0.4mL of bromophenol blue 1% w/v) and heated for 7min at 95ºC.  
Samples and Mw marker were loaded (10μL) into the gel and let 
running for 15min at 90V and the last 45min at 130V.  The gel was 
then rinsed and stained (1h) with Coomassie blue, cleared in distaining 
buffer (35% methanol/ 5% acetic acid) for 24h and then rehydrated in 
a solution composed by 5% methanol/7% acetic acid.   Finally, the gel 
was rinsed with ddH2O.  
Enzymatic activity was also measured after PEGylation following the L-
BAPNA assay protocol describe previously in section 4.2.3.1, in order 
to compare how much biological activity was lost as consequence of 
this chemical process. 
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4.3. Results 
4.3.1. Synthesis and Characterization of Polymer conjugates  
4.3.1.1. Synthesis of amino-pendant PolyAcetals, PAFS (2) 
and PANH2 (3) 
Amino-pendant polyacetals, were synthesized following a 
modification of the methodology proposed by Tomlinson et al.79  as 
describe previously. Before stop the reaction, a sample was taken in 
order to characterize the Fmoc-protected product (PAFS, (2)) to be 
able to quantify by 1H NMR the amount of NH2 groups loaded in the 
main chain. The sample was isolated and precipitated in ether as a 
white loose powder. 1H-NMR analysis confirms the desired compound. 
See Figure 4.4. 
 
Figure 4.4. 1H-NMR of isolated aliquot of PAFS (2) in Acetone-d6. 
 128 
 
 
Figure 4.5. Scheme of chemical structure of PAFS. 
 
Then, reaction was stopped by adding a solution of KOH (2M) in 
MeOH, consequently deproteccting the product. Final solution was 
poured into ether to obtain a white loose powder. Total deprotection 
was confirmed by 1H-NMR (see figure 4.6,). This product was identified 
as PANH2 (3).   
 
Figure 4.6. 1H-NMR of isolated PANH2 (3) in Acetone-d6. 
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Figure 4.7 Scheme of chemical structure of PANH2. 
 
A summary of the polymers obtained with their assigned Mw by GPC 
and the amino groups loading in the polyacetal is depicted in the 
following table 4-1. 
Table 4-1 Comparison of Molecular weight and amount functional 
groups in PAFS (2) and PANH2 (3) 
Polymer 
Mw* 
(g/mol) 
PDI 
FS content 
(wt%)** 
NH2 content 
(wt%)*** 
PAFS (2) 12257 1.9 20 - 
PANH2 (3) 10889 1.8 - 21 
* Determined by GPC 
** Determined by Colorimetric assay 300nm 
*** Determined by Ninhydrin assay 
FS: Fmoc-serinol 
4.3.1.2. Synthesis of PASucc (4) 
Next step was the succinoylation of amino groups in polyacetals, 
PASucc (4). After total deprotection of amino groups in PAFS (2), the 
amount of NH2 (expressed as NH2 molar %) was the same as Fmoc-
Serinol molar % in PAFS (2). According to this, there was 21% molar of 
NH2 in PANH2 (3) polymer main chain.  Average MW for polyacetal was 
calculated (3324g/mol).  The amino groups were derivatized with 
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succinic anhydride in order to introduce a suitable linking moiety to be 
attached to the protein through the amino groups of peripheral 
lysines. The succinoylation reaction was done in proper conditions to 
achieve the total functionalization of all free amino groups present in 
PANH2 (3). Reaction was successfully accomplished with 100% 
succinoylation of NH2 groups, corroborated by 
1H NMR analysis, were 
characteristic multiplet of CH2-CH2 belonging to succinoylated side 
chain was observed at 2.61-2.35 ppm. Qualitative amino test with 
ninhydrin was also performed, which resulted negative for free amino 
groups in succinoylated product and positive for PANH2. 
 
Figure 4.8 1H-NMR of isolated of PASucc, 300MHz 
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Figure 4.9 Chemical structure of PASucc (4) 
4.3.1.3. Synthesis of PACOOH (5) 
The COOH-pendant polyacetals PACOOH (5) were synthesized as 
describe previously in Materials and Methods and characterized by 1H 
NMR and GPC (6mg/mL). Quantification of COOH in the polymer main 
chain was performed by titration with NaOH standard solution 
([]=2,1*10-5M) resulting to be 1.3 wt% of COOH groups. This novel 
carboxylic-pendant polymer from the polyacetals family had similar 
MW than its equivalent amino-pendant, as expected. The resulting 
polymer was completely soluble in a wide range of solvents (aqueous, 
DMSO, Chloroform…) and proven to be stable, as solid (weeks) as well 
as in aqueous solution, under normal atmospheric condition. An 
example of 1H-NMR of PACOOH (5) is shown in Figure 4.10. 
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Figure 4.10. 1H-NMR of isolated PACOOH (5) in Acetone-d6, 300MHz. 
 
 
Figure 4.11 . Chemical structure of PACOOH (5) 
 
4.3.2. Synthesis and characterization of PA-T conjugates 
Next step was the synthesis of a family of trypsin-polyacetals, PASucc-
T (6) and PACOOH-T (7). The protein trypsin (T) was loaded by linking 
the amino group of available lysine residues in the protein to the 
carboxylic groups pendant to polymer main chain, in case of PACOOH 
(5), or in the lateral chains for PASucc (4). Figure 4.12 shows the 
reaction scheme of protein conjugation. 
 
Figure 4.12. Synthetic scheme to reach PA-Trypsin conjugates. 
 
To confirm the conjugation of trypsin with the polymers (PASucc-T, 6 y 
PACOOH-T, 7), different physico-chemical characterization was 
performed. 
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Firstly, SDS-PAGE electrophoresis (SDS-PAGE 10% A.A., 10ug T 
equivalent by well) and FPLC (in PBS 100mM pH 7.4, flow 0.5ml/min 
column Sephacryl S300 16/60) were used to confirm the reaction 
efficiency and the relative amount of free protein, in case it was 
present in the final product. 
SDS-PAGE showed that conjugates were obtained in all cases, as 
expected. Also, reveals that degradation of trypsin under reaction 
conditions is diminished upon conjugation. 
 
Figure 4.13. SDS-PAGE 12.5% A.A., 10ug T equivalent by well, 6a) 
PASuc-T 20/1;  b) PASuc-T 40/1, c) ) PASuc-T 60/1, T) naked Trypsin 
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Figure 4.14. SDS-PAGE 12.5% A.A., 10ug T equivalent by well, 7a) 
PACOOH-T 20/1;  b) PACOOH-T 40/1, c) ) PACOOH-T 60/1, T) naked 
Trypsin, BSA) Bovine serum albumin, 5) PACOOH 
 
FPLC analyses showed that all conjugates presented almost the same 
retention volume (Vr) as shown in figure 4.15 at the same analytical 
conditions than naked trypsin. Values of retention volume for 
conjugates were higher than retention volume of naked trypsin, 
revealing that conjugated had bigger hydrodynamic ratio than trypsin, 
as expect when conjugation is accomplished.   
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Figure 4.15.  FPLC analysis of a) Trypsin; b) PASucc-T 20:1 (6a) c) 
PASucc-T 40:1 (6b) and d) PASucc-T 60:1, in PBS 100mM pH 7.4, flow 
0.5ml/min, column Sephacryl S300 16/60, sample loaded: 1mL, 
5mg/mL T equivalent. 
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Figure 4.16. FPLC analysis of A) Trypsin and PACOOH-T (7) samples;  
B) puried PACOOH-T (7).  Analytical conditions: in PBS 100mM pH 
7.4, flow 0.5ml/min, column Sephacryl S300 16/60, sample loaded: 
1mL, 5mg/mL T equivalent. 
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Likewise, Conjugates PACOOH-T (7) also showed higher retention 
volume (Vr) than naked trypsin at the same analytical conditions, 
corroborating that protein conjugation was accomplished successfully.  
 According to the FPLC analyses, there are no detectable amounts of 
free trypsin, and degradation products from trypsin hydrolysis have 
been removed. The most relevant observation is that the evident 
increase of the hydrodynamic ratio of polymers shows that protein has 
been conjugated to the polyacetals. 
GPC analyses were also performed in aqueous conditions to compare 
the MW increase of Trypsin conjugates with respect to naked T.   
Results are summarized in table 4-2. 
Table 4-2 Comparison between MWp of naked T, PASucc, PACOOH, 
PASucc-T and PACOOH-T. 
 Mw (g/mol)a PDIa 
T 23650 - 
PASucc (4) 10512 1.4 
PACOOH (5) 10307 2.1 
PASucc-T (6) 26531 1.3 
PACOOH-T (7) 27400 1.7 
a. As determined by Gel Permeation Chromatography (GPC) 
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Following, chemical structure of PASucc-T (6) and PACOOH-T (7) were 
analized by 1H NMR. 
In Figure 4.17 draws attention the peak that appears around 5.5ppm 
upon conjugation between PASucc and Trypsin (PASucc-T).  Although 
further experiments should be performed to ratify this effect (2D NMR 
such as TOCSY), it seems there is a displacement of the acetalic –H 
from the serinol (4.6 ppm) due to the shielding induced by the 
presence of conjugated trypsin, this peak is absent in the physical 
mixture. Therefore, it could be said that the conformation adopted by 
the conjugate really induce an important structural change, also 
observed in CD analysis (Fig. 4.18). 
 
Figure 4.17. 1HNMR analysis of a family of PASucc-T, according to 
ratio PA/T: 6a=20/1 , 6b=40/1, 6c=60/1, conjugates by 1HNMR in 
DMSO d6, 300MHz. 
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Instead, the PACOOH-T (7) 1H-NMR spectrum did not show the 
mentioned peak a 5.5pmm.  This observation indicates that electron 
delocalization that presumably occurs with linker mediated polyacetal 
(PASucc, 4) an trypsin, is not taking place when direct bounding is 
performed, as in case or PACOOH (5) and trypsin.  Again, further 
experiments should be performed to unravel this phenomenon (2D 
NMR such as TOCSY), 
 
Figure 4.18. 1HNMR analysis of PACOOH-T (7) conjugate by 1HNMR in 
DMSO d6, 300MHz. 
 
The total protein content in the conjugate was quantified by UV-Vis 
spectroscopy using the colorimetric quantitative assay Bradford, 
commonly used for total protein quantification.   
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Results summarized in table 4.3, show that conjugation was 
accomplished in all cases, and that it is possible to modulate the 
amount of protein linked to the polyacetalic carrier.  In this case it is a 
great advantage that polyacetal are virtually invisible to UV detector at 
280nm and they do not cause any interference, which simplify the 
total protein quantification procedure.  Besides, conjugation efficiency 
was 100% in all cases according to FPLC and SDS-PAGE gels showed 
that conjugation increase the stability of T in comparison to naked T 
under the same environmental conditions, as expected. 
Table 4-3. Quantification of protein content and free amino groups 
available in PASucc-T conjugates  
 
Ratio                    
PA(nCOOH) 
/ T(nNH2) 
% Total 
protein 
(wt%±5)
* 
Ratio 
n NH2/n 
protein 
(n ±2) 
** 
T 0 100 14 
PASucc-T 6a 20 35 2 
PASucc-T 6b 40 22 2 
PASucc-T 6c 60 20 2 
PACOOH-T 7 20 35 2 
*Method of quantification applied: Bradford  
**Determined by TNBSA. 
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Regarding the structural integrity of trypsin after conjugation, CD 
spectra showed there were no significant differences between naked 
and conjugated T under the same aqueous saline solution conditions. 
 
 
Figure 4.19.  Circular Dichroism analysis for naked T, PASucc (4) and 
PASucc-T (6a). 
 
 
 
Figure 4.20.  Circular Dichroism analysis for naked T, PACOOH (5)  and 
PACOOH-T (7). 
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On the other hand, diffusion experiments by NMR (DOSY analyses) did 
not show any relevant information about the possible existence of 
different macromolecular structures, however further studies should 
be performed in this context. 
4.3.3. Study of  PUMPT effect with PA-T conjugates 
The enzymatic activity of T, naked and conjugated, was studied first in 
comparison with PASucc conjugates in order to proof the PUMPT 
concept with polyacetals, which is the main contribution of this study.  
In this case, protein unmasking was supposed to be triggered by 
change of pH, from neutral to acidic conditions, as require to achieve 
the hydrolysis of acetal bounds in the polymer main chain, making 
possible the protein release. 
4.3.3.1. Determination of PUMPT effect in PA-T conjugate 
As it can be seen in figure 4.21, there is actually a clear change in the 
enzymatic activity profile when T is conjugated to PASucc in 
comparison to naked T when both samples are incubated at pH 7.4, for 
10 min at 37ºC.  PASucc-T enzymatic activity is very much lower than 
naked T activity.  This is clear evidence that protein activity was 
masked by the polyacetal.  
On the other hand, when samples of naked T and PASucc-T are 
incubated in the same acidic conditions, PBS solution pH 6.5, for 10 
min at 37ºC, both samples showed almost the same enzymatic activity 
profile, proving that T was release or un-masked from polyacetal and 
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protein recovers its original activity.  PUMPT effect was achieved with 
T and polyacetal conjugation.    
4.3.3.2. Effect of PA/T ratio with PASucc-T conjugate 
At the same time, the influence of nCOOH/nNH2 ratio over the activity 
was evaluated by comparison of T activity from PASucc-T, 6a, 6b, and 
6c, before and after incubation at different pH.  All samples had the 
same concentration of trypsin equivalents, they were incubated during 
the same period of time, and treated in neutral (pH 7.4) and acidic (pH 
6.5) conditions, mimicking the physiological pH, present in healthy and 
wounded tissue, respectively, thinking in a possible application.  The 
results are summarized in table 4-4 and figure 4.20, were it can be 
notice that enzymatic activity of T was partially suppressed at pH 7.4, 
when it was conjugated, in comparison with naked T at the same 
condition.  This means that proteins, or at list the active sites, are 
shielded by polyacetals which are covalently linked to lysine residues 
of trypsin, making possible to observe the masking effect of polymer 
over the enzymatic activity.  
Besides, it was possible to recover the activity after incubation of 
conjugates at pH 6.5 for 2h.  It is interesting to remark that activity was 
recovered in all systems keeping the T protected to the acidic 
degradation.  These results prove that protein was unmasked by effect 
of acidic pH, responsible of hydrolysis of PASucc 2 main chain. 
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Figure 4.21  Comparison of PUMPT effect with different polyacetal-protein conjugates. Enzymatic Activity of Trypsin using L-
BAPNA as substrate at different pH and at 37ºC. 
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Table 4-4. Comparison of enzymatic activity between naked T and 
PASucc-T at different pH (t=2h). Data as mean ± SD (n>3) 
Compound 
% Enzymatic Activity (0.2mg 
protein/mL) 
pH 7.4* 
(masked) 
 
pH 6.5* 
(unmasked) 
 
PASucc-T 6a 17 ± 5 132 ± 5** 
PASucc-T 6b 16 ± 5 71 ± 5 
PASucc-T 6c 20 ± 5 77 ± 5 
* % Activity relative to naked T enzymatic activity at pH 7.4 
**See discussion 
 
4.3.3.3. Effect of the polymer-protein linker: Determination of 
PUMPT effect in PACOOH-T conjugate and 
comparison with PASucc-T 
According with the results summarized in table 3-5, both systems were 
able to hide efficiently the enzymatic activity of trypsin, with the 
possibility to recover the protein activity even increased in comparison 
with naked trypsin under de same conditions.  These observations 
make possible to conclude that there are not a significant effects when 
protein in attached to the polymer by linkers or not.  
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Table 4-5  Comparison of PUMPT effect with PASucc-T 6a and 
PACOOH-T 7 after 2h. Data as mean ± SD (n>3) 
Compound 
Protein 
Content 
wt% 
% Enzymatic Activity* 
pH 7.4* 
(masked) 
 
pH 6.5* 
(unmasked) 
 
PASucc-T 6a 35 17 132 
PACOOH-T 7 35 28 233 
*Assay condition: [S]:1.64mM LBAPNA, [E]: 0.2mg/mL trypsin, T: 37ºC, 
t: 10min of incubation, stirred at 450rpm%.  Activity relative to naked 
T enzymatic activity at pH 7.4 
 
 
4.3.3.4. Study of PUMPT effect over Kinetic parameters of T 
enzymatic activity under different reaction 
conditions  
Data from experiments in section 2.4.3 were used to choose the best 
candidate for kinetic studies, which resulted to be PACOOH-T 
conjugates.  The enzymatic activity of trypsin, masked and unmasked, 
was measured using LBAPNA assay, following the same procedure 
previously described.  Incubation temperature (37 °C) and trypsin-
equivalent concentration were kept constant.  Experimental 
conditions used as variables were: i) substrate concentration (L-
BAPNA, 0.20 mM, 0.40 mM, 0.80 mM, 1.2 mM), ii) incubation time (0h, 
0.25h, 0.5h, 1h, 6h, 8h, 24h), iii) incubation pH (5.5, 6.5, 7.4).   
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Table 4-6. Study of PUMPT effect with PACOOH-T (5) at different 
incubation time at pH 7.4  
T(h) 
T 
(% relative enzymatic 
activity respect naked T) 
PACOOH-T 
(%relative enzymatic 
activity respect naked T) 
0 100 11 
0,5 150 17 
1 105 93 
5 63 10 
8 28 5 
24 34 36 
 
  
Figure 4.22  PUMPT effect with PACOOH-T (5) at different incubation 
time at pH 7.4 
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Table 4-7. Study of PUMPT effect with PACOOH-T (5) at different 
incubation time at pH 6.5 
T 
(h) 
T 
(%relative enzymatic 
activity respect naked T) 
PACOOH-T 
(%relative enzymatic 
activity respect naked T) 
0 82 28 
0,5 89 49 
1 103 34 
5 62 32 
8 55 45 
24 56 62 
  
Figure 4.23  PUMPT effect with PACOOH-T (5) at different incubation 
time at pH 6.5   
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Table 4-8. Study of PUMPT effect with PACOOH-T (5) at different 
incubation time at pH 5.5 
T 
(h) 
T 
(%relative enzymatic 
activity respect naked 
T) 
PACOOH-T 
(%relative enzymatic 
activity respect naked T) 
0 222 23 
0,5 157 83 
1 107 65 
5 100 49 
8 71 55 
24 46 84 
 
  
Figure 4.24  PUMPT effect with PACOOH-T (5) at different incubation 
time at pH 5.5 
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4.3.4. Synthesis and characterization of PEG-Trypsin 
conjugates. 
It is expected that PEG-Trypsin conjugates protect the protein from 
degradation once it was loaded into the membranes and prevent the 
loss of biologic activity.  Studying the activity of trypsin before and 
after PEGylation, and finally after encapsulation and release from the 
scaffold, it will be possible to estimate the behavior of another 
proteins with specific application in tissue regeneration. 
Bicinchoninic acid (BCA) assay kit was used to quantify protein content 
in the conjugates, always using Trypsin standards.  
 
Table 4-9. Quantification of Trypsin conjugates to PEG polymers 
determined by BCA 
Trypsin conjugate Wt% trypsin 
MeO-PEG-Succ-T 20±1 
MeO-PEG-COOH-T 26±1 
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SDS-PAGE electrophoresis was used to assess if trypsin PEGylation was 
accomplished as well as the presence of free trypsin after the reaction. 
 
Figure 4.25  SDS-PAGE electrophoresis with 15% of Acrylamide with 
0.75mm of thickness, running for 15min at 90V and the last 45min at 
130V, and stained with Coomassie blue Volume of each sample: 10 µL. 
T: free Trypsin, A: PEGylated trypsin with MeO-PEG-OH MW 2000 Da, 
C: PEGylated trypsin with MeO-PEG-COOH MW 2000 Da (B), and 
mixture of T and MeO-PEG-OH 2000  
 
SDS-PAGE (figure 4.25) revealed that only the strategy 2, for MeO-
PEG-Succ-T conjugation was successful without free trypsin.  
Therefore, the following experiments of encapsulation were carried on 
using only this conjugate. 
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Figure 4.26.  FPLC analysis of a) Trypsin; b MeO-PEG-Succ-T, in PBS 
100mM pH 7.4, flow 0.5ml/min, 215, 254 and 280nm, column 
Sephacryl S300 16/60, sample loaded: 1mL, 5mg/mL T equivalent 
FPLC chromatogram showed there was not free trypsin after 
conjugation and purification processes.  This results also demonstrated 
that PEGylation reaction  was accomplished successfully. 
Structural integrity of protein after conjugation was corroborated by 
circular dichroism as well as it was done with PUMPT conjugates 4.2.2. 
As it can be seem in figure 4.27, PEGylation do not seem to have had a 
completely change the conformation of protein tertiary structure, 
keeping alfa-helix and random coil proportion similar to free trypsin, 
 UV1_280nm 
 UV2_254nm 
 UV3_215nm 
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but the second peak in PEG2000-T profile reveals that tridimensional 
arrangement of protein structure was modified in some grade. 
 
Figure 4.27.  Circular Dichroism analysis for not conjugated Trypsin 
(T), PEGylated trypsin with MeO-PEG-OH MW 2000 Da (PEG2000-T), 
MeO-PEG-OH MW 2000 Da (PEG2000),   and physical mixture of 
MeO-PEG-OH MW 2000 Da and trypsin. 
In order to corroborate the influence of this structural change over the 
biological activity of the protein, L-BAPNA enzymatic activity assay was 
also accomplished, following the same procedure previously described 
in section 4.2.3.1. 
After PEGylation the enzymatic activity of trypsin decreased 
considerably. Even thought, the enzyme is still active, and therefore 
could be useful for proteolysis of other proteins always that 
concentration of enzyme was enough to accomplish its porpoise in the 
selected environment of application. 
 154 
 
The esterase activity of trypsin was calculate and compared with the 
activity of the conjugate applying the equation of Lineweaver-Burk:    
        Equation 4-2 
Table 4-10. Activity of trypsin and trypsin-PEG conjugates with L-
BAPNA as substrate. Kinetic parameters of native and PEG-trypsin 
conjugates 
 (µg/mL) 
Residual 
activity (%) 
KM 
(mM) 
Vmax 
(min) 
Kcat 
(s-1) 
Kcat/KM          
(s-1 mM-1) 
Trypsin 0,50 100 1,43 0,08 0,21 0,15 
PEG2000-
T 
0,91 64 1,11 0,03 0,50 0,45 
 
According to these results trypsin activity diminish when it is conjugate 
with PEG.  It is interesting that conjugates with PEG also have lower 
Km values indicating a higher affinity for the binding site of trypsin, 
and in fact the increase in the molecular weight is related directly with 
a decrease of kinetic parameters.  This behavior has been observed 
before by Treetharnmathurot (2008)32.  As it was coment before,  
applications the used of PEGylated proteins as in this case implies that 
it would be necessary to find an strategy to protect the protein and 
modulate the localized release of protein during an especific period of 
time.  Therefore it is necessary to test if residual activity before and 
after release would be enouth to provide the thapeutic effect and be 
able to make the adjusments in doses administration.   
𝟏
𝑽𝒐
=
𝑲𝒎
𝑽𝒎𝒂𝒙 𝑺 
+
𝟏
𝑽𝒎𝒂𝒙
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4.4. Discussion 
NMR analyses demonstrated that all polyacetals were successfully 
synthesized.  Also conjugates with both types of polyacetals (4 and 5) 
with trypsin were obtained, according to SDS-PAGE and FPLC analyses.  
The last ones showed there were no detectable amounts of free 
trypsin.  Besides, the clear difference between conjugate elution times 
vs. free trypsin provides evidence of increase in hydrodynamic ratio, as 
expected for these polymer-Trypsin conjugates.    
On the other hand, the comparison among PASucc-T (6) family of 
compounds about the influence of the variation of the ratio between 
NH2-T/PASucc-COOH functional groups with respect to efficiency of 
conjugation and size, is not providing an important difference in terms 
of size.  These results are coherent with the experimental fact that 
after the conjugation reaction the amount of free amino groups 
available, determined by TNBSA is the same for the three products.  
Remember that each trypsin molecule have 14 amino groups from 
lysines (quantified previously by TNBSA assay) available to react with 
activated carboxylic groups from PA. 
Taking into account these results, it was decided to synthesize new 
conjugates with T and PACOOH as the masking polymer.  The chosen 
ratio NH2-T/PACOOH was 1:20.  Results similar to those observed 
previously for PASucc-T family was observed with 1H NMR, SDS-PAGE 
and FPLC analyses.   In this case, it was necessary to use the same kind 
of column for FPLC but smaller, in order to be able to inject small 
amount of sample (200µL) without loss of sensibility.  Here the peak 
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corresponding to conjugate PACOOH-T (5) sample was bigger enough 
to be distinguished clearly from naked trypsin.  Notice, the ratio T/Vr 
for PA-T, which is 3/1, was the same for both families of PA-T 
compounds (4 and 5), which suggest they are in the same range of 
molecular weight. 
Summarizing, results previously described revealed that succinoylated 
linker between polyacetal main chain (2) and trypsin is not providing a 
clear advantage in comparison to the conjugate without linker (3).   
Therefore, novel polyacetal PACOOH seems to be a better alternative 
for PUMPT because, a) the synthesis is one step instead two as in case 
of PASucc, reducing loss of row material and save time with less 
purification steps; and b) once the proteins are unmasked the residues 
that could remain linked to their amino groups in the primary 
structure are significantly smaller than the residues that could be left 
from PASucc, reducing the risk of possible change in the third structure 
of proteins, induced by hydrophilic/hydrophobic interactions, which 
could cause occurrence or increase of hindrance effects  between such 
residues with other aminoacid residues or small molecules like water.   
In this manner, possible increase of inactivation of the active site of 
proteins, in case of enzymes, is prevented, as well as the inhibition of 
site recognition in case of proteins with action over the cell membrane 
surface receptors.  
The sum of all the above issues leads to a very promising system, with 
synthetic and maybe physicochemical advantages pointing to simplify 
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the scale up processes that is critical to be able to go into medical 
applications. 
It was possible to observed that the used of linker do not produce 
specific influence on the accomplishment of the PUMPT effect.   
Nevertheless, the PA/T ratio do have an influence, making necessary 
to take into account the optimization of this proportion, that in this 
study was demonstrated to be 40/1 in PA/T. 
The study of PUMPT effect over kinetic parameters of enzymatic 
activity of T in comparison with PACOOH-T under different reaction 
conditions demonstrated that under neutral pH T and PA-T show 
similar kinetics but under acidic conditions T tend to lose activity, 
while PA-T activity was increasing continuously.   
These behaviors are coherent with expected because trypsin suffers 
degradation by self-proteolysis at neutral pH and due to hydrolysis 
under acidic pH.  
Instead, PA-T was unwrapping trypsin gradually, making possible to 
keep the protein activity for longer even under acidic conditions. 
PEGylated proteins were also obtained, being the most efficient 
strategy the use of Succinoylated MeO-PEG-OH instead of MeO-PEG-
COOH. 
SDS-PAGE as well as FPLC analyses demonstrated the successful 
PEGylating reaction, with 20wt% of total protein loading.  Also 
enzymatic activity was evaluated and it was observe that pegylation 
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process reduce the activity as expected according to previous studies, 
published for other researches32  
PUMPT system proposed in this chapter may provide an alternative to 
PEGylation in those cases where pH could be used as trigger for 
protein release, offering the possibility to improve the biological 
activity perform of conjugated proteins.   
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4.5. Conclusions 
We have successfully designed a novel polymeric system capable of a) 
protect and mask the protein activity under normal pH physiological 
environment, and b) that is completely able to recover its activity in a 
time-dependent manner once arriving to acidic condition similar to 
those proper of damage tissue for example suffering from 
inflammation processes. 
 
PEGylation of trypsin was accomplished and the obtained product is 
stable enough as to be used in the next step of experimentation that is 
the encapsulation into microparticles. 
 
Conjugation of proteins with interesting biological activity for tissue 
repair, like IL-6 is currently ongoing in our laboratory and the biological 
evaluation of protein-polyacetals conjugates will be carried out in 
primary cell cultures and in the appropriate in vivo models. 
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5. SYNTHESIS AND CHARACTERIZATION OF 
CURCUMIN POLY(ACETAL)S 
5.1. Introduction 
As mentioned in the general introduction, nanomedicines known as 
“Polymer therapeutics” (PT) constitute a relatively new technology for 
controlled drug delivery which has become a useful tool for treatment 
and diagnosis of several diseases during the last years, but it is still an 
emerging field with enormous potential to explore. As can be deduced 
by the name, big part of “the secret behind the success” lies in the 
properties of the polymers used to synthesize them and polyacetals 
are members of this special family.  
With 40 products already in the market and more than 70 in cancer 
clinical trials113, the nanomedicine field has experienced a great 
exponential growth within the last decade. This fact is due to its 
potential to serve as a candidate solution for the urgent requirement 
of dealing with unsolved pharmaceutical and clinical needs in life-
threating diseases114. In the recent years, nanomedicine has gained 
special attention in different research areas, especially for drug and 
gene delivery, in diagnostics and molecular imaging as well as in tissue 
repair and engineering115 amongst other uses. 
Nature and virtues of polymer therapeutics were previously described 
in general introduction. Therefore, in this chapter we are going to 
highlight some aspects particularly interesting for this study. 
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5.1.1. Polyacetals as carriers. 
Polyacetals are well-known polymers since 1980 when Heller et al77 
published their synthesis by the reaction of divinyl ether and polyols. 
Their main qualities are that the synthesis is performed under mild 
conditions and products are water soluble, stable in neutral pH but 
degradable under mild acidic conditions and absolutely biocompatible. 
Latter, Tomlinson and co-workers78,79 saw the opportunity to take 
profit of these qualities and published the synthesis of functionalized 
amino-pendant drug-loaded polyacetals as alternative to water 
soluble, high molecular weight, non-biodegradable polymers used as 
carriers for conjugation of bioactive agents, in order to provide a 
solution to the problem of polymer accumulation in the lysosomes116. 
Tomlinson et al. 78,79 demonstrated that these polymers were able to i) 
be stable at physiological pH (~7.4); ii) be able to improve drug 
delivery to cancer cells in vitro and iii) be biodegradable under acidic 
pH, showing pH dependent drug release kinetics, allowing to control 
drug release in acidic cellular compartments such as endosome (pH 
6.5) and lysosomes (pH5.5). In 2006 Vicent et al.80 described for the 
first time, the synthesis of polyacetals with the drug diethylstilbestrol 
(DES) directly linked to the polymer backbone through acetal bonds. 
Such systems demonstrated enhanced in vitro antitumor activity in 
comparison with the drug alone. The versatile synthesis described by 
Vicent and co-workers allows to easily introduce diol-bearing drugs 
without the need of complex linking strategies. From the same group, 
Gimenez et al. 81 applied similar strategies to synthesized novel 
polyacetal-drug conjugates, specially emphasizing the influence of 
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polymer architecture in the biological performance. Furthermore, 
England et al.12 have recently demonstrated the power of polyacetal-
based combination therapy (two drugs in the same polymer) designed 
for antitumor application with very promising in vitro and in vivo 
results. Tang and co-workers82 have also published their results 
regarding the synthesis of a battery of curcumin-bearing polymers as 
anticancer conjugates following the same strategy by means of 
curcumin introduction within polymer backbone. Among their polymer 
structures, polyacetals represented the best candidates for their 
applications as anticancer therapies according with their in vitro and in 
vivo activity. 
5.1.2. Chronic wounds and Curcumin as model drug. 
On the other hand, during the last years, Curcumin, a natural 
polyphenol extracted from Curcuma longa (turmeric) and with 
ancestral use in traditional Asian medicine, caught the attention of 
researchers due to the wide spectrum of biological activities that has 
demonstrated to possess, including antioxidant, anti-inflammatory, 
antiviral, antimicrobial and anticancer agent. Curcumin 
(diferuloylmethane) is a polyphenolic compound derived from 
turmeric spice from curcuma longa117. Naturally occurring 
curcuminoids are a mixture of curcumin (77 %), demethoxycurcumin 
(DMC) (17 %), and bisdemethoxycurcumin (BDMC) (3 %)118. (See Figure 
5.1.). 
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Curcumin antagonizes many steps in the inflammatory cascade, 
including activator protein-1 transcription, activation of nuclear factor-
kB, iNOS, and JNK119–121.   
 
Figure 5.1. Structure of the different curcuminoids present in 
curcuma turmeric spice from curcuma longa. 
It also exerts a potent antioxidant activity for NO-related radical 
generation122  In fact, to date curcumin has become in a very attractive 
candidate for applications related with the treatment of various 
cancers, neurodegenerative deceases and of course, wound healing. 
In this work, PACur conjugates were chosen as candidates for tissue 
repair/regeneration applications, concretely, for wound healing of 
chronic injuries. As it was previously explained in general introduction, 
this pathology is related with aging diseases among other aspects and 
is characterized by occurrences of inflammation and subsequent 
infection of the injury45. Interestingly, during inflammation stages the 
pH of the tissue becomes slightly acidic, around 639.  Therefore a 
rational design of a localized drug delivery system may include a 
polymer-drug conjugate composed by polyacetals because they are 
Curcumin Demethoxycurcumin
Bisdemethoxycurcumin
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biodegradable, biocompatible and their degradation depends on pH 
changes; and curcumin because of its potential antioxidant, anti-
inflammatory and antimicrobial activity. 
5.2. Methodology 
5.2.1. Synthesis and Characterization 
Curcumin polyacetals (PACur) were synthesized following a 
modification of the methodology proposed by Giménez et al.12,81 
applying Schlenk techniques. Briefly, diol-polyethylene glycol (diol-
PEG4000) (1.257mmol, 5.030g) used as monomer and p-Toluenesulfonic 
acid p-TSA (0.074mmol, 0.014g) used as a catalyst for the addition 
reaction, were weighted and added 100mL Schlenk tube (A). 
Curcumin, the second monomer (1.0832mmol, 0.339g) was weighted 
separately in another Schlenk tube (B). Both flasks were purged 3 
cycles of dry N2 and vacuum at room temperature and finally 
completely dried under high vacuum (20min). The contents of each 
flask were dissolved in anhydrous dioxane (20mL for A and 10mL for 
B). Flask A was heated up to 80ºC to dissolve completely the solids and 
it was left to cool down until room temperature (25ºC). Then, the 
curcumin solution was transferred under inert N2 atmosphere with the 
aid of a cannula. Once they were completely mixed, the last monomer, 
Triethyleneglycol-Divinylether, TEGDVE (2.1538mmol, 0.44mL) was 
added dropwise. The reaction was carried out under N2 atmosphere, 
stirring for 3h. After that, pH was adjusted to 8 with triethylamine 
(0.2mL) in order to quench the reaction (by neutralizing pTSA) and 
finally the product was separated by precipitation into a large excess 
of hexane: diethyl ether (ratio 4:1) and filtered off. The product 
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recovered was purified by recrystallization in hexane: diethyl ether (3x, 
100mL) and dried under vacuum. The final product was isolated as a 
yellow loose powder and it was stored at -20ºC for further analyses. 
5.2.1.1.  Structural Characterization by NMR 
Structural characterization of products was carried out by NMR 
spectroscopy. Samples were dissolved in DMSO-d6, Spectra were 
recorded in a Bruker 300 BRUKER ADVANCE AC-300 (300 MHz, ) 
spectrometer and NMR data was processed using the programs 
Topspin 1.3 (Bruker GmbH, Karlsruhe, Germany) and MestreNova 
v6.0.2-5475 (MestreLab Reseach S.L., Galicia, Spain). The chemical 
shifts of the nucleus are reported as s (singlet), d (doublet), t (triplet), 
q (quartet) or m (multiplet) and expressed by  (ppm) taking as an 
intern reference the tetramethylsilane signal (TMS) 0.00 ppm, and the 
intermediate signal in the quintuplet (49.86 ppm) in the carbon 
spectra. The J-coupling constants are expressed in hertzios (Hz). 
Besides 1H and 13C NMR experiments, two-dimensional NMR 
experiments were also performed, concretely, 2D-Correlation 
spectroscopy (COSY). 
5.2.1.2. Determination of Molecular weights and polydispersity 
by GPC 
Molecular weight and polydispersity of all products obtain after 
polymerization reactions with curcumin, PEG4000 and TEGDVE, were 
determined by GPC in aqueous (PBS 1X, pH 7.4) phase. Samples were 
dissolved in PBS and injected in the GPC instrument as explained 
previously in general methodology section. Polymer solution (6mg/mL 
in PBS) was injected in GPC using two TSK Gel columns in series G2500 
PWXL and G3000 PWXL with a Viscotek TDATM 302 triple detector 87 
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with UV detection coupled. The mobile phase used was PBS 0.1 M, 
flow 1 mL min-1. 
5.2.1.3.  Quantification of free drug and total drug loading 
Total drug loading in PACur was determined by UV spectroscopy. First, 
maximum absorbance wavelengths for curcumin were identified by 
registering the UV-Visible spectrum of curcumin in the absorbance 
range between 220nm at 600nm in Acetonitrile ACN, ethanol and PBS 
1X pH 7.4. For quantification, a calibration curve ranging from 0.2-20 
µg/mL of curcumin was performed at fixed wavelengths of at 260nm, 
405nm and 418nm, using quartz cuvettes of 1mm of length path. To 
do that, a mother solution of curcumin in ethanol was prepared at 
1mg/mL and from there; the different concentrations were adjusted 
by diluting with PBS 1X pH 7. In order to establish curcumin loading 
within the PACur, samples were measured at 6mg/mL under the same 
conditions used for the calibration curve. Total drug loading (TDL) was 
determined as percent in weight from total polymer mass, using the 
calibration curve to translate absorbance in curcumin concentration. 
𝑇𝑜𝑡𝑎𝑙 𝑑𝑟𝑢𝑔 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 (%) =  
𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑐𝑢𝑟𝑐𝑢𝑚𝑖𝑛 𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑑 𝑖𝑛 𝑃𝐴𝐶𝑢𝑟 𝑝𝑜𝑙𝑦𝑚𝑒𝑟 (𝑚𝑔)
𝑚𝑎𝑠𝑠 𝑜𝑓 𝑃𝐴𝑐𝑢𝑟 𝑝𝑜𝑙𝑦𝑚𝑒𝑟 (𝑚𝑔)
𝑥100 
Equation 5-1. Total drug loading determination by UV-Vis. 
 
Free drug amount was determined by RP-HPLC, from a PACur solution 
in ACN (6mg/mL), using the gradient mode, with a ramp 
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70A:30B/30A:70B (A:ACN;B:PBS 1X 7.4) in 20 minutes run. Retention 
time of curcumin was 6.6min. Non acidic or basic additives were used 
in any of both mobile phases to prevent sample decomposition due to 
a decrease or increase in pH. For HPLC analysis 50μL of standard and 
sample solution were injected with a 1mL/min flow, into a C18RP 
column. Calibration curve ranging from 0.2-20 µg/mL of curcumin was 
performed under these conditions.  UV-Vis detector was used to 
register HPLC signals, at 260nm, 405 and 418nm. Calibration curves 
were built following the same protocol than used for UV spectroscopy. 
𝐹𝑟𝑒𝑒 𝑑𝑟𝑢𝑔 𝑐𝑜𝑛𝑡𝑒𝑛𝑡 (%) =  
𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑓𝑟𝑒𝑒 𝑐𝑢𝑟𝑐𝑢𝑚𝑖𝑛 𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑑 𝑖𝑛 𝑃𝐴𝐶𝑢𝑟 𝑝𝑜𝑙𝑦𝑚𝑒𝑟 (𝑚𝑔)
𝑚𝑎𝑠𝑠 𝑜𝑓 𝑃𝐴𝑐𝑢𝑟 𝑝𝑜𝑙𝑦𝑚𝑒𝑟 (𝑚𝑔)
𝑥100 
Equation 5-2  Free drug content determination by HPLC analysis. 
 
5.2.2. Hydrolysis of PACur and Curcumin Release kinetics 
3mL solutions of PACur conjugate (6mg/mL) were prepared using PBS 
buffers at different pH: 5.5, 6.5 and 7.4 and incubated up to 5 days at 
37ºC. Aliquots (200μL) were taken and frozen immediately in liquid 
nitrogen at selected time points (0, 15, 30min, 2h, 8h, 24h, 48h, 72h, 
96h, 120h, 260h) and stored at -80ºC until analysis.  Before the 
analysis, acidic samples were neutralized with a solution of ammonium 
formate 0.1M and the volume of all samples was adjusted with PB 
pH7.4 in order to keep the same concentration. Samples were 
analyzed by HPLC and GPC.  
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For HPLC analysis, 50μL of sample were injected using same condition 
as described above for total and free drug content. 
For GPC analysis 100μL of sample were injected and analyzed as 
described in general methodology. 
5.2.3. Cytotoxicity of Cur and PACur 
Cell viability is defined as the percentage of live cells compared with 
untreated controls. Therefore, cytotoxicity of free Curcumin and PACur 
conjugates was determined in a human fibroblast cell line and using 
the standard MTS assay (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) to measure 
cell viability. Cells were cultured in Dulbecco's Modified Eagle Medium, 
DMEM (Fisher, Spain), with 4.5 g/l D-glucose, supplemented with 10% 
de fetal bovine serum FBS (Fisher), 1% of penicillin/streptomycin and 
1% of L-glutamine (Lonza, Switzerland). Cells were used in their 
exponential phase of growth. 
Briefly, fibroblast cells were seeded onto 96-well plate with a density 
of 10.000 cell/cm2 (100µL) and incubated at 37ºC, in a humidified 
atmosphere with 5% CO2 (v/v) up to 24h to allow cells were properly 
adhered. Then the medium was replaced by different concentrations 
of drug (alone or conjugated to the polymer), dissolved in culture 
medium from 0.5 to 38 µg/ml drug-equivalent. 
After 72 h with treatment, combination of MTS/PMS was used to 
assess cell viability after treatments. In brief, after cell incubations, 10 
µL of manufacturer solution of MTS/PMS (20:1) was added to each 
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well, and the cells were incubated for a further 2 hours. Mitochondrial 
dehydrogenase enzymes of viable cells converted MTS tetrazolium 
into a colored formazan product. The optical density of samples was 
measured at 490 nm. Absorbance of the optical density of the solution 
was determined spectrophotometrically in a Perkin Elmer precisely 
1420 Victor 3TM multi-label counter using a microtiter UV plate reader.  
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5.3. Results 
5.3.1. Synthesis and Characterization 
PACur reaction yield was 5.42g, 2.3603mmol, 41%. Total drug loading 
in the polyacetals were 9.5 wt.% with less than 0.2 wt.% of free drug, 
according to UV and HPLC analyses, respectively. Polyacetals had a Mp 
17106 g/mol; Mn=19526g/mol; Mw=51302 g/mol; Mw/Mn=2.6 as 
determined by GPC in PBS.  
 
 
Figure 5.2  PACur synthesis from PEG, curcumin and TEGDVE 
monomers. 
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Figure 5.3 GPC Chromatogram of Polyacetal-curcumin (PACur) 
conjugate, analyzed in PBS 1X, pH 7.4, at 30ºC, 35min running, 
sample concentration 6mg/ml, flow 1mL/min. Detectors: Refractive 
Index, Right angle light scattering, viscometer 
 
The 1H NMR (300 MHz, Acetone) spectrum (Figure 3.3) revealed the 
following chemical shift for main groups in PACur sample: δ 8.28 – 
8.06 (m, 1H, -OH), 7.62 (d, J = 15.8 Hz, 3H, HCd=C), 7.34 (s, 3H, H-ArCb), 
7.19 (s, 5H, H-ArCa), 6.89 (dd, J = 8.1, 2.4 Hz, 2H, H-ArCc), 6.83 – 6.66 
(m, 2H, C= HCe), 6.00 (d, J = 13.8 Hz, 1H, CfH2), 5.51 (s, 2H, Acetal jCH), 
4.76 (dd, J = 10.5, 5.2 Hz, 5H, , Acetal iCH), 3.95 – 3.88 (m, 9H, gCH3-O), 
3.86 – 3.31 (m, 590H, CH2-CH2, PEG+TEGDVE), 1.47 (d, J = 5.2 Hz, 6H, 
CH3-AcetalCj), 1.25 (d, J = 5.2 Hz, 15H, CH3-AcetalCi). 
COSY NMR bi-dimensional experiment spectrum of PACur (Figure 4.3) 
conjugate shows the relation between the groups to make clearer the 
assignments. 
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Figure 5.4 1H NMR spectrum of Polyacetal-curcumin (PACur) conjugate, acquired in DMSO-d6, at 300.5K, 300 MHz. 
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Figure 5.5 COSY NMR bi-
dimensional experiment 
spectrum of Polyacetal-
curcumin (PACur) 
conjugate, acquired in 
Acetone-d6, at 300 MHz,. 
Blue square shows 
relation between CH-
Acetal(PEG-TEGDVE) and 
CH3-CHAcetal(PEG-
TEGDVE). Orange square 
shows relation between 
CH-Acetal(Cur-TEGDVE) 
and CH3-CAcetal(Cur-
TEGDVE). Magenta, green 
and black squares belong 
to Curcumin double bonds 
and aromatic protons. 
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5.3.2. Hydrolysis of PACur and Release kinetics 
After 266h (11 days) in observation, it was determined that curcumin 
polyacetals are able to release curcumin faster at pH 5.5, as expected, 
with an initial burst of 4% on the first 30 seconds, followed by a fast 
released during the next 6 hours until reach 59% of drug release. Then, 
the system seems to be stabilized, showing a progressive release of 
curcumin at a relatively constant rate until 168h (7days). After that 
time, a slight increase in rate is observed until 266h (11 days) reaching 
85% of total drug release. Some precipitated was observed at that 
time, and the sampling was finished at that point in order to avoid 
mistakes due to drug decomposition or saturation of the solution 
analyzed with the drug released. 
Meanwhile, the release at pH 6.5 was also fast at the beginning, 
starting with a bust of 30% and reaching a 34% of drug release during 
the first 7 hours. Then as observed at pH 5.5, the release rate slows 
down and after 11 days only 52% of the total drug loaded was found 
to be released. 
On the other hand, at pH 7.4 curcumin-bearing polyacetals behaved as 
a relatively stable construct. After an initial burst of 7%, only 13% of 
drug was released during the first 8h and then rate release became 
slower during the next hours. From 24h and beyond the rate remains 
stable achieving around 25% release after 266h (11 days). 
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Figure 5.6  Drug release kinetic profile of Curcumin from polymer 
conjugates at different pH.  
 
5.3.3. Cytotoxicity of Cur and PACur 
Fibroblast cells of human origin were used to screen the cytotoxicity of 
PACur conjugates and free curcumin for comparison. Results were 
expressed as % Cell Viability vs Curcumin-equivalent concentration 
determined by MTS assay. Conjugates were found to be slightly more 
cytotoxic than de drug by itself at 72h of treatment, as can be 
appreciated in Figure 5.7. From this data IC50 values were calculated: 
IC50 of free curcumin was 36 µg/mL, while PACur IC50 was 24 µg/mL. 
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Figure 5.7 Cytotoxicity of free curcumin and polyacetal-curcumin 
conjugated (PACurc) measured in a human fibroblast cell line, 72h of 
treatment at 37ºC, in humidified atmosphere with 5% CO2. Mean ± 
SD, n>3 independent experiments. 
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5.4. Discussion 
5.4.1. Synthesis and Characterization 
In the present chapter, the synthesis and characterization of novel 
Polyacetal-Curcumin conjugates (PACur) with potential application in 
wound healing approaches have been addressed. PACur were easily 
obtained by applying a mild polymerization method involving the 
reaction of diols with divinyl ethers. This strategy allowed the 
incorporation of drugs with bis-hydroxyl functionalities (such as 
curcumin) into the polymer main chain. Provided the biodegradable 
character of PAs, such drugs introduced would be released under 
acidic environment by degradation of the polymer backbone, without 
the need for the use of biodegradable linkers. 
Concretely, our strategy was based on the use of cationic addition 
reactions catalyzed by acidic medium (use of pTSA). The mechanism of 
the polymerization reaction performed is depicted in the Figure 5.8.  
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Figure 5.8  Mechanism of polymerization by cationic additions 
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Polymerizations were successfully accomplished yielding well-defined 
PACur conjugates with up to 10.8 wt.% total curcumin loading and less 
than 0.2 wt.% of free drug contain as determined by UV-VIS and HPLC 
techniques. Although the drug loading obtained of the highly 
hydrophobic drug curcumin were considerably high, the PACur 
obtained showed complete solubility in aqueous solutions.  
According to GPC, the molecular weight (MW) obtained was in the 
range of 17000-20000 g/mol with a PDI around 2.6 as could be 
expected from the inherit limitations of this polymerization method. 
This MW is suitable in this desired application due to the fact that, 
even if not all the system is degraded, the MW is under renal clearance 
threshold (below 40000 g/mol).116,123   
1H NMR and COSY experiment confirmed the reaction success (Figures 
5.4 and 5.5), where curcumin molecules were shown to be clearly 
linked to polyacetals backbone. As already stated in Results section 
from this chapter, the 1H NMR spectrum shows the appearance of two 
different multiplets at different chemical shift corresponding to the 
area of the acetal peaks. The first one at 4.74 - 4.79 ppm can be 
assigned to PEG-TEGDVE acetal bond, and the second at 5.51 - 5.53 
ppm was assigned to Cur-TEGDVE acetal bond. The PEG-TEGDVE acetal 
bond peak showed a bigger integration than the other, pointing out 
that polymerization reaction might occur preferentially with PEG. This 
behavior was expected since PEG monomers are better nucleophiles 
than curcumin monomers. This can be attributed to the fact that, in 
the case of PEG, the two hydroxyl groups have their negative charge 
density localized over the oxygen atoms, making these electrons more 
 182 
 
available to attract protons, necessary in the initiation step of the 
polymerization. Instead, hydroxyl groups in curcumin are actually 
phenols, where the negative charge density of oxygen atoms is 
delocalized through the aromatic ring, making this OH groups bad 
nucleophiles in comparison with OH from aliphatic alcohol. For that 
reason, catalyst activates more PEG chains than curcumin molecules, 
resulting in a polymer with a higher proportion of PEG acetal. 
However, despite that line of reasoning, reactivity of curcumin was 
acceptable and the ratio obtained between both kind of acetals 
(Curcumin:PEG) was 1:2.52.  
5.4.2. Hydrolysis of PACur and Release kinetics 
Polyacetals are pH responsive polymers, soluble in water. They are 
designed to be hydrolyzed under acidic conditions. This kind of 
polymers has been successfully used (in vitro) as drug carriers, 
improving the pharmacokinetic and pharmacodynamic profiles of the 
free drug and providing mechanisms to stablish a sustained and 
controlled drug release12,81. Ideally, this system should make possible 
to reduce the number of doses and frequency of drug’s 
administrations, resulting in the improvement of treatment efficacy 
and patience comfort. On the other side, Curcumin is a natural phenol 
with a lot of potential therapeutic properties, including anti-
inflammatory and antioxidant activities, but its applications has been 
limited because of its hydrophobicity and therefore poor water 
solubility, relatively low bioavailability and low stability in solution.124   
 183 
 
Drawing from this premise it was expected that through the 
conjugation of curcumin with polyacetal, it should be possible to 
obtain hydro-soluble polymer conjugates, more stable in solution than 
curcumin alone, opening the door to a wide range of therapeutics 
uses, including wound healing.  
As explain before in the introduction of this chapter, inflammation is 
one of the phases that takes place during the process of chronic 
wounds and it is known that pH of injured area changes from neutral 
(pH 7.4) to slightly acidic (pH around 6) during this inflammatory stage. 
Such conditions make polyacetals one of the best choice as polymer 
carriers since it is expected to be able to tailor drug release by 
controlling pH changes in the specific environment.  
It has been demonstrated that curcumin-polyacetals conjugates 
synthesized through the present methodology explained in this 
chapter are completely soluble in water, because dilutions of different 
concentration between 3 a 25mg/mL were prepared as part of 
procedures for drug loading quantification. Hydrolysis experiments 
demonstrated that the highest drug release takes place at pH 5.5 as 
expected, followed by the release at pH 6.5 while the lower release 
was observed at pH 7.4 (Figure 5.6). 
Acidic pH made possible the hydrolysis of acetal bond through the 
protonation of oxygen atoms, probably following the mechanism 
proposed below in Figure 5.9. Basically, a protonated molecule of 
water, acts as the acid that initiate the hydrolysis, protonating one of 
the oxygen atoms in acetal bond. Probably, in the first step of the 
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mechanism the phenolic group (in case of curcumin or aliphatic 
hydroxyl in case of PEG chain) is recovered and a pseudo-carbocation 
(δC+) is formed. In this case, δC+ is in a secondary carbon with a –CH3 
adjacent. In the second step δC+ promotes the elimination of one of 
the proton from methyl group next, which is passed to another 
molecule of water, then a double bond (-C=C-) is formed between 
them. This mechanism is similar to the bimolecular Elimination 
mechanism used to explain the olefin synthesis by alcohol dehydration 
in presence of acid as catalyst but in this case, heating is not 
necessary125. Polyacetals can be hydrolyzed at 37ºC, natural body 
temperature, as shown in this experiment. Nevertheless, it is logical to 
expect that an increase in temperature produce an acceleration of this 
reaction. This fact represents an advantage to our systems in our 
desired application since inflammation also is companied by a slight 
raise of body temperature.  
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Figure 5.9  Proposed PACur mechanism of hydrolysis under acidic conditions. 
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Hydrolysis reaction takes place in a random way cleaving all acetal 
bonds yielding oligomers and finally the parent monomers: free 
curcumin, PEG and TEGDVE. 
 
Figure 5.10   Final products of PACur total hydrolysis 
It is evident that, in this case, drug release kinetic is directly related to 
polymer degradation, because curcumin is loaded in polyacetals as 
part of the main chain of the polymer. Therefore, when acetal bonds 
that link curcumin molecules to TEGDVE are broken, polymer 
molecular weight diminishes and curcumin is been released. 
In situ degradation of polymers is another positive aspect of this 
system, because prevents their accumulation in the lysosomal 
compartments of cells. Furthermore, the biggest non-biodegradable 
fragments are PEG4000, that are under the maximum MW (40 kDa) of 
renal elimination.  
5.4.3. Cytotoxicity of Cur and PACur 
Curcumin was selected as a drug for this study because of its anti-
inflammatory and antioxidant properties. In addition, it is believed 
that it can protect tissues from oxidative damage improving wound 
healing126. However, due to the other roles of curcumin and 
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curcuminoids related to anti-proliferative activity in cancer 
applications127,128, curcumin dosing in regenerative medicine must be 
carefully control in order to not induce unexpected toxicities.  
As mentioned in the general introduction, repair of injured tissues 
occurs as a sequence of events which include inflammation, 
proliferation and migration of different cell types. In the inflammatory 
phase, bacteria and debris are phagocytized and removed. In addition, 
neutrophils migrate to the wound site. This kind of cells generate free 
radicals, producing oxidative stress leading to local lipid peroxidation, 
DNA breakage and enzyme inactivation. Due to the fact that free 
radicals are produced during inflammatory phase, antioxidants like 
curcumin may inhibit inflammation allowing regeneration. 
Cytotoxicity assays in human fibroblasts were performed in order to 
ensure safety of our PACur at the concentrations to be used in wound 
healing applications. Such experiments revealed that PACur conjugates 
are slightly more cytotoxic than curcumin alone. However, these 
findings could not be necessary bad, because the PACur IC50 is still high 
enough to be sure that we can work in a safety concentration for 
wound healing applications, provided that only low concentrations are 
needed to provoke beneficial effects. Recent studies reveal that a 
concentration of 2µM of free curcumin is enough to reduce ROS in an 
acellular system (without cells) to measure antioxidant activity of 
curcumin129. As a second example, another study published that a 
maximum doses of 8.5µg/ml of curcumin released from nanoparticles 
(chitosan-PEG400) during 24h is enough to promote tissue 
regeneration in a model of murine burn injure29. 
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5.5. Conclusions 
In this part of the thesis, versatile polymer-drug conjugates based on 
the biodegradable polyacetals and the antioxidant curcumin have 
been effectively synthesized. Curcumin molecules were incorporated 
into a poly(ethylene glycol) (PEG) based polyacetal system using a 
reaction of short PEG chains with triethyleneglycol-divinylether 
(TEGDVE) units and an acid catalyst, without the need for 
biodegradable linkers. With an improved polyacetal synthesis strategy 
we obtained high yields of water soluble polymer conjugates with 
desirable drug loadings (total drug loading of 10.8 wt% and less than 
0.2wt% of free drug) and tailored molecular weights (Mw 17,000–
20,000 g/mol) with acceptable polydispersities.  
These polymers were found to be hydrolytically cleaved under acid 
conditions (such as those found in endosomes, lysosomes or the 
extracellular ﬂuid of some inflamed areas) yielding the free drug 
curcumin. Additionally, they were found to be stable over prolonged 
periods of time at pH 7.4 mimicking blood plasma. 
Cytotoxicity assays performed as a proof of safety ensured that PACur 
conjugates are not toxic within the therapeutic window for curcumin 
applications in wound healing. 
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6. SYNTHESIS AND CHARACTERIZATION OF 
HYALURONIC ACID MICROPARTICLES 
6.1. Introduction 
HA is a natural polyelectrolyte based on repeating disaccharides of β1-
4 D-glucuronic acid and β1-3 D-N-acetyl glucosamine ([β-1,4-GlcUA-β-
1,3-GlcNAc]n). Sahiner et al. highlight that it is present in the 
extracellular matrix (ECM) of all higher animals and plays vital roles 
regulation the ECM organization, in cell adhesion, cell motility, and 
cancer metastasis beside its inherent biocompatibility and 
biodegradability makes it an attractive biomaterial in drug delivery and 
tissue engineering.130–133  
Also, HA, an important component of the extracellular matrix, has 
been used as a viscoelastic biomaterial for medical purposes, in 
cosmetics because of its high water retention capacity and in  drug 
delivery systems because of its non-toxicity, biodegradability, and 
biocompatibility.44 
Most studies with HA are directed to hydrogel films or scaffolds 
fabrication93,132,134–145 due to its amazing biocompatibility and because 
it is a naturally occurring biodegradable polymer with a variety of 
applications in medicine, including scaffolding for tissue engineering, 
dermatological fillers and viscosupplementation for osteoarthritis 
treatment133.  
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Nevertheless, there are also interesting researches about the use of 
HA for fabrication of micro and nanoparticles.  For example, Lee et al.51 
studied a laminin-modified infection-preventing collagen membrane 
containing silver sulfadiazine–hyaluronan microparticles. They 
prepared hyaluronan-based microparticles containing silver 
sulfadiazine (AgSD) incorporated into the two collagen layers (AgSD 
content 50mg/cm2) and found that the laminin-coated AgSD-
medicated collagen membrane demonstrated a higher wound size 
reduction and vessel proliferation and lower inflammation  than the 
polyurethane control, suggesting that the laminin AgSD-medicated 
collagen membrane substantially improves dermal wound healing.51 
HA-based hydrogel microparticles are attractive materials for 
biomedical applications because they can provide bigger surface area 
that will improve tissue integrating and facilitate drug delivery130.   
Another interesting approach in this field is the encapsulation of 
nanomedicine like polymers conjugated to drugs or proteins, because 
in is expected that conjugation not only protect the molecules 
conjugated but also increase their potential therapeutic activity146. 
Lately, curcumin has kept the attention in this field as candidate to be 
encapsulated into HA films, vesicles, nanoparticles and 
microparticles147,148 with promising burn-wound healing potential. 
For this reason in this part of the project it was explore the possibility 
to obtain this kind of interested combine systems design for drug 
delivery. 
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6.2. Methodology 
6.2.1. Synthesis of MPs and encapsulation of model drugs and 
Polymer-drug conjugates 
6.2.1.1. Synthesis of HA MPs 
Microparticles of hyaluronic acid (MPs-HA), were obtained following a 
modification of the methodology proposed by Sahiner and co-
workers130 using the synthesis of microparticles by single reverse 
emulsion, a water-in-oil micro emulsion system.  At the beginning, 
MPs-HA without loading was fabricated in order to find the best 
parameter for the synthesis, and also keep this batch of MPs-HA as 
reference for comparison with loaded MPs.  
Theoretical cross-linking was calculated to be 90% as function of 
available reactive groups in HA chains as is shown in the equation 
%𝑪𝒓𝒐𝒔𝒔𝒍𝒊𝒏𝒌𝒊𝒏𝒈 = (
𝒎𝒐𝒍 𝑫𝑽𝑺
𝒎𝒐𝒍 𝒖𝒏𝒊𝒅 𝑯𝑨
)𝒙𝟏𝟎𝟎   Equation 6-1 
Amount of DVS was calculated as shown in the following example: 
𝒙 − 𝒈𝑯𝑨 = 𝟏𝟎𝒈𝒔𝒐𝒍𝒏 𝑯𝑨 𝒙
𝟓𝒈
𝟏𝟎𝟎𝒈 𝒔𝒐𝒍𝒏 𝑯𝑨
= 𝟎. 𝟓    Equation 6-2 
𝑥 − 𝑚𝑜𝑙 𝑈𝑛𝑖𝑑 𝐻𝐴 = 0.5𝑔 𝐻𝐴 𝑥
1 𝑚𝑜𝑙 𝑢𝑛𝑖𝑑 𝐻𝐴
401𝑔
= 0.00125𝑚𝑜𝑙 𝑢𝑛𝑖𝑑 𝐻𝐴 
𝑥 − 𝑚𝑜𝑙 𝐷𝑉𝑆 =
100%𝑐𝑟𝑜𝑠𝑠𝑙𝑖𝑛𝑘𝑖𝑛𝑔 𝑥 0.00125𝑚𝑜𝑙 𝐻𝐴
100
    Equation 6-3 
𝜇𝐿 𝐷𝑉𝑆 = 0.00112𝑚𝑜𝑙 𝑥
 118.15𝑔
1𝑚𝑜𝑙
𝑥
1𝑚𝐿
1.177𝑔
𝑥1000 = 112.9𝜇𝐿  
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Equation 6-4 
Briefly, an aqueous solution of HA 5% wt/v, (12 mL) was prepared 
dissolving the HA powder (0.6 mg, Mw=1000KDa) in a solution of 0.2N 
NaOH (12mL). The mixture was left in 24h at 27º on a back-and-forth 
plate with slow motion, to avoid polymer degradation.   Next day, the 
microemulsion was prepared into a cylindrical flat bottom glass vessel 
reactor of 400 mL of volume capacity, couplet to the stirring system, 
which was constituted by one stainless steel propeller stirrer with 4-
bladed, connected to a digital overhead stirrer (IKA, OST 20 basic 
digital IKA Yellow line or model Eurostar 40 digital).   
The steel stirrer was put into the vessel and the height was adjusted to 
keep the propeller as close as possible to the bottom without touching 
it.  Then the top of the reactor was fixed and sealed with a metallic 
ring to prevent solvent evaporation.   
Following, a volume of dichloromethane (DCM, 100mL) which is the 
dispersant phase used in this case, was transferred into the reactor 
through one of the access in the top of the reactor, followed by 
accurately measured amounts of sodium bis(2-
ethylhexyl)sulfosuccinate (AOT 1.34g, mmol) and 1-heptanol (1-HP, 
1.7mL, mmol). The mixture was stirred at 500 rpm until all 
components were completely dissolved.  Then stirring rate was 
adjusted, from 1300rpm to 1500 rpm to select the best condition. 
Once the stirring rate was stabilized to avoid turbulence in the system, 
HA solution was loaded in a plastic syringe and the aqueous solution 
(10mL) was dropped into the system using a syringe pump at constant 
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flow of 1 mL/min. When the addition was completed, the obtained 
emulsion was stirred by 1h to stabilize it and let the microparticles to 
be formed, then cross linker divinyl sulfone (DVS, 112 µL) was added 
to the system keeping the stirring rate constant for 2h more at room 
temperature (25ºC) to allow cross-linking reaction to take place in situ 
and completing the MPs formation.   
 
Figure 6.1 MPs stirring system 
Following, the reaction mixture was poured into acetone (300mL) to 
precipitate the microparticles.  The suspension was filtered through 
stainless steel sieve (Φ=0.050mm of light) to separate the desired MPs 
from bigger particles and residues of HA gel.  MPs-HA suspended in 
the supernatant were led to sediment in a 500mL beaker cover with 
plastic film at 4ºC by 16h.  Latter, the suspension was shaken 
mechanically and distributed into four centrifuge tubes of 50 mL of 
volume capacity. MPs were separated from liquid phase by 
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centrifugation (4000 RCF, 25 ºC, 5 min, in centrifuge Eppendorf model 
5804, with swinging rotor A-4-44, with four holders for tubes of 50 
mL).  This procedure was repeated until the whole MPs were collected 
from the total volume of suspension.  Once MPs were concentrated 
(to 10 mL) on each one of the four tube of centrifuge, clean acetone 
(30x5 mL) was added on each tube, shaken and centrifuge again in the 
same conditions than before, in order to extract any residual amount 
of reactants. 
The whole process was accomplished under the fume hood to prevent 
the inhalation of toxic substances. 
Finally, MPs were left in a minimum amount of acetone, barely wet, 
frozen at -20ºC 4h and then at -80ºC 16h before been freeze-dried by 
24h.  Product was a white lose powder. 
Samples were weighted and stored at -20ºC until further analyses.       
6.2.1.2. Synthesis of MPs-HA loaded with Curcumin 
To be able of loading curcumin, that is a completely hydrophobic 
compound and degradable under basic pH, into the HA-MPs it was 
necessary to use an additional step.  
First, curcumin (5 mg) was dissolve in DCM (1 mL), then this organic 
solution was emulsify with 12mL of HA solution in 0.2N NaOH, stirring 
at 12000 rpm by 3min at 25ºC with an stirred model IKA T-25-ULTRA 
TURRAX. 
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Immediately, this o/w emulsion was loaded in a syringe and the 
following procedure was the same described previously, but in this 
case it was obtain a double emulsion system o/w/o.  After freeze-
drying process it was obtain a pale yellow lose powder.  Samples were 
weighted and stored at -20ºC until further analyses.      
6.2.1.3. Synthesis of HA MPs loaded with PACurc 
In this case, the procedure was easier than with curcumin because 
PACur conjugates are completely soluble in water and protecting 
curcumin from degradation under basic pH. 
Therefore, PACur (52.63 mg equivalent to 5 mg Cur) was added to the 
solution of HA 5% wt/v in 0.2N NaOH (10 mL) and it was completely 
dissolved. 
Following, the procedure was exactly the same that the one describe 
for the synthesis of MPs-HA.  After freeze-drying process it was obtain 
a light yellow lose powder.  Samples were weighted and stored at 
temperature -20ºC until further analyses.       
 
6.2.1.4. Synthesis of HA MPs loaded with Trypsin and PEG-
Trypsin 
In this case, the procedure was similar to PACur conjugates because 
both Trypsin and PEG-Trypsin conjugates are completely soluble in 
water and relatively stable under basic pH.  Therefore, Trypsin (5mg 
trypsin by 500mg HA) and PEG-Trypsin (20%wt of Trypsin, 25mg of 
PEG-T equivalent to 5 mg Trypsin), were dissolved in their respective 
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solution of HA 5% wt/v in 0.2N NaOH (10mL).  Following, the 
procedure was exactly the same that the one describe for the 
synthesis of MPs HA. 
In both cases, after freeze-drying process it was obtain a white lose 
powder.  Samples were weighted and stored at -20ºC until further 
analyses.      
6.2.2. Characterization of loaded and un-loaded MPs systems 
6.2.2.1. Morphology by SEM 
The particles surface was analyzed with Scanning Electron Microscopy 
(SEM) using an equipment JEOL model JSM-6300 (JEOL Ltd., Tokyo, 
Japan).  Samples were previously sputtered-coated with gold under 
vacuum. Analyses were carried out at 15kV of acceleration voltage and 
15mm of distance working. 
6.2.2.2. Particle Size Distribution 
The particles distribution and average size was measured with laser 
diffraction technique, using an instrument model Mastersizer 2000, 
Laser light scattering, based on Mie and Fraunhofer scattering 
analytical methodology.  Data Analysis was accomplished with 
Malvern Software Mastersizer 2000 v.5.60.    
6.2.2.3. Encapsulation Efficiency an Total Drug Loading 
To be able to determine the total drug loading (TDL) in MPs-HA it was 
necessary to degrade them completely.   With this porpoise, a known 
 199 
 
amount of MPs were suspended in a volume of 0.01M acid chloride 
solution and heated at 80ºC overnight.  
In case of curcumin systems, due to curcumin is hydrophobic and 
stable in acidic medium, ACN was added to prevent free drug 
precipitation and warranty that all free curcumin was dissolved in the 
aqueous phase. Notice that in case of PACur loaded HA-MPs, 
polyacetals should have been completely degraded in acid medium so 
curcumin would be free too. Samples of un-loaded HA-MPs and both, 
PACur and Cur loaded HA-MPs where processed this way. Then, 
solutions were analyzed and curcumin concentration was determined 
spectroscopically.  Samples were measured at 260 nm with an UV-Vis 
double-beam equipment model Jasco UV-670. Samples were analyzed 
in quartz cuvettes with a light path 1mm. 
Alternative methodology was also tried. Total drug loading (TDL) was 
determined dissolving completely an accurately measure amount (5 
mg) of loaded MPs-HA in a solution of 0.2N NaOH (900μl) and ethanol 
(100 μL) to improve the solubility of free curcumin.  The suspension 
was centrifuge at 18000 rcf in an Eppendorf centrifuge model 5804 
with fix angle rotor.  Supernatant was separated and diluted with PBS 
the curcumin concentration was determine spectroscopically.  
Samples were measured at 260 nm with an UV-Vis double-beam 
equipment model Jasco UV-670. Samples were analyzed in quartz 
cuvettes with a light path 1mm.  Curcumin calibration curve (from 1 to 
30 μg/mL) dissolve in the same condition than sample was used to do 
quantification calculus. 
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In case of trypsin systems, total degradation of MPs were also 
accomplished in the same conditions because trypsin is stable under 
acidic conditions (between pH 3 and 6.5); not only it is not denaturized 
but also its proteolytic activity is reduced.  Quantification was 
performed using BCA kit with a calibration curve made with the same 
trypsin used in the experiments. 
In all cases, the encapsulation efficiency (E.E.) in HA MPs was 
calculated from the actual loading with respect to the theoretical 
loading of drug/protein in the MPs. 
6.2.3. Drug Release Kinetic studies from loaded HA-MPs 
To study drug release kinetics in microparticles un-loaded and loaded 
HA-MPs samples were analyzed.  Previously all samples were dried 
under vacuum at 60ºC and weighted but 24h, then suspended in a 
volume of 1.5 ml of PBS solutions. 
 In case of MPs HA unloaded, and loaded with curcumin or PACurc it 
was desire to study the influence of pH in the system, because PACur 
is susceptible to be degraded under acidic conditions, so it was 
expected to observe difference in the system’s release kinetic under 
neutral and slightly acidic conditions.  Therefore, they were used two 
different PBS 1X solution at pH7.4 and pH=6.5, respectively.  
In case of Trypsin and PEG-Trypsin loaded system they were studied 
only at pH 7.4 because PEG-T conjugate was also stable under acidic 
pH, so difference in behavior would not be related with change of pH  
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In all cases, every suspension was tempered at 37ºC and 1 ml was 
taken out in different times and replaced with 1 ml of fresh solution. 
Curcumin concentration in samples was determined by UV-Vis 
spectroscopy following similar procedure describes before for TDL.  In 
this case, curcumin was previously dissolved in ethanol, and then 
dilutions in PBS pH 6.5 and 7.4 were done to prepare the calibrations 
curves.  
In case of trypsin systems, quantification was performed using BCA kit 
with a calibration curve made with the same trypsin used in the 
experiments. 
6.3. Results 
 
6.3.1. Synthesis of MPs and encapsulation of model drugs and 
Polymer-drug conjugates 
The methodology proposed made possible to obtain microparticles of 
hyaluronic acid both un-loaded and loaded.   
Following, characterization of products is presented.  
6.3.2. Characterization of loaded and un-loaded MPs systems 
6.3.2.1. Curcumin systems 
 Morphology by SEM 
Surface analysis by SEM showed that HA MPs are spherical and not 
completely regular, also, they look polydisperses.  Particles sizes 
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clearly increase when loading process is accomplished as well as 
polydispersity.   
HA MPs un-loaded are smaller and more homogeneous, but particles 
surface is rough. HA MPs loaded with curcumin, show a less rough 
surface but broader range of sizes.  Nevertheless, the smallest 
particles seem to be in the same order of magnitude but the main 
difference is reflexed in the size of bigger particles that are produced.  
In any case, o/w/o emulsions do not affect significantly   the 
morphology.   
HA MPs loaded with PACur were the biggest of three groups and 
higher polydispersity, but particles shape is uniform, spherical, and 
softer than un-loaded HA MPs.  Amphiphilic nature of loaded 
compound has a clear effect on microparticles morphology, with 
respect at size and polydispersity, but particles have still the 
appropriate shape and size for the desire approach. 
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Figure 6.2 MPs surface morphology analyzed by SEM 
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 Particle Size Distribution 
Particles size analyses with laser diffraction support the information 
provided by SEM. 
HA MPs unloaded are the smallest of three groups, with average size 
of 6.441 µm when measure in acetone, which is a solvent where MPs 
are not swollen (figure 6.4 a).  
A sample of the same HA MPs was suspended in water (double 
distilled water) and measured after 10s of sonication, and swollen 
effect was immediately produced as can be clearly appreciated in 
lower panel (b) of fig 6.4.  
Particles average size increased to reach 42.518 µm; 6.6 times their 
original size.  This behavior was expected due to HA is a hydrogel, but 
the fact that MPs were able to remain their structural integrity shows 
that cross-linking process works, making possible to keep the MPs 
after swollen. 
Cross-linking was accomplished by DVS reaction with hydroxyl groups 
of HA, through an Oxa-Michael addition mechanism (figure 6.3).  
According to some authors, it could be expected that the reaction 
occurs mainly on the hydroxyl of C6 of the N-acetylglucosamine 
moiety of HA, because of the better accessibility of reagents to 
primary alcohols149,150. 
 Hydroxyl groups are negatively charged under basic condition, as is 
the case when HA is dissolved in NaOH 0.2N solution.  
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Figure 6.3. Oxa-Michael addition mechanism proposed for DVS 
crosslinking with HA in basic medium23. 
Then, –OH performs a nucleophilic attack over the double bonds 
promoting electronic delocalization through -SO2 functional group.  
Negative charge is compensated   with a proton from water molecules 
of the solution.  This way, step “a” is completed, then process stars 
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over again by the other double bond of DVS (step “b”) in the same way 
as happened in step “a”.    
 
Figure 6.4 Comparison of Particle size analyses of HA MPs Systems by 
laser dispersion HA-MPs in acetone and water 
 
This technique was also used to measure de size distribution of HA 
MPs loaded with Curcumin and PACur only with water as dispersive 
medium.  The stability of microparticles after been sunk, swollen and 
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sonicated in water demonstrated that these groups of microparticles 
are crosslinked too (Figure 6.5). 
 
Figure 6.5 Particle size analyses of HA MPs Curcumin and PACur 
Systems by laser dispersion in water  
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 Encapsulation Efficiency an Total Drug Loading  
Encapsulation efficiency was determined accurately following the 
methodology previously described, and it was possible to obtain the 
following values. 
Table 6-1. Total drug loading and encapsulation efficiency for 
different systems of MPs HA loaded with curcumin and PACur. 
 TDL (%) EE (%) 
MPsHA2%-Curcumin 0.23±0.04 23±4 
MPsHA2%-PACur 0.44±0.03 40±3 
MPsHA5%-Curcumin 1.0±0.3 82±24 
MPsHA5%-PACur 1.1±0.1 90±11 
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 Drug Release Kinetic studies 
Due to one of the possible application of the propose system is for 
local administration of therapeutic agents to contribute with wound 
healing, the sensitivity to pH is an important property to take in 
account because it is crucial for transdermal delivery systems.  It is 
reported that the pH of the skin surface, or stratum corneum (SC), is 
typically in the range 5.0–6.0151.  And it is very important to keep the 
homeostasis of the system during the treatment. 
 
Figure 6.6 Profile of MPs-HA degradation at pH 6.5 and pH 7.4 after 
180h 
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Figure 6.7 Profile of MPs-HA degradation at pH 6.5 and pH 7.4 after 
the first 8h. 
 
Because of that it was decided to evaluate the behavior of MPs-HA at 
two different pH, which are similar to physiological conditions. 
First, a qualitative evaluation of MPs-HA degradation was carried on 
under the same conditions that drug release was going to be studied. 
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According to these results, MPs-HA are degraded faster under acidic 
pH than under neutral pH.  Possible explanation is that acidic medium 
promotes the hydrolysis of glycosaminoglycan polymer chain or the 
bond with DVS. 
It has been described in literature151 that HA is a linear polysaccharide 
composed of repeating units of β-1,4-linked N-acetyl-D-glucosamine 
and glucuronic acid. The pKa of the carboxyl groups of the HA is in the 
range 3–4, and these groups are ionized at pH 7.  This explains why HA 
is capable of binding to peptides, matrix proteins, and growth factors.  
Besides, HA is a hydrophilic polymer that can absorb large quantities 
of water and can contain up to 1000 fold more water than its solid 
volume, due to formation of the hydrogen bonding between carboxyl, 
and N-acetyl groups of HA with water151. 
Nevertheless, deeper analyses are required to provide a better 
explanation to this observation. 
Taking in account this information, release experiment data were 
analyzed. 
As shown in figure 6.8, drug release from both systems of 
microparticles at different pH was collected and represented.  
According to the profiles describes on each case, there is not a big 
difference on release kinetic between MPs loaded with curcumin or 
PACur under acidic pH, reaching the equilibrium at the same time.  In 
the other hand, at pH 7.4 the amount of drug release is three times 
smaller when MPs-HA are loaded with PACur in comparison with MPs 
loaded with curcumin without conjugation. 
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It has been reported that when increasing pH levels, the carboxyl 
groups of the HA residue can become ionized, forming carboxylate 
groups (-COO-). The negative charge of the carboxylate leads to 
electrostatic repulsion, increasing the pore size in the hydrogel 
network. Furthermore, the negatively charged group forms a hydrated 
membrane, which increases water binding, leading to an ability to 
absorb large quantities of water151. 
In the systems that were studied in this work it seems that the swelling 
ratio is also related with the increase of the pH levels and in 
consequence with the drugs release kinetic.   
When pH is slightly acidic, pH 6.5, carboxylic groups are less ionized, 
therefore interaction with other groups would be hydrogen bonds, 
making narrow the pore size in hydrogel.  Besides, curcumin that is 
hydrophobic is going to diffuse to the outside.  On the other hand, 
PACur is degraded under pH 6.5, then it is possible that curcumin was 
been released from polymer conjugated this is de reason of the similar 
behavior.  The difference is that during the first hours, there was no 
burst in system loaded with PACur, contrary to the system loaded with 
Curcumin, because during this time PACur is starting to be degraded. 
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Figure 6.8 Profile % drug release from MPs-HA loaded with curcumin 
in comparison with MPs-HA loaded with PACur at pH 6.5 
 
Figure 6.9 First hour of Profile % Curcumin release from MPs-HA 
loaded with curcumin in comparison with MPs-HA loaded with PACur 
at pH 6.5 
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Due to swelling process happened almost immediately, fickian 
diffusion model could be used to better understand this behavior134 
Taking in account the shape the corresponding equation for Fick law152 
is: 
 
Equation 6-5 
Where: 
Mt= masa a tiempo t 
M∞=masa en el equilibrio 
D= coeficiente de difusión 
t= tiempo 
a= radio de la MP 
 
Then: 
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Figure 6.10 Profile of diffusion for drug release from MPs-HA loaded 
with curcumin in comparison with MPs-HA loaded with PACur at pH 
6.5 
On the other hand, when pH is 7.4, carboxylic groups are ionized and 
in consequence the hydrogel is going to be able to interact with more 
molecules of water and is going to absorb more water. 
But in this case, the curcumin is going to diffuse to outside as 
happened at pH 6.5 because it is repelled by water at p<h 7.4 as well 
as pH 6.5 because it is highly hydrophobic. 
Instead, PACur is not going to diffuse so fast, because at pH 7.4 PACur 
is not degraded so fast as it happened at pH 6.5.  Besides, PACur is 
hydrophilic, possibly interacts with ionic groups as well as with the 
polar chain or glicosaminoglycans, remaining stack inside the 
microparticles longer time, as can be appreciated in figures 6.11 and 
6.12.   
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Figure 6.11 Profile % drug release from MPs-HA loaded with 
curcumin in comparison with MPs-HA loaded with PACur at pH 7.4 
 
 
Figure 6.12 First hour % drug release from MPs-HA loaded with 
curcumin in comparison with MPs-HA loaded with PACur at pH 7.4 
 
Again, it is possible to represent these data following the model of 
fickinan diffusion as it was done before with pH 6.5 
Similar profile as expected because it is possible that curcumin was the 
specie release in both cases, but when it is conjugated it do not reach 
the 100% of release. 
These pH sensitive behavior could be exploited to release a 
pharmaceutical agent at a specific pH in a controlled manner, that is 
one of the objectives of this research. 
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Figure 6.13 Profile of diffusion for drug release from MPs-HA loaded 
with curcumin in comparison with MPs-HA loaded with PACur at pH 
6.5 
 
Table 6-2  Fick diffusion coefficient for trypsin and PEG-Trypsin 
 D [μm2/h] 
 pH 6.5 pH 7.4 
Curcumin 0.697 0.393 
PACur 0.203 0.484 
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6.3.2.2. Trypsin systems 
 Morphology by SEM 
Images from SEM show clearly that MPHA loaded with trypsin are 
much bigger than unloaded MPsHA, MPsHA loaded with curcumin and 
MPsHA loaded with PACur. 
Nevertheless, MPsHA loaded with PEGylated Trypsin, PEG-T, are 
significantly smaller than MPsHA loaded with naked Trypsin.  In fact, 
they are almost in the same range of the other two kind of loaded 
MPsHA.  Another interesting difference between these two systems is 
the polydispersity size distribution.  MPsHA loaded with trypsin seem 
to present less polydispersity than those loaded with PEG-T 
 
Figure 6.14 MPs surface morphology analyzed by SEM at different 
magnification taken at 15KV and 9 mm of wd : (a-b) MPs HA + 
Trypsin. (c-d) MPs HA + PEG-Trypsin  
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 Particle Size Distribution 
Particles size analyses with laser diffraction technique support the 
information provided by SEM. 
Average size of MPsHA-T is 30.6µm, measured in acetone and 
dispersive medium.  In comparison to unloaded MPsHA analyzed in 
the same conditions, the system with trypsin is almost 5 times bigger 
than unloaded system. 
In case of MPsHA loaded with PEG-T the analysis showed a bimodal 
distribution, where most of MPs have a particle average sizes of 4.3, 
even smaller than unladed MPsHA.  Bigger sizes particles could be 
adjudicated to the presence of aggregates. 
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Figure 6.15 Particle size analyses of HA MPs Trypsin and PEG-Trypsin 
Systems by laser dispersion in acetone  
 Encapsulation Efficiency an Total Drug Loading  
Encapsulation efficiency was properly determined and obtain values 
are shown in the next table  
Table 6-3  Total drug loading and encapsulation efficiency for 
different systems of MPs HA loaded with curcumin and PACur. 
 TDL (%) EE (%) 
MPs HA + Trypsin 1.0±0.3 99±1 
MPs HA + PEG-Trypsin 1.0±0.3 97±1 
 
 
 Drug Release Kinetic studies 
Again, drug release seems to follow the same kinetic mechanism 
during the first hour, after this time, rate of release becomes slower 
for PEG-T system, and finally, MPs loaded with trypsin were able to 
release almost 80% of total loading while MPs loaded with PEG-T only 
release almost 40% of total loading in the same time. 
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Figure 6.16 Release Kinetic of Trypsin and PEG-Trypsin from MPs HA 
in PBS 1x pH7.4 at 37º 
 
Figure 6.17  Release Kinetic of Trypsin and PEG-Trypsin from MPs HA 
in PBS 1x pH7.4 at 37º 
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Figure 6.18  Release Kinetic of Trypsin and PEG-Trypsin from MPs HA 
in PBS 1x pH7.4 at 37º 
 
Table 6-4  Fick diffusion coefficient for trypsin and PEG-Trypsin 
 D [μm2/h] 
Trypsin 0,071 
PEG-Trypsin 0,097 
 
 
Figure 6.19 Profile of diffusion for drug release from MPs-HA loaded 
with curcumin in comparison with MPs-HA loaded with PACur at pH 
6.5 
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6.4. Discussion 
The result presented previously demonstrated that stirring rate is a 
crucial parameter to define MPs size, as expected.  But there are other 
parameters that also affect the morphology of the final product.   
Loading process implies the addition of components which nature 
affects the interactions of HA molecules when final emulsion is 
formed.  Because of that when loaded compounds are hydrophobic, it 
is possible than most of the molecules try to migrate to organic phase 
of emulsion, causing a low drug loading.  Nevertheless, as probable 
their interaction with HA chain are weak it does not affect the size and 
polydispersity so much. 
In the other hand, amphiphilic compounds as PACur and T-PEG are 
able to dissolve completely in aqueous phase, improving the drug 
loading.  They probable have more interaction with polar groups of HA 
chain but not enough to interfere in MPs formation, but produce an 
increase in size a polydispersity of the product. 
In case of trypsin, it is possible that the process condition modify the 
tertiary structure of the protein, or even produces the denaturing of 
some amount of protein added; modifying the characteristic of the 
emulsion, and this result in bigger MPs despite the rate stirring was 
the same in all the experiments  
When release kinetic was studied, it was observed a fast release in all 
cases.  This behavior was expected because HA is a hydrogel that 
swells immediately in aqueous medium.   
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It was expected than smaller molecules were released faster.  
Nevertheless, it was observed that under acidic pH, release kinetic was 
independent of the size of loaded compound.  This behavior could be 
attributed to HA will be more restricted in shape, positive charge 
formed will repel each other and there is not going to be interaction 
between loading compound and HA MPs walls, so the compounds 
inside will be release and rate will depend only of swelling. 
In case of neutral pH, affinity of loading compounds affect the rate of 
release, the molecules closer to the MPs surface will be release 
immediately, but those close to the middle could interact with 
functional groups of HA and released will be delay. 
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6.5. Conclusions 
Stirring rated, organic solvent used for final emulsion, as well as 
chemical nature and hydrophilicity of loaded compound affect the 
morphology of resulting microparticles. 
Release kinetic of MPs-HA systems depends on pH of aqueous medium 
In neutral pH interaction of loaded compounds with MPs-HA matrix 
defined the release kinetic of the system 
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7. POLYMERIC COMPOSITE SYSTEM DESIGNED 
TO PROMOTE A LONG LASTING, STABLE, 
LOCALIZED AND CONTROLLED DRUG RELEASE 
7.1. Introduction 
ES technique is so versatile than it can be successfully adapted to 
elaborate 3D-scaffolds for the healing and repair of diseased 
musculoskeletal tissues, that is a very complex matrix rely on many 
signaling pathways, involving numerous growth factors and their 
receptors. One of the great challenges in this field, according to Tao 
Jiang et al, is to mimic closely the hierarchical architecture and 
properties of the extracellular matrices (ECM) of the native tissues 38 
However, not always cell adhesion is a property desirable in some 
application. This is the case of the work published by Arnal-Pastor64 
and colleagues. They accomplished to elaborate electrospun 
adherent–antiadherent bilayer membranes based on cross-linked 
hyaluronic acid for advanced tissue engineering applications where 
was sought to transplant cells on a tissue surface and keep them 
protected from the environment. To be more specific, the concept was 
to obtain a patch to prevent post-surgical adherences, which are a 
major issue in many surgeries. In vitro assays with L929 cell line of 
mouse fibroblasts shows very promising results. Their materials 
resulted to be not cytotoxic. Furthermore, the PLLA nanofiber face was 
cell friendly and promotes cell attachment and spreading therefore it 
could be used as a cell supply vehicle, while the HA face hindered cell 
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adhesion and thus might prevent undesired adherences. Co-axial 
electrospinning technique was used in this case.  
Likewise, during the last years several studies have been published 
that supports the fact that electrospun fibers can be associated with 
angiogenic and/or vasculogenic factors, epidermal factors and 
molecules with anti-inflammatory and antimicrobial properties to 
favor and enhance skin regeneration19,21,38,58,59,65–69.  Taking into 
account the wide range of opportunities, we decided to explore the 
possibilities of composites material which combine ES with 
encapsulation of therapeutic agents directly into de fibers or inside a 
vehicle such as microparticles to promote tissue regeneration/repair.  
Several recent studies have focus their attention on the encapsulation 
of curcumin into nanofibers of PLLA or blend of other polymers with 
PLLA 61,62,74,153, due to the multiples therapeutic applications of this 
compound, since carcinoma treatment to neurodegeneration and 
cutaneous wound healing.  For this reason it was consider 
appropriated the use of this molecule as model drug for the present 
study. 
Variations of nanofibrous films made by electrospinning have also 
been study as improved alternative biomaterials.  For example, 
Ionescu et al.73 in 2010 designed a fabrication technique to entrap 
drug-delivering microspheres within nanofibrous scaffolds to obtain an 
anisotropic nanofiber/microsphere composite with controlled release 
of biomolecules to promote musculoskeletal tissue regeneration. Their 
results showed that microspheres ranging from 10 ~ 20 microns in 
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diameter could be electrospun in a dose-dependent manner to form 
nanofibrous composites. In this case, the release profiles of the 
composite structures were similar to free microspheres, with an initial 
burst release followed by a sustained release of the model molecules 
over 4 weeks.  
Taking in account all this interesting experiences, it was decided to 
embrace the challenge to propose a n alternative methodology for the 
fabrication of a novel composite material based in these previous 
technologies  with the objective to obtain a new biomaterial which 
work as platform for control and localized delivery of nanodrugs  like 
polymer conjugates, with the porpoise to promote tissue 
regeneration, for example, with application in wound healing among 
other possible therapeutic targets. 
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7.2. Methodology 
7.2.1. Synthesis of Poly(L-lactic) acid membranes by 
electrospinning and encapsulation of model drugs and 
polymer conjugates 
Ultra-thin nanofibers microporous membranes were obtained by the 
electrospinning technique.   
The objective in this part of the work was the production of two 
different kinds of materials. First, PLLA random nonwoven fibers 
membranes, loaded with a model drug, which were describe with the 
name of “simple membranes” for practical reasons in this research.  
Second, PLLA nonwoven fibers membranes with micro particles 
inserted among or inside the fibers also loaded with a model drug.  
The resulting material was designated in this work with the name of 
“composite membranes”.   
The electrospinning process was carried out using a device composed 
by: a) a syringe pump, b) a syringe of 12mL of volume capacity (14.72 
mm of inner diameter), c) with a metallic tip, which was a flat end 
needle of 25G and 0,5x16mm (electrode), d) a metallic sheet covered 
with aluminum foil (counter-electrode) to collect the fibers, and e) a 
high voltage source power, to generate the electric field.  The whole 
setup was located in a fume hood previously prepared to avoid 
undesired electric discharges. 
The parameter optimized to obtain PLLA random nonwoven fibers 
with nanometric diameters were: a) PLLA solution concentration, b) 
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the voltage applied, c) distance between the needle tip and the 
collector, and d) feeding rate. 
 
 
Figure 7.1.  Picture of Electrospinning device used to produce the 
simple and composite membranes 
 
The procedure was accomplished at room temperature (25 to 26 ºC). 
The needle tip was in perpendicular position with respect to the 
collector sheet; this is called a perpendicular spinning configuration. 
PLLA solution concentration was from 3 to 9 wt%, using 
dichloromethane (DCM) as solvent. 
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The applied voltages were: 17, 20, and 27 kV, driven by a high voltage 
power supplied.  
 Fibers were collected on an electrically grounded aluminum foil, place 
at 15 – 20 cm from the needle tip.   
Feeding rate were 0.01mL/min, 0.02mL/min, 0.1mL/min, 1mL/min 
The process was carried out until the required thickness of the fibrous 
mats (scaffold) was reached (from 5min to 1h). 
Samples were previously observed with optic microscope as regular 
control of the procedure and finally analyzed by scanning electron 
microscopy (SEM).   
Fist the procedure was used to produce membranes of PLLA alone.  
When optimal working conditions were fixed for this material, these 
were used as initial conditions to produce materials loaded with drugs 
and polymer conjugates.  This membrane made of PLLA, was the first 
in the family of simple membranes (since now named ES01) and it was 
used as reference to compare the properties of the others simple and 
composite membranes. 
Model drug used for these experiments was curcumin, and PACur was 
the polymer conjugate.  It was desired to obtain membranes with final 
drug loading of 1wt% of Curcumin.   
Therefore to obtain the simple membrane of PLLA loaded with 
curcumin (named as ES05 from this point in this work), it was dissolved 
0.05g of Curcumin and 5.00g of PLLA in 100mL of DCM. 
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To obtain the simple membrane of PLLA loaded with the polymer 
conjugated with curcumin, PACur, it was dissolved 0.53g of PACur (9.5 
wt% of Curcumin) and 5.00g of PLLA in 100mL of DCM. This simple 
membrane is going to be named as ES04 since this moment for this 
work. 
Both, curcumin and PACur, are completely soluble in DCM, therefore, 
to obtain the starting solution for electrospinning experiments, an 
accurately weighted amount of Curcumin or PACur was added to the 
PLLA solution with the selected concentration (12 mL, in DCM). 
Summarizing, three different materials, called simple membranes 
type, were produce: 
ES01: random nonwoven fiber membranes of PLLA 
ES04: random nonwoven fiber membranes of PLLA loaded with PACur 
ES05: random nonwoven fiber membranes of PLLA loaded with 
Curcumin 
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7.2.2. Synthesis of polymeric composite systems: thin 
membranes loaded with microparticles. 
The methodology propoused by Hongxu Qi and co-workers was used 
as reference71 to develop our own procedure.  
The fist material produce was the composite membranes of PLLA with 
unloaded HA-MPs.  Optimal working conditions found for this system 
were used as starting condition to produce composite membranes 
with HA-MPs loaded with curcumin or PACur. 
Preparation of Mixture for electrospinning: 
Two different strategies were followed to obtain the mixture 
necessary to manufacture the composite system. 
a) First method: Mixture in Two steps 
Step 1: Synthesis of microparticles in reverse emulsion.   
First step was the production of HA micro particles (HA-MPs) following 
the protocol describe in chapter 5.    
HA-MPs were poured in acetone and washed.  Resulting microparticles 
were stored in a 50 mL plastic conical-bottomed centrifuge tube 
suspended in 20mL of acetone in order to be dehydrated and preserve 
their structure until mixing with PLLA. 
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Step 2: Inclusion of HA-MPs into the PLLA fibers by electrospinning.   
Second step was the production of membranes made of PLLA fibers 
with micro particles included in the mat.   
With this porpoise, HA-MPs (0.060 g) obtain in the first step were 
separated from acetone by centrifugation and decantation.  Remaining 
solid was carefully mixed with a PLLA solution in DCM (12 mL, 5 wt.%).  
Mixture was stirred with a magnetic stirrer at 300rpm by 5 min and 
loaded in a syringe with 10 mL volume capacity, ready to by 
electrospun. 
b) Second method: Mixture in One step of production  
In this case the procedure started also with the formation of HA-MPs, 
following the same procedure described in chapter 5 but without 
microparticles precipitation.   After 1h from DVS addition, PLLA pellets 
(5g, to achieve a final concentration of 5 wt %) were incorporated to 
the emulsion and dissolved in the organic phase (100 mL, DCM).  
Subsequently, the electrospinning protocol was carried out. 
 
Inclusion of HA-MPs into the PLLA fibers by electrospinning and 
Membrane production  
The electrospinning process was carried out at RT in a diagonal and 
perpendicular spinning configuration using a different needles (25G 
0.5x16mm, G21 0.8x25mm and G18 1.2x40mm) flat end needle.  The 
applied voltages were 15KV, 17, 20, 25 and 27KV, driven by a high 
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voltage power supplied.  Fibers were collected on an electrically 
grounded aluminum foil place at 15 or 20cm from the needle tip.  The 
process was carried out until the required thickness of the fibrous 
mats (scaffold) was reached.  Samples were analyzed by optic 
microscope and scanning electron microscopy (SEM).   
 
Summarizing, three different materials, called composite membranes 
type, were produce: 
ES02: random nonwoven fiber membranes of PLLA with MPs-HA 
unloaded 
ES03: random nonwoven fiber membranes of PLLA with MPs-HA 
loaded with PACur 
ES06: random nonwoven fiber membranes of PLLA with MPs-HA 
loaded with Curcumin 
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Figure 7.2.  Sketch of composite membrane production procedure 
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7.2.3. Characterization of Poly(L-lactic) acid membranes and 
composite systems 
7.2.3.1.  Characterization of membranes morphology by SEM 
The membranes surfaces were analyzed with Scanning Electron 
Microscopy (SEM) using an equipment JEOL model JSM-6300 (JEOL 
Ltd., Tokio, Japan).  Samples were previously sputted-coated with gold 
under vacuum. Analyses were carried out at 15kV of acceleration 
voltage and 15mm of distance working (wd). 
7.2.3.2.  Analysis of membrane thermal properties and 
composition by TGA and DSC 
Thermogravimetric analyses (TGA) were performed to determine the 
composition of all membranes (simple and composites) and compared 
this results those obtain by spectroscopic technique.  The equipment 
used was a METTLER-TOLEDO model TGA/SDTA 851 operated through 
the software provide with the device STARe.  Samples were weighted 
in platinum crucibles and scanned from 30ºC to 800ºC at 10ºC/min 
under N2 flow of 20 mL/min. 
Differential scanning calorimetry (DSC, model 823e (Mettler-Toledo 
Inc., Columbus, OH, USA) was used to measure the effect of the 
emulsification and cross-linking process on the thermal properties of 
empty and drug-loaded microparticles.  Approximately 3 mg samples 
were heated in a pierced aluminum pan under nitrogen atmosphere, 
in a range of temperature of -20 to 300 ºC, with a heating rate of 10 
ºC/min. 
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7.2.3.3.  Study of Membranes wettability by Contact angle 
measurement 
The wettability of simple and composite type membranes was 
determined by measuring the contact angle of a water drop on the 
surface of the samples.  A Dataphysics OCA instrument was used for 
these analyses.  Double distilled water was used for the experiments.  
To ensure the reproducibility of results 10 drops of water were 
analyzed for each material.  Samples were previously dried under 
vacuum at 40ºC by 24h. 
7.2.3.4.  Study of Mechanic Tensile properties of membranes  
The stretching assay of electrospun mats were performed in a stress-
strain machine model Microtest SCM3000 95 (Microtest SA, Madrid, 
Spain). Samples were cut as rectangles of 0.5 x 1.5 cm2 approximately.  
Stress rate was 0.2mm/min until fracture.  Row data was process and 
plotted as stress (σ) vs strain (ε), in order to calculate the elastic 
moduli from the slope of the linear region of the curves.  Final value is 
the average of at least 5 measures.  
7.2.3.5. Determination of Total Drug Loading and 
Encapsulation Efficiency  
To be able to determine the total drug loading (TDL) in membranes it 
was necessary to degrade them completely.   With this porpoise, a 
known amount of material was suspended in a volume of DCM and 
stirred by 5min. 
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Then, solutions were analyzed and curcumin concentration was 
determined spectroscopically.  Samples were measured at 260 nm 
with an UV-Vis double-beam equipment model Jasco UV-670. Samples 
were analyzed in quartz cuvettes with a light path 1mm. 
Curcumin calibration curve (from 1 to 30 μg/mL) dissolve in the same 
condition than sample was used to do quantification calculus. 
7.2.3.6. Drug Release Kinetic studies 
To study drug release kinetics from membranes samples all materials 
were analyzed.  Previously all samples were dried under vacuum at 
60ºC and weighted after 24h, then suspended in 1.0 ml of PBS 
solutions pH 7.4. 
In all cases, every suspension was tempered at 37ºC and 1 ml was 
taken out in different times and replaced with 1 ml of fresh solution. 
Curcumin concentration in samples was determined by UV-Vis 
spectroscopy following similar procedure describes before for TDL.   
7.2.3.7. Preliminary studies of simple and composite 
membranes degradation 
Degradation studies were accomplished by comparison of SEM images 
at different times: 0, 1, 7, 28, and 90 days. Samples of each kind of 
material were weighted and put in a well of a P48 plate.  Then, they 
were immersed in 1 mL of PBS solution 1X, pH 7.4 at 37ºC. 
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After each time the samples were remove from the well, washed with 
distilled water to remove the residues of salts and dried under vacuum 
at 40ºC by 24h. 
Samples of each material were analyzed by triplicate for each time. 
 
7.2.4. Preliminary Biologic Evaluation though in vitro assays 
7.2.4.1. Study of Membranes Cytotoxicity  
Cytotoxicity experiments by indirect contact were undergone. The 
L929 cell-line of mouse fibroblasts in its 13th passage was used for 
these purposes. In order to obtain the extracts, samples were 
immersed overnight in a Dulbecco’s Modified Eagle’s Medium (DMEM; 
high glucose (4.5 g L-1) Invitrogen), supplemented with 10% fetal 
bovine serum (FBS; Fisher) and 1% penicillin-streptomycin (P/S; 
Fisher), 0.1 g of sample per ml of medium. Complete medium was 
used as positive control and extract of latex was employed as negative 
control.  
In parallel, L929 fibroblasts were seeded at a density of 104 cells on the 
bottom of each well in 96-well plates with the medium described 
above and incubated in a humid atmosphere with 5% CO2 at 37ºC for 
24 h. Next, this culture medium was replaced by the extracts of the 
different samples, or of latex in the negative controls. The medium 
was changed by fresh medium in the positive controls. 
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The MTT assay was performed with an MTT-based toxicology assay kit 
(Sigma Aldrich, M5655)   after 24 and 48 h. At each time, the medium 
in the wells was removed and the cells were incubated in 100 µl of a 
90% DMEM and 10% MTT (1 mg/mL) mixture for 2.5 h in the dark in 
5% CO2 at 37°C. Next, the MTT solution was replaced by 120 µl of 
isopropanol and plates were shaken for 1 min. 100 µl of each well 
were transferred to a new 96-well plate to read its absorbance at 550 
nm in a Victor Multilabel Counter 1420 (Perkin Elmer, Waltham, MA; 
USA). Three replicates of each material were tested. 
 
7.2.4.2. Study of cellular adhesion and morphology  
 Analysis of Cellular Density and morphology by 
Immunofluorescence 
After culture, cell proliferation and distribution were observed by 
fluorescence (Leica DM6000) or confocal laser scanning microscopy 
(Olympus, FV1000). Previously, the samples were rinsed with PBS, 
fixed with 4% paraformaldehyde (PFA; Panreac) for 20 min at room 
temperature, and washed twice with PBS for 5 min. Cells were 
permeabilized with 0.1 vol.% Triton X-100 for 30 min at room 
temperature. After two rinses with DPBS, the samples were incubated 
with BIODIPY-FL phalloidin (Invitrogen, 1:200) for 1 h at room 
temperature in the dark, then washed twice with DPBS and 
counterstained for 5 min with 4,6-diamidino-2-phenylindole 
dihydrochloride (DAPI; Sigma, 1/ 5000). For microscopy observation, 
the slices were mounted with Fluorsave reagent (Calbiochem). 
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 Analysis of cell proliferation and distribution by 
Immunofluorescence and Scanning Electron Microscopy (SEM) 
The morphology of L929 fibroblasts and ADSCs after culture on the 
substrates was analyzed by SEM. After 7 days of incubation, culture 
medium was removed and samples were rinsed with PB. Fixation of 
the samples was carried out with a 3% glutaraldehyde (GA; Electron 
Microscopy Science, 25% purity) solution in PB for 1 h, followed by a 
rinse with PB. Post-fixation was performed with 1% osmium tetroxide 
in PB, along with a smooth shaking for 1 h at room temperature, and 
followed by four rinses with distilled water. Then, samples were 
dehydrated through a series of graded ethanol (30º, 50º, 70º, 96º, and 
100º) at 4ºC for 10 min each. Finally, samples were sequentially 
desiccated with hexamethyldisilazane (HMDS; Sigma Aldrich) at 
proportions of 1:2, 1:1 and 1:0 with absolute ethanol at 4ºC for 10 
min. HMDS was allowed to evaporate at room temperature overnight. 
After sputter-coating samples with gold, they were examined in a 
Hitachi S-4800 SEM at 25 kV and 15 mm of working distance (wd).  
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7.3. Results 
 
7.3.1. Synthesis and characterization Poly (L-lactic) acid 
membranes and composite systems 
After a systematic evaluation of different operative conditions it was 
determined that the best parameters to obtain PLLA random 
nonwoven fibers by electrospinning were: 
a) PLLA solution concentration: 5%  
b) Flat end needle 25G 0.5x16mm 
c) Voltage applied: 27KV 
d) Distance between the needle tip and the collector: 15cm in 
perpendicular spinning configuration 
e) Feeding rate: 0.02mL/min 
With these conditions already established to produce PLLA 
membranes by electrospinning, it was possible to find the best 
operative conditions for the manufacture of PLLA membranes loaded 
with Curcumin and PACur. 
It was found that best conditions to produce PLLA loaded with 1wt% of 
Curcumin are: 
a) PLLA solution concentration: 5%  
b) Flat end needle 25G 0.5x16mm 
c) Voltage applied: 25 KV 
d) Distance between the needle tip and the collector: 20cm in 
perpendicular spinning configuration 
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e) Feeding rate: 1mL/min 
Same condition were appropriate for elaboration of PLLA membranes 
loaded with PACur (1wt% of total drug loading with respect to 
curmumin) 
In the other hand, composite membranes resulted to present better 
quality (minimum amount of beats, regular distribution of MPs 
through the mat) under the following conditions: 
a) Mixture for electrospinning formed following the “in one step” 
methodology. 
b) Flat end needle 25G 0.5x16mm 
c) PLLA solution concentration: 2.5%  
d) Voltage applied: 25 KV 
e) Distance between the needle tip and the collector: 20cm in 
perpendicular spinning configuration 
f) Feeding rate: 0.1mL/min 
7.3.1.1. Characterization of membranes morphology by SEM 
Fibers´ size and distribution were determined analyzing the images 
obtained by SEM with the software ImageJ 1.50a.     
With this porpoise, it was measured the diameter of 100 fibers by 
image on three different pictures taken by SEM with 1500X (ES01 and 
ES03), 3500X (ES02) 300X (ES04) 100X (ES05) or 5000X (ES06) 
magnification.   
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Likewise, in composite systems the amount and distribution of 
microparticles was determined following a similar procedure but 
measuring the diameter of at least 30 particles on three different 
images with 1500X (ES02 and ES06) or 300 X (ES03) magnifications.  
These results are represented in the following frequency histograms. 
 
 
Figure 7.3. A) Histogram of frequency for fibers size in material ES01: 
ES  simple membrane made of PLLA  B) Scanning Electron Microscopy 
image of ES01 carried out at 1500X, 15mm wd and 15KV. 
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Figure 7.4.  Comparison of SEM images of the different materials obtained by electrospinning, taken at 1500X magnification 
for analysis of fiber size distribution and microparticles distribution.  
ES01: Simple membrane of PLLA; ES02: Composite material of PLLA fibers and HA microparticles; ES03: Composite material of 
PLLA fibers and HA microparticles loaded with PACur; ES04: Simple membrane of PLLA loaded with PACur; ES05: Simple 
membrane of PLLA loaded with curcumin; and ES06: Composite material of PLLA fibers and HA microparticles loaded with 
curcumin.
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Figure 7.5. A) Histogram of frequency for microparticles size in 
material ES02: ES  composite membrane made of PLLA fibers and 
MPs of HA B) Scanning Electron Microscopy image of ES02 carried 
out at 1500X, 15mm wd and 15KV. 
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Figure 7.6. A) Histogram of frequency for fibers size in material ES02: 
ES  composite membrane made of PLLA fibers and MPs of HA B) 
Scanning Electron Microscopy image of ES02 carried out at 3500X, 
15mm wd and 15KV. 
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Figure 7.7. A) Histogram of frequency for microparticles size in 
material ES03: ES  composite membrane made of PLLA fibers and 
MPs of HA loaded with PACur B) Scanning Electron Microscopy image 
of ES03 carried out at 300X, 15mm wd and 15KV. 
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Figure 7.8. A) Histogram of frequency for fibers size in material ES03: 
ES  composite membrane made of PLLA fibers and MPs of HA loaded 
with PACur B) Scanning Electron Microscopy image of ES03 carried 
out at 1500X, 15mm wd and 15KV. 
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Figure 7.9. A) Histogram of frequency for fibers size in material ES04: 
ES  simple membrane made of PLLA loaded with PACur  B) Scanning 
Electron Microscopy image of ES04 carried out at 300X, 15mm wd 
and 15KV. 
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Figure 7.10. A) Histogram of frequency for fibers size in material 
ES05: ES  simple membrane made of PLLA loaded with Curcumin  B) 
Scanning Electron Microscopy image of ES05 carried out at 100X, 
15mm wd and 15KV. 
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Figure 7.11. A) Histogram of frequency for microparticles size in 
material ES06: ES  composite membrane made of PLLA fibers and 
MPs of HA loaded with Curcumin B) Scanning Electron Microscopy 
image of ES06 carried out at 1500X, 15mm wd and 15KV. 
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Figure 7.12. A) Histogram of frequency for fibers size in material 
ES06: ES  composite membrane made of PLLA fibers and MPs of HA 
loaded with Curcumin B) Scanning Electron Microscopy image of 
ES06 carried out at 5000X, 15mm wd and 15KV. 
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7.3.1.2. Determination of membrane composition and thermal 
properties by TGA and DSC  
Thermal stability of raw materials, model drugs and all materials 
produced for this part of the research was analyzed by 
thermogravimetric analysis (TGA). 
These graphics summarized the thermal behavior of all different 
systems analyzed.  
 
Figure 7.13 Profiles of weight loss obtained by Thermogravimetric 
Analyses of raw materials, simple and composite systems 
0
20
40
60
80
100
30 230 430 630 830 1030
%
 W
e
ig
h
t 
lo
ss
 
Temperature (ºC) 
Curcumin
PEG4000
PACur
MPsHA
MPHA + Curcumin
MPHA+PACurc
ES01 (ES PLLA)
ES02 (ES PLLA + MPsHA)
ES03 (ES PLLA + MPsHA + PACur)
ES04 (ES PLLA + PACur)
ES05 (ES PLLA + Cur)
Es06 (ES PLLA + MPHA + Cur)
 257 
 
As it can be seen in figure 7.13, there are significant differences 
between the raw material weight loss profiles and the simple or 
composite systems. 
Following, the results for particular cases are going to by describe. 
 
 
 
Figure 7.14 Comparison among thermogravimetric analyses of simple 
membrane systems ES01 and ES05: A) % weight loss curve B) 
Derivative Thermogravimetric curve (DTG).  
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Curcumin, was used as model drug for release kinetic studies.    
Therefore, it was necessary to analyze the thermal stability of this 
compound by itself, as starting point to be able to stay comparisons 
between the simple and composite membrane systems which contain 
this substance. 
Result of thermogravimetric analyses of Curcumin are presented in in 
figure 7.14, together with the results for to simple membrane 
material: ES01 and ES05. 
It is observed in figures 7.14.A and 7.14.B that curcumin presents two 
process of weight loss. First, curcumin suffers a decomposition 
reaction at 300ºC, and later at 400ºC took place a second process, 
identified as the pyrolysis of the resulting solid that left 27% of 
residues. 
In the other hand, ES01, that is a membrane made by electrospinning 
composed only by PLLA, was pyrolized in a single step process 
between 250 and 400ºC as shown in figure 7.14A.  The DTG profile of 
ES01 in figure 7.14 confirmed this observation. 
In the case of the simple membrane ES05, made of PLLA and loaded 
with Curcumin, it was observed a degradation pattern with similar 
trend to ES01 but at slightly lower temperature.  According to DTG 
curve of ES05 (Figure 7.14B), this material did not undergo 
decomposition as happened with curcumin but a single step of 
pyrolysis as is clearly observed in figure 7.14B.  The onset temperature 
was 240ºC and complete pyrolysis was achieved at 350ºC.  Besides, 
the solid residue left after the pyrolysis (2.2 %wt) was higher than the 
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residues left by ES01 (0.6 %wt), and it should come from curcumin 
present in the fibers.   
The composition of ES05 was calculate using the data of fraction mass 
obtained from the isothermal at 500ºC in the graphic of weight loss.  
The following equations were applied: 
 Fraction mass equation  
𝟏 = 𝒙𝒂 + 𝒙𝒃 + ⋯+ 𝒙𝒏             Equation 7-1 
𝑥𝑛 = 𝑚𝑎𝑠𝑠 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑜𝑓 𝑒𝑎𝑐ℎ 𝑐𝑜𝑚𝑝𝑜𝑛𝑒𝑛𝑡 
Total weight loss, which can be defined as: 
∆𝒎𝑻 = ∆𝒎𝒂 ∗ 𝒙𝒂 + ∆𝒎𝒃 ∗ 𝒙𝒃 + ⋯+ ∆𝒎𝒏 ∗ 𝒙𝒏       Equation 7-2 
Where: 
∆𝑚𝑇 = 𝑇𝑜𝑡𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡 𝑙𝑜𝑠𝑠 𝑜𝑓𝑐𝑜𝑚𝑏𝑖𝑛𝑒 𝑚𝑎𝑡𝑒𝑟𝑖𝑎𝑙 𝑎𝑡 𝑡𝑒𝑚𝑝𝑒𝑟𝑎𝑡𝑢𝑟𝑒 𝑇 
 ∆𝑚𝑛 = 𝑤𝑒𝑖𝑔ℎ𝑡 𝑙𝑜𝑠𝑠 𝑜𝑓𝑝𝑢𝑟𝑒 𝑐𝑜𝑚𝑝𝑜𝑛𝑒𝑛𝑡 𝑎𝑡 𝑡𝑒𝑚𝑝𝑒𝑟𝑎𝑡𝑢𝑟𝑒 𝑇 
𝑥𝑛 = 𝑚𝑎𝑠𝑠 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑜𝑓 𝑒𝑎𝑐ℎ 𝑐𝑜𝑚𝑝𝑜𝑛𝑒𝑛𝑡 
In case of ES05, it is constituted by two components: PLLA (a) and 
Curcumin (b). 
It was traced an isotherm at 500ºC in the graphic % weight loss (Figure 
7.14A), and corresponding values of Δm total and of each components 
were taken and substituted in equation 7.2.  Then, the values of xn 
where calculated, solving the system of equation with Equation 7.1 
and equation 7.2.  Results are summarized in table 7.1. 
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ES04 is a single membrane, similar to ES05, made of PLLA fibers but 
loaded with the polymer conjugated with curcumin (PACur).  In this 
case it was used the same procedure to determine the composition of 
this material, using the information given by the profiles of weight loss 
shown in figure 7.15A.   
As well as ES05, membranes of material ES04 suffer pyrolysis at lower 
temperature in comparison with ES01, revealing the influence of the 
payload over the thermal properties of both kinds of membranes.  
DTG curves (Fig 7.15B) corroborate these results.  It is interesting to 
highlight that a closer sight of DTG curve in Figure 7.16 provides very 
important information about the chemical nature of the different 
materials. 
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Figure 7.15Comparison among thermogravimetric analyses of PACur 
and the simple membrane systems ES01 and ES04: A) % weight loss 
curve B) Derivative Thermogravimetric curve (DTG).  
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Figure 7.16 Closer view of Comparison among derivative 
Thermogravimetric (DTG) curve of PACur and the simple membrane 
systems ES01 and ES04 
For example, unlike ES05 membranes which are loaded with curcumin, 
the ES04 membranes, which are loaded with the polymer conjugated 
PACur, presented a two steps thermal decomposition.  This material 
was pyrolized mainly in step 1 (onset temperature 210ºC) and left only 
4% of residue.  Step two (onset temperature 365ºC) was shorter than 
the first, and left 1.6% of residue. 
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 Figure 7.17 Comparison among thermogravimetric analyses of 
simple membrane systems ES01, ES04 and ES05: A) % weight loss 
curve B) Derivative Thermogravimetric curve.  
Nevertheless, the fact that ES04 as well as ES05 experienced the 
maximum grade of pyrolysis in one step means that there is one 
principal component, PLLA, which is responsible of these behaviors. 
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On the other hand, the variation observed among the three different 
simple membranes, ES01, ES04 and ES05, are related to the presence 
or absence of payload.  The loss of weight in both loaded membranes 
present similar trend, and suffer pyrolysis at slightly lower 
temperature with respect to unloaded simple membrane, that is 
composed only of PLLA 
In other to obtain a better understanding about the payload influence 
on PLLA fibers thermic resistance, curcumin and PACur where analyzed 
individually.  
Figure 7.18A and B show that curcumin started to lose weight at 
160ºC.  The pyrolysis took place gradually apparently in one step with 
a gentle slope.     DTG curve (figure 7.18B) reveals that actually there 
are two different process overlapped between 200 and 432ºC, and 
another one between 160 and 200ºC.  After 800ºC there is still 27% of 
residue. 
Instead, PACur, which is a copolymer of polyethylene glycol and 
curcumin, underwent thermal decomposition in two steps clearly 
differentiated as it can be appreciated in figure 7.18A.  Step 1 has the 
onset temperature at 130ºC with 90% of residue and step two has the 
onset in 330ºC with 2% of residue.   If it is compared with polyethylene 
glycol weight loss profile it seems that in the first step the copolymer is 
broken and in the second step all PEG is pyrolized quickly, therefore 
residue should come mainly from curcumin.   
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Figure 7.18 Comparison among thermogravimetric analyses of 
curcumin, PEG4000 and PACur: A) % weight loss curve B) Derivative 
Thermogravimetric curve C) Zoom of (B) between 0 and 250ºC.  
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Composite membranes where also analyzed in order to determine 
their composition and verify if the desire component ratio was 
achieve. 
The first composite membrane analyzed was ES02, which is 
constituted by PLLA fibers and microparticles of hyaluronic acid (MPs 
HA).  Results are shown in figure 7.19. 
 
 
Figure 7.19 Comparison among thermogravimetric analyses of simple 
membrane systems ES01, with microparticles of HA (MPs HA) and 
the composite membrane system ES02: A) % weight loss curve B) 
Derivative Thermogravimetric curve.  
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The weight loss profile (figure 7.19A) shows that MPs HA suffered and 
initial loss due to the presence of water in the material.  According to 
these experiments the water content in these microparticles after 
drying is around 24% of total mass. 
The second step correspond to hyaluronic acid pyrolysis which was 
degraded up to 55% between 160 and 260ºC,  then remains relatively 
stable, and finally it was obtained 25.5% of residue at 800ºC. 
ES02, the composite membrane that is supposed to be constituted by 
PLLA fibers and microparticles of hyaluronic acid (MPs HA) shows a 
small initial weight loss with onset temperature of 54ºC.  This belongs 
to water present in the material.  Then, pyrolysis took place in one 
step, with similar slope to ES01 membranes, which are made with 
PLLA, but the onset temperature of ES02 (200ºC) is lower than the 
onset temperature of ES01 (250ºC).  Likewise, after 500ºC ES02 
presented 4.6% of residues while ES01 only presented 0.8% at the 
same temperature.  These results corroborates the presence of MPs 
HA together with PLLA in the composite material.  Composition was 
calculated as explained before for ES05. 
ES03, is also a composite membrane, similar to ES02, but in this case 
MPs HA were loaded with PACur.  Figure 7.20 shows the results for 
TGA experiments. 
ES03 suffered pyrolysis process in two steps.    First step is related to 
the presence of water in the membrane despite it was dried 
previously.   Second step showed similar profile than ES01 but with 
lower onset temperature (210ºC) as it was observed for ES02.  
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Figure 7.20 Comparison among thermogravimetric analyses of simple 
membrane systems ES01, with microparticles of HA (MPsHA), PACur 
and the composite membrane system ES03: A) % weight loss curve B) 
Derivative Thermogravimetric curve.  
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Also the amount of residues after 500ºC were higher for ES03 (4.8%) 
than the residues for ES01 (0.8%) at the same temperature. 
These results corroborated the presence of PLLA and MPs HA.  The 
amount of curcumin in this case was too small to produce a particular 
variation in the weight loss profile of the material.  
Nevertheless, a sample of MPs HA loaded with PACur, as those 
included in the PLLA fibers of ES03, where analyzed by separated, as 
cam be seen in figure 7.20.  
The results demonstrated the presence of an additional step with 
onset temperature at 107ºC, which was not observed in unloaded MPs 
HA that corresponded to PACur encapsulated into the MPs HA. 
Figure 7.20B shows clearest the different processes that took place on 
each material.   
The last composite membrane material analyzed was ES06, which is 
made of PLLA fibers with MPs HA loaded with curcumin. 
The results were similar than obtained for ES03, as can be appreciated 
in figure 7.21.  Following the same logical reasoning than before with 
ES03 it was determined that ES06 was composed by PLLA and MPs HA 
loaded with curcumin. 
When the results obtained for the three composite membranes were 
compared, it was observed that the curves were overlapped as can be 
seen in Figures 7.22 and 7.23, with small differences, related to the 
kind of substances loaded in the microparticles.   
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Composition were estimated  using the procedure explained for ES05 
but including de values of two or more different isotherms to solve the 
system of equation with the help of the tool “solver” included in the 
software EXCEL.  Calculation results are summarized in table 7-1. 
 
 
Figure 7.21 Comparison among thermogravimetric analyses of simple 
membrane systems ES01, with microparticles of HA (MPsHA), 
Curcumin and the composite membrane system ES06: A) % weight 
loss curve B) Derivative Thermogravimetric curve.  
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Figure 7.22 Comparison among thermogravimetric analyses of simple 
membrane ES01 and composite membrane systems ES02, ES03 and 
ES06: A) % weight loss curve B) Derivative Thermogravimetric curve.  
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Figure 7.23 Closer view of comparison among thermogravimetric 
analyses of simple membrane ES01 and composite membrane 
systems ES02, ES03 and ES06: A) Derivative Thermogravimetric curve 
between 0 and 350ºC B) Derivative Thermogravimetric curve 
between 0 and 150ºC 
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Table 7-1 Composition calculated from data obtain by 
Thermogravimetric Analyses 
Material % PLLA % HA % Cur 
PACur - - 9.2 
ES01 
(ES PLLA) 
100 - - 
ES02 
(ES PLLA + MPHA) 
90 10 - 
ES03 
(ES PLLA + MPHA + 
PACurc) 
90 9.7 
0.3 (PACur) 
0.02 (Curcumin) 
ES04 
(ES PLLA + PACur) 
71.8 - 
28.0 (PACur) 
2.5 (Curcumin) 
ES05 
(ES PLLA +Curcumin) 
95 - 5 
ES06 
(ES PLLA + MPHA + 
Curcumin) 
88 7 5 
 
The influence of the different composition of the simple and 
composite membranes was also studied by dynamic scanning 
calorimetry (DSC). 
The thermograms obtained are represented in figure 7.24 and the 
values of different thermodynamic parameters are summarized in 
table 7.2. 
As can be appreciated in figures 7.24 and 7.25 crystallization 
temperatures as well as melting temperature are moved with respect 
the pure PLLA fibers membrane, demonstrating the influence of 
additional components: MPs HA, Curcumin and/or PACur. 
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Figure 7.24 Thermograms obtained after the first heating cycle by Dynamic Scanning Calorimetry (DSC) analyses of simple 
and composite systems 
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Figure 7.25 Thermograms obtained after the first heating cycle by Dynamic Scanning Calorimetry (DSC) analyses of 
hyaluronic microparticles, curcumin and PAcur 
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Table 7-2 Values of Thermodynamic properties determined by the 
experiments of Dynamic Scanning Calorimetry (DSC) 
Material 
Tm 
[ºC] 
ΔHm 
[J/g] 
Tg (ºC) 
ΔCp 
[J/(g K)] 
Tc [ºC] 
ΔHm 
[J/g] 
ES01 
(ES PLLA) 
59.09 5.94 
  
100.93 13.6 
 
152.27 22.86 
    
ES02 
(ES PLLA + 
MPHA) 
56.98 1.06 41.27 0.375 81.48 7.62 
 
149.98 16.6 
    
ES03 
(ES PLLA + 
MPHA + 
PACurc) 
50.08 3.76 
  
78.25 10.01 
 
145.42 12.48 
    
ES04 
(ES PLLA + 
PACurc) 
56.1 4.52 
  
90.6 14.75 
 
152.77 11.2 
    
ES05 
(ES PLLA 
+Curcumin) 
54.65 6.49 8.03 0.024473 98.15 18.91 
 
150.49 4.01 
    
 
150.32 22.96 
  
  
ES06 
(ES PLLA + 
MPHA + 
Curcumin) 
64.30 9.50   96.06 12.04 
 149.55 20.87     
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7.3.1.3. Study of Membranes wettability by Contact angle 
measurement 
The behavior of water drops in contact with membranes surface was 
different for simple and composite materials. 
In some cases it was impossible to register a measurement due to the 
sample absorbed immediately the water drop. 
Table 7-3 Values of contact angles measured between drops of water 
and the surface of simple and composite membranes 
Material Contact angle Drop of water 
Left right 
ES01 
(ES PLLA) 
109.4 109.4 
 
ES02 
(ES PLLA + MPHA) 
- - 
 
ES03 
(ES PLLA + MPHA + 
PACurc) 
- - 
 
ES04 
(ES PLLA + PACurc) 
117.7 117.4 
 
ES05 
(ES PLLA +Curcumin) 
121.3 120.9 
 
ES06 
(ES PLLA + MPHA + 
Curcumin) 
- - 
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7.3.1.4. Mechanic Tensile properties of membranes  
The study of mechanic tensile properties of simple and composite 
membranes provides interesting information about the resistant of the 
different material to some kind of mechanical stress, that is necessary 
to a better idea of the suitability of these systems for future 
application in the field of regenerative medicine as for example, 
wound healing. 
The modulus of longitudinal elasticity – the Young's modulus (E) – 
defines the relation between stress (σ) and strain (ε) in elastic 
materials. 
The modulus characterizes materials resistance to elastic elongation. 
This dependence is generally presented by the Hooke's Law: ε = E/σ.  
In the elastic range the relationship between stress and strain is linear 
and the factor of proportionality is expressed by the Young's 
modulus154. 
The values of Young modulus (E) were calculated from the slope of the 
elastic (initial, linear) portion of the stress–strain curve shown in figure 
7.26, which was the result to apply the equation 7-3 to the row data 
collected with the tensile experiments. 
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Figure 7.26 Tensile Stress (σ’) – extensional strain (ε) curves for 
different simple and composite membranes: A) complete profiles, B) 
closer view of strength –stain curves. 
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Figure 7.27 Comparison of Young moduli values calculated for simple 
and composite membranes. 
𝑬 ≡
𝒕𝒆𝒏𝒔𝒊𝒍𝒆 𝒔𝒕𝒓𝒆𝒔𝒔 (𝝈)
𝒆𝒙𝒕𝒆𝒏𝒔𝒊𝒐𝒏𝒂𝒍 𝒔𝒕𝒓𝒂𝒊𝒏 (𝜺)
=
(
𝑭
𝑨𝒐
)
(
∆𝑳
𝑳𝒐
)
=
𝑭𝑳𝒐
𝑨𝒐∆𝑳
      Equation 7-3 
Where  
E: Young's modulus (modulus of elasticity) 
F: force exerted on an object under tension 
A0: initial cross-sectional area through which the force is applied 
ΔL: amount by which the length of the object changes 
L0: initial length of the object 
 
In order to be able to establish an appropriate comparison among the 
E values of the different membranes a variation was introduced in 
equation 7-3, dividing the registered strength by the samples wide (w) 
and the surface density (sd) determine experimentally for each 
sample, as shown in equation 7-4.   
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𝒔𝒅 =
𝒄𝒓𝒐𝒔𝒔 𝒔𝒆𝒄𝒕𝒊𝒐𝒏𝒂𝒍 𝒂𝒓𝒆𝒂
𝒎𝒂𝒔𝒔 
            Equation 7-4 
Analyses were done with five independent samples of each kind of 
material.   
Finally, the equation used to build the stress-strain curve was: 
𝐸 ≡
𝑡𝑒𝑛𝑠𝑖𝑙𝑒 𝑠𝑡𝑟𝑒𝑠𝑠 (𝜎′)
𝑒𝑥𝑡𝑒𝑛𝑠𝑖𝑜𝑛𝑎𝑙 𝑠𝑡𝑟𝑎𝑖𝑛 (𝜀)
=
(
𝐹
𝑠𝑑∗𝑤
)
(
∆𝐿
𝐿𝑜
)
       Equation 7-5 
As can be appreciated in figure 6.26 the composite materials 
presented the lowest elastic moduli and there was no significant 
difference between the values of the composites ES02 and ES06, 
instead ES03 resulted to have the less elastic modulus of all six 
materials analyzed. 
In the other hand it was observed that simple membrane ES04, 
composed by PLLA fibers loaded with PACur, presented the lower 
elastic modulus in comparison with the other simple membranes ES01 
and ES05.  ES04 had similar elasticity than the composite systems. 
ES01, ES04 and ES05 do present significant difference among their E 
values.  ES04 was the most elastic, followed by ES01 (PLLA), and the 
less elastic of all six materials was ES05 (PLLA + Curcumin). 
Similar tendency was observe for breaking strength and maximum 
strain. 
These results can be explain because the heterogeneity of composite 
makes them more elastics but also weaker.  Instead the structure of 
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simple membranes is more homogeneous, but their mechanical 
properties are related to influence of PACur and Curcumin over the 
PLLA fibers. 
Curcumin made PLLA fibers less elastic and harder, instead PACur 
made them more elastic and soft as cotton. 
Intermolecular interactions between curcumin and PLLA, or PACur and 
PLLA, in the solid phase are responsible of these behaviors. 
 
Table 7-4 Values of Young Modulus, Breaking Strength and maximum 
strain determined for simple and composite membranes with tensile 
strength assays 
 
Young 
Modulus 
(mPa/g) 
err 
Breaking 
Strength 
(N*g/m3)*10
-6
 
err 
ε 
maximum 
strain 
error 
ES01 
(ES PLLA) 
0.08 0.02 12 3 0.6 0.1 
ES02 
(ES PLLA + 
MPHA) 
0.025 0.008 3 1 0.19 0.07 
ES03 
(ES PLLA + 
MPHA + 
PACurc) 
0.003 0.001 0.5 0.2 0.35 0.05 
ES04 
(ES PLLA + 
PACurc) 
0.016 0.009 6 2 1.3 0.2 
ES05 
(ES PLLA 
+Curcumin) 
0.12 0.09 8 1 1.2 0.5 
ES06 
(ES PLLA + 
MPHA + 
Curcumin) 
0.03 0.01 1.2 0.3 0.06 0.02 
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7.3.1.5. Quantification of Total Drug Loading and 
Encapsulation Efficiency 
The encapsulation efficiency was determined by UV spectroscopy.  
Results are summarized in table 7-5. 
These values are different to obtain by TGA, maybe due to the 
limitation associated to each technique.  Amount of drug loaded were 
too small to by properly detected by TGA. 
In any case it was observe that the elaboration procedure of drug 
loaded membranes resulted to have a high efficiency except in case of 
ES03, which must be improved. 
Table 7-5 Encapsulation Efficiency and Total Drug Loading 
 
wt % Total drug 
loading 
Curcumin (TDL) 
Efficiency 
Theoretic 
loading 
ES03 
(ES PLLA + MPHA + 
PACurc) 
0,04 44 0,1 
ES04 
(ES PLLA + PACurc) 
0,10 99 0,1 
ES05 
(ES PLLA +Curcumin) 
1,22 81 1,5 
ES06 
(ES PLLA + MPHA + 
Curcumin) 
0,09 100 0,1 
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7.3.1.6. Release Kinetic studies 
Release kinetic profiles of different simple and composite membranes 
were represented in figure 7.28.  
 
 
Figure 7.28  A) Complete profile of curcumin release kinetic from ES 
PLLA membranes and composite systems.  B) Closer view of the 
curcumin profile release kinetic from ES PLLA membranes and 
composite systems  
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It was observed that ES05, the membrane of PLLA fibers loaded with 
curcumin was the slowest system, follow by the two composite 
membranes, ES03 (PLLA fibers with MPs HA loaded with PACur) and 
ES06 (PLLA fibers with MPs HA loaded with Curcumin) which present 
very similar profiles, and finally, ES04, composed by PLLA fibers loaded 
with PACur resulted to be the fastest system of release. 
It is interesting to mention that, in comparison with the profile of drug 
release obtained from MPs HA, there was no significant difference 
between the composite material loaded with PACur (ES03) and the 
MPs HA loaded with PACur when released is study at pH 7.4 a 37ºC. 
Instead, the composite system loaded with curcumin (ES06) did slow 
down the releases of the drug in comparison with the MPs HA loaded 
with curcumin, when released is study at pH 7.4 a 37ºC. 
 
Figure 7.29  Closer view of the curcumin profile release kinetic from 
MPs HA systems 
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7.3.1.7. Preliminary studies of simple and composite 
membranes degradation 
Time of degradation is a very important parameter to be taken into 
account to establish the suitability of materials for a specific 
biomedical application. 
For this reason, a preliminary degradation study was carried on 
simulating the most basic physiological condition in wet environment: 
aqueous PBS solution 1X concentration and pH 7.4 at 37ºC.  Enzymatic 
degradation was not included in this study. 
ES01: PLLA simple membranes 
As can be appreciated in figure 7.30, PLLA fibers of this material did 
not experience significant change in fibers morphology after 7d.  
Fibers kept the same dimensions; there is no evidence of breaking or 
wear.  
Figure 7.30  Comparison of change in PLLA fibers morphology of ES01 
membranes after different times of soaking in PBS 1X at pH 7.4 and 
37ºC, by SEM images taken at 15KV and 9mm of working distance 
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ES02: Composite membranes of PLLA fibers with MPs HA 
Composite membranes ES02 did not show any significant change after 
7 days of soaking as far as can be observed in figure 7.31 
 
Figure 7.31  Comparison of change in PLLA fibers and MPs HA 
morphology of ES02 membranes after different times of soaking in 
PBS 1X at pH 7.4 and 37ºC, by SEM images taken at 15KV and 9mm of 
working distance 
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ES03: Composite membranes of PLLA fibers with MPs HA loaded with 
PACur 
SEM images in figure 7.32 show that composite membrane ES03 a 
slight increase in fiber sizes, but there is any signal of degradation.   
Figure 7.32  Comparison of change in PLLA fibers and MPs HA 
morphology of ES03 membranes after different times of soaking in 
PBS 1X at pH 7.4 and 37ºC, by SEM images taken at 15KV and 9mm of 
working distance 
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ES04: PLLA simple membranes loaded with PACur 
Fibers stayed without change after 7 days in PBD at pH 7.7 and 37ºC 
 
Figure 7.33  Comparison of change in PLLA fibers morphology of ES04 
membranes after different times of soaking in PBS 1X at pH 7.4 and 
37ºC, by SEM images taken at 15KV and 9mm of working distance 
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ES05: PLLA simple membranes loaded with PACur 
PLLA fibers of ES05 kept the same appearance since time cero until 
7days in aqueous solution.  Any hydrolysis or degradation was 
observed. 
 
Figure 7.34  Comparison of change in PLLA fibers morphology of ES05 
membranes after different times of soaking in PBS 1X at pH 7.4 and 
37ºC, by SEM images taken at 15KV and 9mm of working distance 
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ES06: Composite membranes of PLLA fibers with MPs HA loaded with 
Curcumin 
SEM images in figure 7.35 did not give evidence of degradation after 
7days of study. 
 
Figure 7.35  Comparison of change in PLLA fibers and MPs HA 
morphology of ES06 membranes after different times of soaking in 
PBS 1X at pH 7.4 and 37ºC, by SEM images taken at 15KV and 9mm of 
working distance  
 
According with these results, all the six system are stable after seven 
days of soaking in aqueous solution of PBS 1X at pH 7.4 and 37ºC. 
This behavior was expected because it is well known that PLLA is a 
material highly resistant to aqueous hydrolysis at neutral pH.  
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7.3.2. Preliminary Biologic Evaluation though in vitro assays 
7.3.2.1. Study of Membranes Cytotoxicity  
Cytotoxicity experiments were undergone by indirect contact.  Results 
shown that after 48h cell viability was over 70%, which means that any 
of the systems analyzed were cytotoxic.   
 
Figure 7.36  Cytotoxicity comparison for different composite systems. 
ES01: membrane of PLLA fibers; ES02: composite membrane of PLLA 
fibers with MPs HA;  ES03: Composite membranes of PLLA fibers with 
MPs HA loaded with PACur; ES06: Composite membranes of PLLA 
fibers with MPs HA loaded with Curcumin. (*) No statistical 
significant difference 
 
Result demonstrated that after 48h there are not significant 
differences statistically among any of the systems analyzed.  That 
means that composite membrane materials are not cytotoxic in any 
case.   
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7.3.2.2. Study of cellular adhesion and morphology  
 Analysis of Cellular Density and morphology by 
Immunofluorescence 
L929 fibroblast cells were seeded onto the materials. To determined 
cellular density microscopy of fluorescence was used, staining the 
nucleic acid with DAPI.  Besides, to determine how were distributed 
the cells the cytoskeleton was stained with Phalloidin to determined 
roundness by confocal microscopy.  Images are shown in the next 
figure.  
 
Figure 7.37 Images taken by fluorescence microscopy to estimate the 
cellular density and cellular distribution of L929 cells after 1d of 
culture on different composite materials. Nuclei stained in blue with 
DAPI, images with 10X magnification. Cytoskeleton stained in green 
with Phalloidin, images with 40X magnification. ES01 (A, A’): Simple 
membrane of PLLA; ES02 (B, B’): Composite material of PLLA fibers 
and HA microparticles; ES03 (C, C’): Composite material of PLLA fibers 
and HA microparticles loaded with PACur and ES06 (D, D’): 
Composite material of PLLA fibers and HA microparticles loaded with 
curcumin. 
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Using ImageJ software for image analyses, the following results were 
obtained.  
As can be appreciated in figure 7.38, cellular density resulted to be 
bigger in composite systems loaded with curcumin and PACur.  It was 
determined that there is a statistically significate differences between 
drug loaded composite materials and the unloaded.  Also demonstrate 
the favorable influence of curcumin, conjugated or not, over cell 
proliferation morphology. 
 
Figure 7.38  Cellular density of L929 cells on different composite 
systems.  (*) no significant differences statistically, (**) significant 
statistical difference  
Likewise, cellular distribution happens to be better in the same both 
composite materials which are loaded with curcumin (ES06) or PACur 
(ES03).  There were no significant difference between ES03 and ES06, 
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which means that conjugation of curcumin do not produce any 
additional effect on cell proliferation under these conditions. 
On the other hand, cell proliferation on ES01 (ES PLLA) and ES02 (ES 
PLLA + MPs HA) was statistically equal between them, but significantly 
lower in comparison que the drug loaded composite material. 
That means that morphology of composite material by itself did not 
have an additional effect on the rate of proliferation of cells L929, but 
it was clear that curcumin, conjugated or not is having an additional 
effect on this cells proliferation.  The higher proliferation observed in 
ES03 and ES06 composite membranes was due to curcumin and PACur 
influence on cells behavior.   
Results shown in figure 7.39 corroborated the observations previously 
mention. 
Cell morphology, in terms of the shape that cells adopt in contact with 
the materials was also affected mainly by the presence or absence of 
drugs (Curcumin o PACur without significant difference between them) 
more that the topology of the material surface under the conditions 
on these preliminary in vitro assays. 
According to the graphic of cell roundness (Figure 7.39) cells were 
more extended when composite membranes were loaded with 
curcumin or PACur in comparison with cell observed in ES01 (ES PLLA) 
and ES02 (ES PLLA + MPs HA), where cells adopted a spherical shape, 
as can be appreciated in figure 6.36. 
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Figure 7.39  Cellular distribution of L929 cells on different composite 
systems.  (*) no significant differences statistically, (**) significant 
statistical difference  
 
 Analysis of cell proliferation and distribution by 
Immunofluorescence and Scanning Electron Microscopy (SEM) 
After 1 day, confocal microscopy images (Figure 7.40) demonstrated 
those fibroblasts are growing in all membranes but with special affinity 
a higher rate over composite materials with Curcumin and PACur. 
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Figure 7.40.  Comparison of confocal microscopy images of the different simple and composite materials after 1day of 
culture with fibrobroblasts L929 cells with phaloydin (green) to stain the cytoskeleton of cells and DAPI (blue) to  stain the 
nuclei.  Images were taken at to magnification 10X (A-F) and 40X (A’-F’) 
ES01 (A, A’): Simple membrane of PLLA; ES02 (B, B’): Composite material of PLLA fibers and HA microparticles; ES03 (C, C’): 
Composite material of PLLA fibers and HA microparticles loaded with PACur; ES04 (D, D’): Simple membrane of PLLA loaded 
with PACur; ES05(E, E’): Simple membrane of PLLA loaded with curcumin; and ES06 (F, F’): Composite material of PLLA fibers 
and HA microparticles loaded with curcumin. 
 298 
 
Figure 7.41.  Comparison of confocal microscopy images of the different simple and composite materials after 7 day of 
culture with fibrobroblasts L929 cells with phaloydin (green) to stain the cytoskeleton of cells and DAPI (blue) to  stain the 
nuclei.  Images were taken at to magnification 10X (A-F) and 40X (A’-F’) 
ES01 (A, A’): Simple membrane of PLLA; ES02 (B, B’): Composite material of PLLA fibers and HA microparticles; ES03 (C, C’): 
Composite material of PLLA fibers and HA microparticles loaded with PACur; ES04 (D, D’): Simple membrane of PLLA loaded 
with PACur; ES05(E, E’): Simple membrane of PLLA loaded with curcumin; and ES06 (F, F’): Composite material of PLLA fibers 
and HA microparticles loaded with curcumin. 
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After 7 days fibroblast had completely covered the surface of all 
simple and composite membranes (Figure 7.41). Nevertheless, it was 
difficult to observe the cells seeded on simple membranes ES04 (ES 
PLLA + PACur) and ES05 (ES PLLA + Curcumin) due to the self-
fluorescence of the fibbers which interfered with the cells 
fluorescence. 
Scanning Electron Microscopy images of the same samples provides 
more information about the changes in cells morphology seeded in 
these materials after two different times: 1day and 7d. 
Images n figure 7.42 corroborated the observations described for ES01 
(ES PLLA: A, A’) simple membrane and the composites (ES02: B, B’, 
ES03: C, C’ and ES06: D, D’).  In all tis cases, cells are extending by the 
whole mats surface.   Different behaviour was observed in simple 
membranes of PLLA fibbers loaded with curcumin (ES05: F, F’)   and 
PACur (ES04: E, E’).  In these cases, it was observed that cells were 
growing not only adhered to the fibbers but along the fibbers. 
SEM images of samples after 7d to have been seeded (figure 7.43) 
showed that the simple membranes ES01 and ES04, as well as the 
composites membranes (ES02, ES03 and ES06) were almost 
completely covered by cells which look like a “cell carpet”. 
In contrast to these observations, cells seeded onto ES05 (ES PLLA + 
Curcumin) made a different structure with channels.  Fibbers were 
gathered by the cells and adopted a completely different arrangement 
in comparison with the other systems.   
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Figure 7.42   Comparison of scanning electron microscopy images of 
the different simple and composite materials after 1 day of seeded 
with fibroblasts L929 cells.  Condition: 10kV and WD=9mm. Images 
were taken at to magnification 100X (A-F) and 700X (A’-F’).  
ES01 (A, A’): Simple membrane of PLLA; ES02 (B, B’): Composite material of PLLA fibers and HA 
microparticles; ES03 (C, C’): Composite material of PLLA fibers and HA microparticles loaded 
with PACur; ES06 (D, D’): Composite material of PLLA fibers and HA microparticles loaded with 
curcumin. ES04 (E, E’): Simple membrane of PLLA loaded with PACur; and ES05 (F, F’): Simple 
membrane of PLLA loaded with curcumin 
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Figure 7.43   Comparison of scanning electron microscopy images of 
the different simple and composite materials after 7 day of culture 
with fibroblasts L929 cells.  Condition: 10kV and WD=9mm. Images 
were taken at to magnification 100X (A-F) and 700X (A’-F’).  
ES01 (A, A’): Simple membrane of PLLA; ES02 (B, B’): Composite material of PLLA fibers and HA 
microparticles; ES03 (C, C’): Composite material of PLLA fibers and HA microparticles loaded 
with PACur; ES06 (D, D’): Composite material of PLLA fibers and HA microparticles loaded with 
curcumin. ES04 (E, E’): Simple membrane of PLLA loaded with PACur; and ES05 (F, F’): Simple 
membrane of PLLA loaded with curcumin 
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7.4. Discussion 
7.4.1. Synthesis and characterization Poly (L-lactic) acid 
membranes and composite systems 
According with the results showed in the previous section, it was 
possible to obtain “simple membranes” as well as “composite 
membranes” following the methodology proposed in this work. 
As expected, each system require specific condition of operation to be 
able to produce materials with the desire characteristics, which are 
fibers with nanometric diameter size, very few defects as beats, and in 
case of composite materials, relative homogeneous distribution of 
microparticles through the mat. 
Likewise, images obtain by SEM microscopy showed that the “one step 
procedure” is more efficient than “the two steps procedure” 
methodology for mixture preparation.   
These results are very interesting because demonstrate that the 
original emulsion plays a relevant function to obtain the composite 
membranes.  The emulsion not only guarantee that HA-MPs will 
preserve their spherical, dehydrated structure but also that the will be 
well disperse and distributed in the final mixture.    This condition is 
critical to be able to electrospun the MPs, otherwise, MPs could 
aggregate and form sediments before it was possible to for the fiber, 
making as consequence that only a few amount or nothing of MPs 
were present in the final material after electrospinning process. 
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Besides, the “One step procedure” guaranties that even the drug that 
was not possible to encapsulate into de microparticles is going to be 
retained in the second structure, constituted by the ES PLLA fiber mat.  
Also, loss of material is reduced, because HA MPs do not need to be 
separated from the emulsion, preventing aggregation of smaller 
microparticles during the purring step in acetone. 
The main disadvantage of this methodology is that resulting 
membranes must be carefully washed to eliminate any possible 
residue of any toxic reactive used during the fabrication procedure. 
7.4.1.1. Characterization of membranes morphology by SEM 
Image analyses of SEM pictures reveals that it was possible to obtain 
nanometric fibers with very few defects with PLLA alone, and then it 
was also possible to include microparticles in the net, which were 
enveloped by the PLLA fibers, providing an additional point of control 
for the release kinetic of drug molecules encapsulated into de 
microparticles. 
It is important to notice that the addition of curcumin or PACur to 
PLLA solution produced a very big difference among the morphology 
of the fibers of those called as “simple membranes materials”. 
ES01, which is composed 100% by PLLA present very thin fibers, the 
surface is smooth, and the weave was tighter than the weave of ES05 
or ES06. 
ES05 was the result of a ternary solution composed by 
dichloromethane (DCM) as solvent, PLLA and Curcumin as solutes. 
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Both PLLA and curcumin are completely soluble in DCM, so in this case 
we have dissolution similar to the PLLA in DCM. 
Viscosity was not measure but, even though, it is possible to expect to 
this value should be similar because the polymer is in higher 
concentration than curcumin and  therefore PLLA is going to be the 
main responsible of the value of this property. 
Nevertheless, the presence of curcumin molecules in the solution 
caused that it was necessary to increase the feeding rate during the 
electrospinning process, because it was observed that under the same 
condition used for PLLA solution electrospun, it was impossible to 
obtain fibers.   
Similar behavior was observed with ES04, which came from a ternary 
dissolution of PLLA and PACur in DCM. 
Notice that PACur is an amphiphilic compound.  These polyacetals are 
completely soluble in organic non-polar solvent, as DCM, as well as, in 
polar solvents as water.   
PACur is not able to form micelles, but due to the polar chain of PEG 
present in their structure it is able to interact with polar molecules like 
water.   
Curcumin molecules in the main chain represent the hydrophobic 
moiety, increasing the affinity of PACur with non-polar solvents. 
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ES04 and ES05 have in common that the fibers obtain by 
electrospinning are much bigger that fibers of PLLA alone, besides they 
have porous. 
It is possible that during the electrospinning process when solvent is 
evaporated a phase separation took place, PLLA and Curcumin (or 
PACur) become solid again, then the low affinity between them due to 
their different chemical nature (PLLA is hydrophobic and PACur is 
hydrophilic), the way they interact may be responsible of producing 
the porosity in the fibers. 
But this microscopic characteristic is not the only important difference 
when the “simple membranes” are compared. 
Macroscopically there are clear changes from one material to the 
other. 
The most obvious is the color.  Curcumin is bright yellow, so, ES05 is 
also bright yellow, ES04 is pale yellow despite PACur is dark yellow, 
and ES01 is white as PLLA powder. 
But the really interesting difference is in texture, mechanical 
properties and wettability. 
These aspects will be considered later on following sections.  
 At this point we it could be said that incorporation of curcumin to the 
PLLA solution modifies the fiber properties in comparison with PLLA 
fibers alone.  Also, conjugation of curcumin as PACur, print similar 
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behavior for electrospinning process, similar microscopic morphology 
but clear different macroscopic characteristic. 
In the other hand, it was observed when composite membranes were 
compared that the main difference in the microparticles density.  
ES06, the membrane with PLLA fibers and HA-MPs loaded with 
curcumin is the material with the higher density of MPs, followed by 
ES02, the membrane with PLLA fibers and HA-MPs without load, and 
finally, ES03 the membrane with PLLA fibers and HA-MPs loaded with 
PACur.  
In this case the presence of PACur seems to have an unfavorable effect 
over the system.  Even though, the microscopic morphology is very 
similar for the three materials, with thin fibers in the same order of 
magnitude but MPS from ES03 are much bigger than MPs in ES02 and 
ES06. 
Nevertheless, macroscopic properties seem to be very similar, as 
shown in next sections. 
7.4.1.2. Determination of membrane composition and thermal 
properties by TGA and DSC  
TGA analyses corroborated that in all cases for composite systems the 
main component is PLLA, as expected, always around 95-72% for PLLA, 
10-7% for HA and 5-0.3% for curcumin conjugated or not. 
Taking in account this results, information from DSC analyses could by 
better understood. 
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 PLLA Tm remains with relative small variation, but melting enthalpy 
values change significantly when MPsHA loaded and unloaded are 
present in the system as well as in simple system where PLLA is mixed 
with curcumin or PACur, as expected because on each case the mass 
fraction of PLLA in the system is bigger than the other components.  
7.4.1.3. Mechanic Tensile properties of membranes  
Composition also affects the mechanical properties of these materials.  
As shown in result section there is a very clear relation between the 
presence of MPs and the increase or decries of tensile strength.  But it 
is absolutely clear than in simple systems the additions of curcumin 
increase considerably the tensile strength of the mat in comparison 
with PLLA alone, due to it high hydrophobicity y bigger size of the fiber 
this material results easier to handle in comparison with PLLA ES with 
equivalent   dimensions.  Also, ES04 (ES PLLA + PACur) are very easy to 
handle but its texture in similar to cotton and is very hydrophilic, able 
to absorb water as a cotton patch.    
7.4.1.4. Encapsulation Efficiency and Total Drug Loading 
As explain before, TGA and DCS analyses corroborate that membranes 
are loaded with curcumin or PACur, depending on the system 
analyzed. 
Direct measures by UV spectroscopy support the previous results. 
Nevertheless, the composite system with MPsHA loaded with PACur 
resulted to have the worst encapsulation efficiency.  That means that 
the protocols still need to be improved for this kind of system. 
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7.4.1.5. Release Kinetic studies 
As can be observed in the graph of profile release, the slower is the 
system composed by the mixture of PLLA and Curcumin.  This is logical 
because curcumin is hydrophobic; therefore these molecules possess 
higher affinity for PLLA fiber than for the aqueous medium 
surrounding.   
On the other hand, the system with the mixture PLLA and PACur is the 
faster because PACur in amphiphilic, by possess high affinity for 
aqueous medium, so these molecules will diffuse throw the surface of 
fibers, taking advantage of the high porosity of this fibers, which is 
product of this mixture. 
Finally, systems with microparticles of HA loaded with curcumin seem 
to present an initial fast release, maybe due to the heterogeneity of 
the system, but immediately adopt the same kinetic than system with 
MPHA loaded with PACur.  This could be explained because both 
loaded components are into the matrix of MPS and they should wait 
until PLLA shell led them diffuse to the surface. 
That is why the behavior observed when only loaded MPs release 
kinetic are compare at pH 7.4 is different to the behavior of those 
when MPs are into the PLLA fiber. 
7.4.1.6. Preliminary degradation studies 
SEM images revealed that the six materials produced by the proposed 
procedure, the simple membranes as well as the composite 
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membranes are stable in aqueous medium when pH is 7.4 and mild 
temperatures as 37ºC, similar to the internal human body 
temperature. 
Supernatant in contact with samples at different times where analyzed 
by GPC and RP-HPLC in order to determine degradation products 
dissolved in the aqueous medium, but any kind of compound was 
detected.  Samples of each time of degradation where weighted after 
drying under vacuum at 40ºC by 24h and weight loss was not 
detected. 
This behavior can be attributed to PLLA high stability in front to 
hydrolysis under neutral conditions and mild temperatures.  As 
demonstrated through thermogravimetric analyses, the main 
component in all membranes is PLLA, and the absence of change in 
surface morphology of MPs HA present in the composite materials 
point at MPs are inside the PLLA fibers as it was desired to be able to 
provide and additional point of control in the release kinetic of drug 
loaded, besides a matrix to keep MPs immobilized in the membranes. 
7.4.2. In vitro studies  
Cytotoxicity study demonstrated that any of the analyzed materials 
resulted to be cytotoxic; therefore it is possible to conclude that the 
procedure proposed for simple as well as composite membranes do 
not left any toxic residual substance. 
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On the other hand, there were clear differences with respect the cell 
affinity when surface density and cell distribution it are compared 
among the different materials. 
Another interesting result was the influence of curcumin, conjugated 
or not, on cells proliferates.  Surface materials did not show any 
particular difference when membranes are unloaded.  Instead, cells 
showed a significant higher proliferation in drug loaded simple as well 
as composite materials.  In fact cells are able to adopt extended shape, 
similar to the elongate shape describe in literature for fibroblast 
morphology in normal skin tissue.  Besides, seeded cells were able to 
completely cover the surface material, that it a desirable characteristic 
for system design for wound healing.   
Particularly interesting was the case of structures formed be the cells 
after 7 days in material ES05, the simple membrane constituted by 
PLLA fibers loaded with curcumin. 
Some kind of channels were built by cells which were growing along 
the fibers, then cells created links among them until forming micro 
structures through the membrane, joining the PLLA fibers intro wide 
columns envelop by cell’s shells.  
More biological studies should be done in order to unravel the entire 
biologic and biomechanics potential of these materials and as well as e 
better understanding of how curcumin is influencing the cells 
proliferation. 
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7.5. Conclusions 
One step methodology was corroborated as the most efficient 
technique for fabrication of composite systems based of combination 
of microparticles with electrospinning membranes. 
Image analyses of SEM pictures reveals that it was possible to obtain 
nanometric fibers with very few defects with PLLA alone, and then it 
was also possible to include microparticles in the net, which were 
enveloped by the PLLA fibers, providing an additional point of control 
for the release kinetic of drug molecules encapsulated into de 
microparticles 
This technique makes possible to obtain relatively homogenous 
systems with typical thermal properties of materials that could be 
used as parameters for quality control for standardized fabrication. 
At this point we it could be said that incorporation of curcumin to the 
PLLA solution modifies the fiber properties in comparison with PLLA 
fibers alone.  Also, conjugation of curcumin as PACur, print similar 
behavior for electrospinning process, similar microscopic morphology 
but clear different macroscopic characteristic. 
Mechanical properties are dramatically affected for different 
composition of the system. 
It was corroborated that the six systems of membranes studied are 
stable after seven days of soaking in aqueous PBS 1x pH 7.4 and 37ºC. 
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It was possible to modulate the drug released kinetic from the 
different systems.   As expected, the composite material provides an 
additional point of control on the release kinetic of loaded molecules 
in comparison with the release from microparticles by themselves, but 
only with the non-conjugated drug. 
The conjugation of Curcumin do not exerts a significant influence on 
the release from “composite membranes” but it does have difference 
when it is release from “simple membranes”.  In the last case, the 
higher affinity of PACur with aqueous medium promotes the diffusion 
of conjugate molecules from the fibers to outside.  
Biological in vitro studies demonstrated that composite system are 
non-cytotoxic, and promotes fibroblast proliferation with cell 
morphology similar to normal tissue 
Composite membrane materials loaded with curcumin or PACur 
promotes fibroblast to adopt an elongated morphology, in contrast 
with unloaded composite membrane, demonstrate the influence of 
drug loaded into the material. 
Simple membranes loaded with Curcumin and PACur also allowed the 
proliferation of fibroblast but with preferment orientation longwise 
the fiber.  
Morphological difference observed between the fibroblast cultured on 
“composite membranes” and those cultured on “simple membranes” 
reflex the influence of mechanical properties of the surface over the 
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interaction with cells independently from the biochemical stimuli from 
drugs loaded. 
Composite systems proposed in this research could be good 
candidates to by evaluated in vivo models for promoting wound 
healing. 
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8. GENERAL DISCUSSION 
 
Current approaches for the replacement of damaged tissues/organs 
based conventional treatment and strategies lack of effectiveness in 
many clinical situations. Thus, there is an urgent need for alternatives 
to overcome most of the limitations of existing techniques. In this 
context, innovative approaches including tissue engineering or 
regenerative medicine, controlled drug delivery systems and 
nanomedicines (such as Polymer Therapeutics) are emerging as 
promising options to solve this problem. Moreover their combination 
offers countless advantages and a myriad of possibilities to face a vast 
range of disease targets that will not be possible with a single 
technology. 
With that in mind, the aim of this thesis was to design intelligent 
composite system for tissue regeneration through the combination of 
biomaterial science and nanoconjugate synthesis, in order to have a 
structure with double control on drug release kinetics, and with the 
possibility to be used on different clinical applications, such as 
implants in damage tissue. We combine the use of Polymer 
Therapeutics with an appropriate scaffold made with innovative 
techniques aiming to obtain an innovative construct to be used as 
topic or surgical implants able to promote tissue regeneration with the 
aim of both act as support for cellular growth, and as therapeutic 
device by the local release of bioactive agents. This novel biomedical 
device consisted on composite systems composed by three main 
elements: Polymer conjugates (Polymer-Protein Trypsin and/or 
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Polymer-Drug Curcumin conjugates); biodegradable polymeric micro-
particles (MPs) of hyaluronic acid (HA) and biodegradable polymeric 
membranes of Poly(L-lactic acid). The combination of these complex 
systems will result in a novel structure with particular physico-
chemical, mechanical and biological properties, which are 
characteristics of a new biomaterial. 
In order to accomplish the already exposed goals of this highly 
ambitious project, the initial efforts were devoted to the synthesis 
optimization of biodegradable polyacetals to be used as polymer 
carriers for the development of both, Polymer-Protein Conjugates and 
Polymer-Drug Conjugates.  
On one hand, Polymer-Protein Conjugates were developed by applying 
two different approaches: a) Protein PEGylation, as example of system 
with non-biodegradable polymer carriers and b) Protein conjugation 
with polyacetals, as example of system with a biodegradable 
polymeric carrier under acidic conditions. The second one, pursued to 
develop the so called polymer-masking-unmasking-protein therapy 
(PUMPT), described first by Duncan et al87,99,101–104,155,156. This latter 
strategy will enable the protein protection while traveling to the 
therapeutic target and/or will allow controlled release at the target 
site promoted by the polymer degradation.  
Regarding the first strategy, it consisted on the PEGylation of the 
model protein Trypsin32,33,112,157 with MeO-PEG-COOH and 
succinoylated MeO-PEG-OH both with the same molecular weight 
(2000 g/mol) in order to compared the possibility to have two 
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different linkers with PEG chain: a) biodegradable ester link 
(succinoylated PEG-OH) and b) not biodegradable amide link (PEG-
COOH).  Reaction was successfully accomplished with MeO-PEG-OH 
succinoylated, achieving a Trypsin loading of 20wt% of total conjugate 
weight.  Although the enzymatic activity of Trypsin was shown to be 
reduce upon conjugation (64% of total activity for Trypsin-PEG2000), 
this system resulted to be stable enough to be used as model for its 
encapsulation in HA microparticles. 
For the PUMPT strategy, polyacetals functionalized with COOH groups 
following different strategies and based on fragments of PEG-diol 4000 
Da units were synthesized and physico-chemically characterized. Once 
again Trypsin has been used as a model protein. Two different PA-
COOH were obtained, one of them including a succinoylated linker in 
order to study the linker influence in the PUMPT effect. Moreover, 
different conjugates with various polymer to protein ratios were 
developed with total protein contain ranging from 20-35wt%, in order 
to study the influence of such ration in the masking/unmasking 
capability of the system. 
The biological activity of the masked and unmasked protein was 
assessed using N-benzoyl-L-arginine-p-nitroanilide (L-BAPNA) as a 
substrate. This way, the ability of the protein to recover its full initial 
activity after the PUMPT process could be studied. Results obtained 
showed that enzymatic activity of Trypsin was partially suppressed at 
pH 7.4, when it was conjugated, in comparison with naked protein at 
the same condition. Moreover, Trypsin activity could be recovered 
after incubation of the conjugates at pH 6.5 for 2h, regardless the 
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linker used. These results proved that protein was unmasked by effect 
of acidic pH, responsible of hydrolysis of polyacetals. 
On the other hand, polymer-drug conjugates based on the 
biodegradable polyacetals and the antioxidant drug curcumin have 
been effectively synthesized and physico-chemically characterized. 
Curcumin molecules were incorporated into a poly(ethylene glycol) 
(PEG) based polyacetal carrier by applying an improved polyacetal 
synthesis. This approach consisted on the reaction among short PEG-
OH chains, curcumin and triethylene glycol-divinylether units using p-
toluensulfonic acid as acid catalyst, without the need for 
biodegradable linkers. With this strategy we were able to obtained 
high yields of water soluble polymer conjugates with desirable drug 
loadings (total drug loading of 10.8 wt% and less than 0.2wt% of free 
drug) and controlled tailored molecular weights (Mw 17000–20000 
g/mol) with acceptable polydispersities. Controlled drug release under 
acidic pH was obtained with this system since PACur were found to be 
hydrolytically cleaved under acidic conditions (such as those found in 
endosomes, lysosomes or the extracellular ﬂuid of some inflamed 
areas) yielding the free drug curcumin. Additionally, they were stable 
over prolonged periods of time at pH 7.4 mimicking blood plasma 
scenario. Additionally, cytotoxicity assays were performed as a proof 
of safety of these constructs for their application in wound 
healing/tissue repair. The tested PACur resulted to be non-toxic within 
the therapeutic window for curcumin application in wound healing, 
validating its application. 
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Once our Polymer-Protein/Drug Conjugates were synthesized and 
properly characterized, the next stage involved their encapsulation 
into hyaluronic acid microparticles (MPs-HA). HA was selected due to 
its multiple roles in nature, as well as its inherent biocompatibility and 
biodegradability what makes HA an attractive biomaterial in drug 
delivery and tissue engineering.130–133,148,158–162 In our concrete final 
system, HA microparticles can provide bigger surface area that could 
presumably improve tissue integrating and facilitate drug delivery130.  
Two different model systems were developed at this stage: on one 
side, MPs-HA were loaded with the polymer-drug conjugate PACur and 
free Cur148. These systems were physico-chemically characterized, and 
their drug release profiles were evaluated under acidic and neutral pH. 
From the results obtained, it could be concluded that as expected, a 
controlled drug release was only possible with MPs-HA loaded with 
PACurc. In this system, a sustained release of curcumin is achieved at 
pH 6.5 (up to ~60% drug release) while the system is relatively stable 
at pH 7.4 (only 15% drug release). In the case of MPs-HA loaded with 
Curcumin, the same release profile (up to ~60% drug release) was 
obtained in both cases. These results validated our system for the 
purposes of this thesis dissertation. 
On the other hand, hyaluronic acid microparticles were loaded with 
the polymer-protein conjugate PEG-Trypsin and free Trypsin. These 
systems were also physico-chemically characterized, and their drug 
release profiles were evaluated only at neutral pH due to Trypsin 
degradation at acidic pH. In this case, a sustained release was 
obtained, validating our MPs for the controlled delivery of Trypsin. The 
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next step would be the encapsulation of our PUMPT conjugates that 
will provide additional benefits regarding protein stability and 
controlled release under acidic pH, our real scenario. 
Once hyaluronic microparticles were preliminary validated, the 
following step was their inclusion in our final device, based on a 
polymeric composite system. In order to accomplish our goal, the 
versatile methodology utilizing electrospinning techniques (ES) was 
optimized for our purposes. Poly (L-lactic acid) (PLLA), a biodegradable 
and biocompatible polymer, was exploited to generate nonwoven 
fiber membranes which will provide a second point of control for a 
controlled and sustained drug release in our dually-controlled final 
system.  
First, the synthesis of PLLA random nonwoven fibers with nanometric 
diameters was optimized by varying different parameters: a) PLLA 
solution concentration, b) the voltage applied, c) distance between the 
needle tip and the collector, and d) the feeding rate.  
Then, in order to validate the PLLA technology, PLLA random 
nonwoven fibers membranes were loaded with the model drug 
Curcumin61 or PACur (simple membranes) or with micro particles 
loaded with Cur or PACur, inserted among or inside the fibers 
(composite membranes71). The introduction of MPs into the PLLA 
fibers was performed by means of two methodologies: one direct 
approach without MPs precipitation, and a two-step approach that 
includes MPs isolation. The first approach resulted to be the most 
efficient. 
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A complete and exhaustive physico-chemical characterization was 
performed through the subsequent analysis: (i) membrane 
composition and thermal properties by TGA and DSC, (ii) membranes 
wettability by contact angle measurement, and (iii) mechanic tensile 
properties of membranes systems. 
Selected membranes were evaluated in terms of drug release profile 
obtaining adequate drug release profiles for membranes loaded with 
MPsHA-Cur and MPsHA-PACur at pH 7.4. Furthermore, as membrane 
degradation time is a highly important parameter to be taken into 
account to establish the suitability of materials for a specific 
biomedical application, membrane degradation profile was also 
investigated in preliminary studies. The compiled results showed that 
our PLLA membranes were not degraded up to 7 days of soaking in 
aqueous solution of PBS 1X at pH 7.4 and 37°C. This behavior was 
expected since PLLA is a material highly resistant to aqueous 
hydrolysis at neutral pH. Longer degradation times and membrane 
degradation under acidic conditions are planned to be done. 
In vitro cytotoxicity studies were performed in L929 fibroblast cells and 
none of the systems resulted to be cytotoxic at the concentrations 
tested after 48 hours of treatment. Finally, studies of cell adhesion and 
morphology were performed in the same cell line. Analysis of cellular 
density and morphology by immunofluorescence cells showed that 
morphology of composite material by itself did not have an additional 
effect on the rate of proliferation of cells. However, it was clear that ES 
systems loaded with MPs with curcumin, conjugated or not in PACur 
were having an additional effect on cell proliferation. These results 
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were corroborated by the analysis of cell proliferation and distribution 
by Immunofluorescence and Scanning Electron Microscopy which 
demonstrated that cells owned a significant higher proliferation in 
drug loaded simple as well as composite materials. In fact, cells were 
able to adopt their typical fibroblast morphology. Besides, seeded cells 
were able to completely cover the surface material, a desirable feature 
in a system designed for wound healing.  
Further in vitro as well as in vivo biological studies are planned to be 
done in order to unravel the entire biologic and biomechanics 
potential of these materials in the biological settings. 
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9. FINAL CONCLUSIONS 
 
Synthesis and Characterization of Polymer-Protein conjugated 
systems by two approaches: PEGylation and Protein-Polyacetal 
Conjugates 
1.  Polymer-Protein Conjugates have been effectively synthesized 
and characterized by applying two different approaches: i) Protein 
PEGylation, as example of system with non-biodegradable polymer 
carriers and ii) Protein conjugation with polyacetals (PA), as example 
of system with a biodegradable polymeric carrier under acidic 
conditions aiming to obtain a PUMPT system. 
2.  PEGylation of Trypsin with MeO-PEG-COOH of 2000 g/mol 
resulted in a partial reduction of Trypsin activity, and an increase in its 
stability, what encouraged us in its use as models to be encapsulated 
in HA microparticles. 
3.  Functionalized PA backbones have been synthesized and 
physico-chemically characterized for the conjugation of Trypsin to 
generate an acid sensitive PUMPT system. Influence of the presence of 
a linker (succinoylated PA) and the effect of the proportion of polymer 
to protein in the masking/unmasking capability of the PA has been 
studied. The protein conjugate was stable and protein activity was 
hidden at neutral pH (7.4). However, the ability of the protein to 
recover its full initial activity after the PUMPT process under acidic pH 
has been demonstrated. 
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Synthesis and Characterization of Curcumin Polyacetals, PACur 
4.  Within this thesis, Polymer Therapeutics for the conjugates 
based on the biodegradable polyacetals and the antioxidant curcumin 
have been effectively synthesized (PACur), with high yields and the 
expected desired drug loadings.  
5. Controlled drug release of the free drug curcumin from PACur 
was achieved under acidic conditions (such as those found in 
endosomes, lysosomes or the extracellular ﬂuid of some inflamed 
areas). Additionally, they were found to be stable over prolonged 
periods of time at pH 7.4 mimicking blood plasma.  
6.  Cytotoxicity assays performed as a proof of safety ensured 
that PACur conjugates are not toxic within the therapeutic window for 
curcumin applications in wound healing, what validates its use in this 
disease target. 
Hyaluronic acid microparticles, MPs HA 
7.  HA microparticles have been effectively synthesized and 
characterized with good encapsulation efficiencies. From the systems 
built, it could be concluded that that the stirring rated, the organic 
solvent used for final emulsion, as well as chemical nature and 
hydrophilicity of the loaded compound do affect the morphology of 
resulting microparticles. 
8.  Release kinetics of all systems encapsulated from MPs HA was 
highly dependent on the pH what could be attributed to the swelling 
properties of HA and interaction of loaded compounds with MPs HA 
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matrix. Nevertheless, For MPs HA- PACur, controlled release of PACur 
was achieved under acidic pH as expected. In the case of MPs HA- PEG-
Trypsin, sustained release was achieved at neutral pH.  
Polymeric composite system designed to promote a long lasting, 
stable, localized and controlled drug release 
9.  Composite systems based on PLLA fibers and loaded MPs HA 
with dual mechanism of controlled release have been synthesized and 
characterized.  
10. For that, several methodologies for the fabrication of 
electrospinning-based systems have been explored. For the 
development of composite systems based of combination of 
microparticles with electrospinning membranes, the one-step method 
has been demonstrated to be the most efficient.  
11. This technique allowed us to obtain relatively homogenous 
systems with adequate thermal and mechanical properties in parallel 
with solution stability for materials to be used in bioapplications.  
12. As expected, the composite material provides an additional 
point of control on the release kinetic of loaded molecules in 
comparison with the release from parent microparticles, but only with 
the non-conjugated drug. 
13. Biological in vitro studies demonstrated that composite system 
is non-cytotoxic, and promotes fibroblast proliferation with cell 
morphology similar to normal tissue. However, cell proliferation was 
higher in those systems with Cur, conjugated or not. Furthermore, 
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morphological differences were observed between the fibroblast 
cultured on “composite membranes” and those cultured on “simple 
membranes” reflecting the influence of mechanical properties of the 
surface material over the interaction with cells. 
14. Composite systems proposed in this research are considered 
promising candidates to by evaluated in vivo models for promoting 
wound healing. 
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ABBREVIATION LIST  
 
AD Alzheimer’s disease 
1-HP 1-heptanol 
3x triplicate 
A.A. Acrylamide, 2-Propenamide, Acrylic acid amide 
AcOH Acetic acid 
ADSCs Adipose-Derived Stem Cells 
AgSD Silver Sulfadiazine 
Ala Alanine 
ALL Acute lymphoblastic leukemia 
AMD Age-related Macular Degeneration 
AOT sodium bis(2-ethylhexyl)sulfosuccinate 
APAF-1 Apoptotic Protease Activating Factor 1 
APS Ammonium peroxodisulfate, Ammonium peroxydisulfate 
BBB Blood-Brain-Barrier 
BCA Bicinchoninic Acid solution 
BHMPA 2,2-tris (hydroxymethyl) propionic acid  
BM Bone Marrow 
BSA Bovine Serum Albumin 
BuOH n-Butanol, Butyl alcohol 
CD Cyclodextrin 
CD circular dicroism 
CDCl3 deuterated chloroform 
CHCL3 Chloroform 
CKD Chronic Kidney Disease 
CMFDA 5-chloromethylfluoresein diacetate 
Cur curcumin 
d doublet 
DACH 1,2-diaminocyclohexane 
DCM Dichloromethane 
dd double doublet 
ddH2O double distiled water 
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DEGDVE Tri(ethylene glycol) divinyl ether 
DMF N,N-Dimethylformamide,  Dimethylformamide 
DMPA N,N-Dimethylpyridin-4-amine, DMAP  
DMSO dimethyl sulfoxide 
DMSO-6d dimethyl sulfoxide deuterated 
DOSY-NMR Diffusion-ordered spectroscopy 
DOX Doxorubicin 
DOXY Doxyclycline 
DTT 
threo-1,4-Dimercapto-2,3-butanediol, DL-Dithiothreitol, 
Cleland’s reagent, DTT  
DVS Divinyl sulfone 
E.E. encapsulation efficiency 
ECM Extracellular Matrix 
EDAC 
N-Ethyl-N′-(3-dimethylaminopropyl)carbodiimide 
hydrochloride 
EIF Epidermal Induction Factors 
EPO Epoetin beta 
EPR Enhanced Permeability and Retention 
ES Electrospinning 
ES PLLA electrospinning of PLLA 
ES01 simple membrane constituted by PLLA fibers  
ES02 
composite membrane constituted by PLLA fibers and 
Microparticles of hyaluronic acid 
ES03 
composite membrane constituted by PLLA fibers and 
Microparticles of hyaluronic acid loaded with PACur 
ES04 
simple membrane constituted by PLLA fibers loaded with 
PACur 
ES05 
simple membrane constituted by PLLA fibers loaded with 
Cur 
ES06 
composite membrane constituted by PLLA fibers and 
Microparticles of hyaluronic acid loaded with Cur 
Et3N Triethylamine,   N,N-Diethylethanamine 
EtOH ethanol 
Fab Fragment antigen-binding 
FAP Familial Amyloidotic Polyneuropathy 
FDA US Food and Drug Administration 
 361 
 
FMOC 
9-Fluorenylmethoxycarbonyl chloride, 9-Fluorenylmethyl 
chloroformate, Fmoc-Cl 
FPLC Fast Protein liquid chromatography 
GI Gastro-Intestinal 
GPC Gel permeation chromatography 
HA hyaluronic acid 
HCl Hydrochloric acid 
HGH Human Growth Hormone 
HPMA N-(2-hydroxypropylmetacrylamide) 
HrGCSF 
human recombinant Granulocyte-Colony Stimulating 
Factor 
HYD Hydrazone 
i.m. Intramuscular 
i.v. Intravenous 
IgE Immunoglobulin E 
KOH potassium hydroxide 
L-BAPNA Nα-Benzoyl-L-arginine 4-nitroanilide hydrochloride 
m multiplet 
MeOH methanol 
MeO-PEG-
COOH 
alpha-Methoxy-omega-carboxylic acid poly(ethylene 
glycol) 
MeO-PEG-
OH alpha-Methoxy-omega-hydroxy poly(ethylene glycol) 
MPs Micro-particles 
MPs microparticles  
MPs HA microparticles of hyaluronic acid 
MSC Mesenchymal Stem Cells 
MW molecular weight 
MWCN Multi-Walled Carbon Nanotubes 
MWCO molecular weight cut-off 
Na2CO3 sodium carbonate 
NaHCO3 sodium bicarbonate 
NaOH Sodium hydroxide solution 
NCS Neocarzinostatin 
NGF Nerve Growth Factor 
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NMR nuclear magnetic resonance 
NSCLC Non-Small Cell Lung Cancer 
NTFs Neurothrophic Factors 
O/W Oil/Water 
PACOOH carboxylate pendant group polyacetal 
PACOOH-T 
carboxylate pendant group polyacetal-conjugated with 
trypsin 
PACur Polyacetal conjugated with curcumin 
PAFS FMOC protected amino-pendant polyacetal  
PAMAM Polyamidoamine 
PANH2 deprotected amino-pendant polyacetal 
PASUcc Succinoylated Polyacetal 
PASUcc-T Succinoylated Polyacetal conjugated with trypsin 
PA-T polyacetal conjugated with trypsin 
PBS Phosphate Buffer Saline 
PC Polymer Conjugates 
PDGF Platelet Derived Growth Factor 
PEG Poly(ethylene glycol) 
PEG polyethyleneglicol 
PET Positron Emission Tomography 
PGA Poly(glutamic acid) 
PLA Poly(lactic acid) 
PLACL poly(L-lactic acid)–co-poly(3-caprolactone) 
PLGA Poly(lactic glycolic acid) 
PLLA Poly(l-lactic acid) 
PLLA Poly-L-lactic acid 
pNA p-Nitroanilide 
PPAR Peroxisome Proliferation Activated Receptor 
PT Polymer Therapeutics 
PT polymer therapeutics 
pTSA para-toluene sulfonic acid 
PUMPT polymer-masking-unmasking-protein therapy  
PVA Poly(vinyl alcohol) 
PVP Poly(vinylpirrolidone) 
qt quadruplet 
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RES Reticuloendothelial system 
ROS Reactive Oxygen Species 
s singlet 
s.c. Subcutaneous 
SDS 
Sodium dodecyl sulfate,  Dodecyl sodium sulfate, 
Dodecyl sulfate sodium salt, Lauryl sulfate sodium salt, 
SDS, Sodium lauryl sulfate 
SDS-PAGE 
The method is called sodium dodecyl sulfate 
polyacrylamide gel electrophoresis 
SF Silk Fibroin 
SMA Styrene-co-maleic Anhydride 
SMANCS Styrene-co-maleic Anhydride- Neocarzinostatin 
sulfo-NHS 
N-Hydroxysulfosuccinimide sodium salt,   Hydroxy-2,5-
dioxopyrrolidine-3-sulfonicacid sodium salt, Sulfo-NHS  
T trypsin 
t triplet 
td triplet of doublet 
TDL Total drug loading 
TE Tissue Engineering 
TEGDVE Di(ethylene glycol) divinyl ether 
TEMED 
N,N,N′,N′-Tetramethylethylenediamine,  1,2-
Bis(dimethylamino)ethane, TEMED, TMEDA 
THF Tetrahydrofuran 
TLC Thin layer chromatography 
TNBSA 
2,4,6-Trinitrobenzenesulfonic acid solution,  
Picrylsulfonic acid solution 
TNF Tumor Necrosis Factor 
TRIS 
2-Amino-2-(hydroxymethyl)-1,3-propanediol, THAM, Tris 
base, Tris(hydroxymethyl)aminomethane, Trizma® base, 
Trometamol  
TRIZMA 
base 
2-Amino-2-(hydroxymethyl)-1,3-propanediol, THAM, Tris 
base, Tris(hydroxymethyl)aminomethane, Trometamol  
Tyr Tyrosine 
VE Vitamin E 
VEGF Vascular Endothelial Growth Factor 
W/O Water/Oil 
wt% Percentage in weight 
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